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ABSTRACT	
 
 
 
Current research supports a link between osteoarthritis (OA) and the decline in 
oestrogen levels at menopause.  It is not known whether altered hormone levels exert 
their effect primarily on articular cartilage, or whether associated degeneration of other 
oestrogen-responsive joint tissues such as cruciate ligaments may significantly 
contribute. This study investigated the influence of ovariectomy and/or the presence of 
concurrent osteoarthritis (bilateral meniscectomy model) on the fibrillar structure of 
collagen within the anterior cruciate ligament (ACL).   
 
Sheep (n=24) were treated experimentally with one or more of the following treatments: 
ovariectomy (OVX), meniscectomy (MENX) or non-operated control (NOC). ACLs 
were examined using transmission and scanning electron microscopy (TEM & SEM), 
gene expression, biochemical analysis and histology.  
 
TEM studies showed OVX and MENX affect collagen fibril size and arrangement, 
while the combination of prior OVX and concurrent osteoarthritis (MENX) produced a 
different pattern of derangement to either treatment alone and may indicate a synergistic 
effect. Observed structural changes complemented molecular findings of altered mRNA 
expression, and changes in the collagen and sulphated glycosaminoglycan content of 
ACL tissue.   
 
This study demonstrates that ovariectomy significantly affects ACL collagen fibril 
structure, and influences the response of the ACL to surgical OA (MENX). These 
results show the potential for changes in ACL structure post-menopause to influence 
joint integrity.  
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PREFACE	
	
This study was conducted to investigate the influence of knee osteoarthritis on other 
important joint structures, specifically the anterior cruciate ligament, and determine 
what effect the decline in ovarian hormones associated with menopause has on ligament 
tissue.   It was conducted concurrently with another study investigating cartilage 
changes in ovariectomised and meniscectomised sheep. The author was involved both 
studies, including all surgical procedures and tissue harvesting, and is personally 
responsible for all ligament investigations presented in this thesis.   Prof Rick Read and 
his research team, in co-operation with the Raymond Purves Bone and Joint Research 
Laboratories (Royal North Shore Hospital, Sydney) generated the cartilage results, 
some of which have been included to confirm the occurrence of osteoarthritis as 
induced by the meniscectomy model.     
 
For efficiency, and to minimise the number of animal subjects used, several hypotheses 
were tested within the design of a single large trial.  The reader is initially provided with 
a general introduction relevant to all subsequent chapters (Chapter 1) followed by 
details of the methods and materials used in the study (Chapter 2).  The thesis then 
discusses the effect of each treatment individually by chapter, first investigating the 
effect of osteoarthritis alone (Chapter 3), and then the effect of ovariectomy with or 
without concurrent osteoarthritis (Chapter 4).  Chapters 3-4 are presented each with 
their own specific introductory information, results and discussion, while the combined 
results, providing the opportunity to compare and contrast the results from all test 
groups, are available to view in the appendices. For each method of investigation, all 
samples from the four groups were processed as a single batch to avoid variation 
between groups and therefore allow them to be directly compared.   Finally, Chapter 5 
presents a review of all hypotheses and potential areas for future research are discussed.
 
 
1
CHAPTER	1	
	
	
	GENERAL	INTRODUCTION	TO	CONNECTIVE	TISSUE	AND	THE	
CRUCIATE	LIGAMENTS	
 
 
 
1.1 CONNECTIVE TISSUE 
There are four traditional classes of living tissue which together comprise the human (or 
animal) body, namely epithelial, muscle, nervous and connective tissue [1, 2].  Of these, 
connective tissue encompasses the widest variety of tissues, exhibiting significant 
differences in structure, form and function.  The main characteristic shared by all types 
of connective tissue is that it consists of cells surrounded by an extracellular matrix of 
fibres, fluid and ground substance.  Variations in the characteristics of this extracellular 
matrix provide a basis for further classification of connective tissue into subgroups and 
reflect the functional requirements of each type of connective tissue [1-4].    
 
In general, the key functions of the connective tissues are to provide a fibrous container 
for soft tissues, to function as a medium for the transmission of mechanical forces, to 
provide structure and support to the body, to provide transport for substances such as 
nutrients, oxygen and hormones around the body [3, 5]. 
 
1.1.1 Classification of Connective Tissues 
Connective tissue is further classified into subgroups based on differences in the 
structure of the extracellular matrix and its functional properties.  Differentiation of 
connective tissue into subgroups can be difficult due to a degree of overlap between 
characteristics of the many tissues which fall into this category.  Therefore, any 
classification system is somewhat subjective and open to dispute.  The following is one 
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possible outline of the connective tissue subgroups and successive subtypes, and 
provides examples of body tissues belonging to each (Figure 1.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The three main subgroups of connective tissue may be described as: embryonic 
connective tissue, connective tissue proper and specialised connective tissue [1, 3, 6]. 
 
 
EMBRYONIC 
CONNECTIVE TISSUE 
MESENCHYME 
MUCOUS  Umbilical cord 
 Embryo 
 
CONNECTIVE  
TISSUE PROPER 
LOOSE 
CONNECTIVE 
TISSUE 
DENSE 
CONNECTIVE 
TISSUE 
 Subcutaneous tissue layer 
 Lamina propria 
IRREGULAR 
REGULAR 
 Dermis 
 Pericardium 
 Scar tissue 
 
 Tendon 
 Ligament 
 
SPECIALISED  
CONNECTIVE TISSUE 
BLOOD 
CARTILAGE 
BONE 
ADIPOSE 
LYMPHATIC 
Figure 1.1: Flow diagram illustrating the classification of connective tissues into subgroups and 
successive subtypes based on differences in the structure of the extracellular matrix and its functional 
properties (Image A. Daniel).  
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1.1.1.1 Embryonic Connective Tissue  
Embryonic connective tissue is derived from the mesoderm, which is the middle layer 
of the trilaminar germ disc of the embryo.  Almost all of the connective tissues of the 
body originate from this embryonic germ layer.  An exception to this is the head where 
some progenitor cells are derived from the ectoderm [3, 6].  
 
The formation of connective tissue begins through proliferation and migration of the 
mesodermal cells and specific neural crest cells.  This leads to the formation of a 
primitive connective tissue known as mesenchyme [1, 3].  Mesenchyme is primarily found 
in the embryo and consists of small spindle-shaped, as yet unspecialised (pluripotent) 
cells.  The mesenchymal cells are progenitors of the various types of connective tissues 
as well as other tissues such as muscle, and the vascular system [7, 8].  The cells are 
loosely packed and suspended in a viscous extracellular matrix.  Extending from these 
cells are processes which enable contact between neighbouring cells via gap junctions, 
thereby forming a cellular network.  Fine reticular (collagen) fibres are sparsely 
dispersed throughout the mesenchyme [3, 6]. 
 
Mesenchyme is one of two embryonic tissue subtypes.  The other subtype is mucous 
connective tissue which is found in the umbilical cord.  It is similar to mesenchyme but 
more space exists between cells and fewer reticular fibres are present.  Mucous 
connective tissue consists largely of a specialised type of extracellular matrix which has 
a gelatinous or mucous-like consistency.  The ground substance of this extracellular 
matrix is also known as 'Wharton's jelly' [1, 6].  
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1.1.1.2 Connective Tissue Proper 
This connective tissue subtype is comprised of cells and an extracellular matrix 
consisting of protein fibres and a gelatinous or viscous ground substance [2, 3, 5].  Within 
this category the tissues can be further divided into two subtypes: 
 
1.1.1.2.1 Loose Connective Tissue (or Areolar Tissue)  
This is a cellular connective tissue in which the protein fibres within the extracellular 
matrix are thin and form a sparse meshwork.  There are numerous spaces between the 
cells and fibres, which are filled by an abundance of viscous ground substance [2-4].  This 
ground substance serves as a medium for diffusion of oxygen & nutrients between 
blood vessels and connective tissues, and facilitates the exchange of waste products 
such as carbon dioxide and metabolites.  For this reason, loose connective tissue is often 
found surrounding small blood vessels [2, 3].  Another function of this subtype is as a 
loose space-filling or packing material between organs or other structures in the body.  
It permits motion to occur between structures while still providing support due to its 
ability to shorten and elongate when necessary (within limits) [4, 5], and the viscous 
nature of its ground substance also facilitates the free migration of many cell types such 
as fibroblasts lymphocytes and macrophages [3, 4].   
 
1.1.1.2.2 Dense Connective Tissue  
This subtype contains an abundance of fibres which are packed tightly together, and it 
has fewer cells and ground substance than loose connective tissue.  A majority of the 
fibres present are collagenous, as well as some reticular and elastic fibres.  Its main 
functions are to support and connect body parts [1, 2].  Dense connective tissue can be 
further divided in two subcategories: 
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Dense Irregular Connective Tissue – in this tissue type the abundant fibres are arranged 
in a random meshwork.  The cells present are typically fibroblasts and are relatively few 
in number, with little ground substance surrounding them.  This tissue tends to occur in 
sheets and is resilient, able to withstand pulling forces exerted in many different 
directions.  Examples include the dermis of the skin, the pericardium surrounding the 
heart and the submucosa of the intestinal tract [1-4].  This type of connective tissue is also 
produced in the development of scars [9].   
 
Dense Regular Connective Tissue – like dense irregular connective tissue, fibres are the 
prominent feature of dense regular connective tissue and there are fewer cells and little 
ground substance present.  The major difference between these two types of dense 
connective tissue lies in the arrangement of their fibres, with the fibres of dense regular 
connective tissue being arranged in a parallel manner, and are very densely packed into 
fibre bundles.  This arrangement provides the tissue with great tensile strength and 
enables it to withstand the greatest forces along the axis of its fibres, reflecting the 
mechanical requirements of the tissue. Fibroblasts, which produce and maintain the 
fibres, are positioned between the fibre bundles.  This tissue tends to occur as thick 
bands or cord-like structures.  Examples of dense regular connective tissue are the 
tendons joining muscle to bone, and the ligaments which join bone to bone [1-4].     
 
1.1.1.3 Specialised Connective Tissue 
This category encompasses the more individual or atypical connective tissues, which 
serve various important and specific functions throughout the body.  Like all connective 
tissues, they consist of cells surrounded by a non-living extracellular matrix of fibres 
and ground substance, while also possessing certain individual structural characteristics 
enabling them to perform a specific function [6].   Blood and bone are two forms of 
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specialised connective tissue with significant structural differences.  Blood has a fluid 
ground substance which allows it to travel around the body and function as a transport 
medium for nutrients, wastes, respiratory gases, hormones etc, while in contrast bone 
has ground substance which is completely mineralised and rigid, thereby providing 
exceptional support and protection for other body structures [2, 6].  Specialised connective 
tissues also contain varying cell types depending on their location, and each tissue type 
has some fibres (collagenous, elastic or reticular) present but to varying degrees [1-3].  
Types of specialised connective tissues found in the body are adipose tissue, blood, 
bone, cartilage, lymphatic tissue and haemopoietic tissue [3].   
 
 
1.2 COMPOSITION OF LIGAMENT  
As previously discussed, ligament is a form of dense, regular connective tissue.  Most 
ligaments are found in the musculoskeletal system where they join bone to bone [3, 10], 
although the body also contains a number of suspensory ligaments which support 
various organs in the body such as the eyeball and ovary [6, 11].  Ligaments of the 
musculoskeletal system function across joints with both a wide range of motion such as 
the hip, and with very little movement such as the sacroiliac joint [10, 11].  They are named 
based on their bony attachments, their gross function, their position in relation to the 
joint, their shape and their arrangement with respect to other ligaments [5, 10].  
 
In addition attaching articulating bones to one another, skeletal ligaments serve a 
number of other roles which are important to correct joint function.  They are 
responsible for accurately guiding the movement of joints and restricting joint 
movement to within set limits, and often contain mechanoreceptors that act as position 
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sensors for joints.  Ligaments also provide maintenance of joint congruency and 
stability, therefore preventing wear and tear of the articulating surfaces [11]. 
 
Grossly, skeletal ligaments vary in shape, length and thickness depending on their 
location.  They appear as glossy white, firm, fibrous tissue which may be arranged in 
bands, sheets or thickened strips of joint capsule and are composed of a complex 
extracellular matrix (ECM) of fibres and ground substance, with cells interspersed 
throughout.  The composition of the ECM may vary slightly between ligaments, or even 
between different regions of the same ligament [10-12].  
   
As ligament (in particular the cruciate ligaments of knee) is the focal tissue of this 
project, the individual structural components of this connective tissue will be discussed 
in further detail.   
 
1.2.1 The Cells of Ligament 
It is the specific cell populations present which give each connective tissue type its 
unique characteristics.  In the case of ligament, the predominant cell type is the 
fibroblast [10, 13-15].  The morphological appearance of the fibroblast may vary and it is 
thought that the shape variation represents different metabolic states of the same cell [14].  
Most often it appears as an elongated or spindle-shaped cell [3, 5, 8], but may also appear 
as ovoid or spheroid.  Many fibroblasts have very long, thin and sheet-like cytoplasmic 
processes which extend between the collagen fibrils of the ECM [3, 10].  During periods of 
active growth or repair, the cytoplasm of the cell is more extensive with an abundant 
rough endoplasmic reticulum (ER) (Figure 1.2).  The nucleus is either elliptical or disc-
shaped and may have multiple nucleoli [1, 10]. 
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Fibroblasts are responsible for the formation of the collagen, elastic and reticular fibres 
and complex carbohydrates found in ground substance (Figure 1.3) [8, 11].  They are 
solitary cells and are found anchored to the parallel collagen fibrils [13], but also have the 
ability to migrate through the connective tissue, especially in response to trauma [5].  In 
addition, the fibroblast is responsible for the maintenance process during which it 
enzymatically breaks-down and removes old collagen from the matrix [8].  During 
periods of inactivity where the cell is completely surrounded by matrix, it may be 
termed a fibrocyte [6, 12].   
 
 
Golgi 
Apparatus 
Nucleoli within 
 Nucleus 
Rough Endoplasmic 
Reticulum 
 
Mitochondrion 
Secretory  
Vesicles Coves in Cell 
Surface 
Cytoplasmic  
Processes 
Figure 1.2: Diagrammatical representation of the active form of a fibroblast, demonstrating 
the long cytoplasmic processes and abundant rough ER.  Note the depressions or "coves" on 
the cell surface where the Golgi apparatus concentrate the release of the collagen molecules.  
(Image A. Daniel).    
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The concentration of cells synthesising new matrix is naturally higher in younger 
ligaments or in ligaments undergoing repair, however with increasing age, the 
fibroblasts become less active.  Despite this they do retain the ability to grow and 
synthesise new matrix elements throughout life, with each individual fibroblast being 
capable of producing all of the components found in the ECM [10].  This ability to 
regenerate is essential for maintaining structural and functional integrity of the ligament, 
thus preventing joint instability.   
Figure 1.3: (TEM 4800x) Transmission electron micrograph of a fibroblast 
surrounded by an abundance of type I collagen fibrils in sheep anterior cruciate 
ligament. (Image A. Daniel).    
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While ligament has relatively few cells compared with most other tissues, the cells do 
not exist in isolation from one another.  Resting fibroblasts (fibrocytes), have a spider-
like appearance, with long cell processes that join adjacent cells together in an extensive 
interconnected cellular network [16] (Figure 1.5).   Located on the cell bodies and their 
processes are special gap junctions, which allow communication between adjacent 
fibrocytes via diffusion of small molecules (<1000Da) such as metabolites, ions, second 
messengers, water and electrical impulses between cells [17-19]. 
 
At the gap junction are proteins called connexins which mediate cell to cell coupling.  
Six connexin subunits join together to form a conduit known as a hemi-channel (also 
called a connexon) in the plasma membrane.  This can dock with another connexon in 
the plasma membrane of an adjacent cell, thereby forming a complete gap junction 
channel [17, 18] (Figure 1.4).  Currently there are 21 known connexin genes in the human 
genome [18, 20].  Of these, connexin 43 (Cx43) is the most ubiquitous, being found in 46 
different tissue types in the body, including ligament.  However, Cx43 is not the only 
connexin found in ligament, with a second type Cx32 also being isolated, suggesting 
that there are two distinct communication networks present [16, 17]. The ability of cells to 
communicate via gap junction coupling is essential for maintaining ligament 
homeostasis and its ability to remodel in response to mechanical stimuli [19, 21].   
 
  
Figure 1.4: Schematic drawing of 
gap junction channels.  Each 
apposed cell contributes a hemi-
channel to the gap junction.  The 
six connexin subunits may change 
configuration to allow the channel 
to open or close the hemi-channel.  
(Image from Sohl & Willecke, 
2004).  
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Figure 1.5: (TEM 850x) Transmission electron micrograph of sheep anterior cruciate ligament, 
showing the interconnection of fibroblasts and fibrocytes via long cellular processes to form a cellular 
network (arrow heads). (Image A. Daniel).    
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In addition to the fibroblast, several other cell types may be present in ligament in low 
numbers.  One such cell type is the chondrocyte, a cell normally native to cartilage, but 
which is also found in certain ligaments such as the anterior cruciate ligament (ACL) 
near its tibial insertion where the ligament consists of fibrocartilage [13].  Endothelial 
cells may also be found in ligament due to the presence of small blood vessels and 
nerve cell processes [10]. 
 
1.2.2  The Extracellular Matrix 
The ECM is a complex, non-living structural network that is secreted by and surrounds 
the widely spaced fibroblasts, and gives each connective tissue its physical qualities. 
The ECM of ligament is strong and fibrous, yet flexible and in some cases elastic. It 
consists of protein fibres, water and a proteoglycan rich ground substance.  Together 
these elements allow the ligament to withstand the tensile forces applied to it [1, 12].   
 
1.2.2.1 Fibres   
In dense regular connective tissues such as ligament, the fibres are the predominant 
feature [3]. There are three main types of fibres present in connective tissues; collagen, 
elastic and reticular [2, 4].  Reticular fibres, common in loose connective tissue, are not 
typically found in ligament: therefore, only collagen and elastic fibres will be discussed 
further.   
 
1.2.2.1.1 Collagen Fibres 
Collagen is the predominant macromolecule of the ECM of ligament, providing it with 
its form and high tensile strength.  It is estimated that collagen contributes 70-80% of 
the dry weight of ligament [22].   
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Collagen is a form of secretory protein produced by fibroblasts.  Each collagen 
molecule is actually a right-handed triple-helix of three polypeptides known as α-chains 
[11, 23].  The amino acids that make up the α-chain generally follow a particular sequence, 
in which every third amino acid is a glycine.  This glycine is usually followed by a 
proline, which is succeeded by either a hydroxyproline or a hydroxylysine.  In short it is 
a repeating sequence of glycine – χ – γ [where χ = proline, γ = hydroxyproline or 
hydroxylysine].  This repeating sequence is essential for the triple-helix formation [8, 11, 
24].  Weak covalent intramolecular cross-links are present between the three α-chains of 
the triple-helix (Figure 1.6).  These cross-links contribute to the strength of the tissue [11, 25].   
 
 
 
 
 
 
 
 
 
 
The triple-helix molecules are also known as tropocollagen, and are aligned head to tail 
in staggered rows (overlapping by one quarter of a molecule), to form a collagen fibril 
(Figure 1.7).  Gaps are present between the tropocollagen in each row.  Strong covalent 
intermolecular cross-links occur between the adjacent rows of tropocollagen, rather than 
between the heads and tails of the molecules in a row.  These cross-links are formed by 
enzymatic reactions between the amino acids lysine and hydroxylysine.  This specific 
staggered arrangement of tropocollagen imparts the greatest mechanical and 
 
α1 
 
 
α1  
 α2
     INTRAMOLECULAR CROSS-LINKS 
Figure 1.6:  Simplified diagrammatical representation of a collagen I tropocollagen molecule, 
demonstrating the three α-chains and the intramolecular cross-links between each chain (represented by 
arrows). (Image A. Daniel). 
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biochemical stability to the fibril [8, 11, 25].  The intramolecular and intermolecular cross-
links are also essential for imparting strength and stability to the ligament tissue.  
Without these cross-links, the tissue would be extremely weak and friable [8, 25].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The assembly of collagen fibres is complex, with a number of recognisable hierarchical 
levels of organisation between the tropocollagen and the fibril (Figure 1.8).  These are 
outlined below in ascending order: 
Microfibril –  tropocollagen molecules are tightly packed into groups of 5, forming 
microfibrils.  These are approximately 3.5nm in diameter. 
Subfibril –  the microfibrils assemble together to form subfibrils of 10-20nm. 
OVERLAPPING PATTERN OF TROPOCOLLAGEN 
Figure 1.7: Basic arrangement of the tropocollagen molecules in a collagen fibril. The 
triple helices align side by side, overlapping by one quarter of a molecule, in a 
repeating pattern (red arrows).  Many strong intermolecular covalent bonds occur 
between adjacent molecules (yellow arrows).  (Image A. Daniel). 
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Fibrils –  are formed from the aggregation of subfibrils.  They have a diameter of 
50-500nm.  It is these fibrils which ultimately go on to form the collagen 
fibres [12, 14, 23]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The production of fibrillar collagen involves a series of intracellular and extracellular 
events.  It begins within the cell, where the polyribosomes of the rough ER produce the 
initial polypeptide chains mediated by messenger ribonucleic acid (mRNA).  The newly 
synthesised polypeptides are then released simultaneously into the cisternae of the 
rough ER.  It is here, and in the Golgi apparatus, that a number of post-translational 
modifications are made to the polypeptides, including the congregation of three 
polypeptides to form a triple-helix molecule.  These modifications lead to the 
production of procollagen, the precursor of the collagen molecule.   
 
   Tropocollagen       Microfibril Subfibril      Fibril     Fibre 
Figure 1.8: Depiction of the hierarchical organisation of collagen in midsubstance ligament.  EM 
= electron microscope; SEM = scanning EM; OM = optical microscope.  (Image modified from 
Ng G., 2005). 
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The procollagen is packed into secretory vesicles and is moved to the outside of the cell 
via exocytosis.  During its movement out of the cell, it comes into contact with 
procollagen peptidase, an enzyme associated with the cell membrane.  This enzyme 
cleaves the uncoiled ends of the procollagen molecule, resulting in a collagen molecule 
(or tropocollagen).  It is outside the cell that the tropocollagen molecules are organised 
into microfibrils, subfibrils, fibrils and finally fibres [3, 11, 22].   
 
To date, there are at least 27 different types of collagen in the body, with new types 
being discovered regularly [24].  Each collagen type is designated a Roman numeral, 
reflecting the chronological order in which they were discovered [11].  The different types 
of collagen arise from differences in the α-chains that make up the triple-helices.  
Collagen I, for example, consists of 2 identical α1 chains, and 1 different α2 chain.  It is 
designated the collagen nomenclature [α1(I)]2 α2(I). Using collagen III as a further 
example, this consists of three identical α1 chains, and so is designated [α1(III)]3.   Each 
collagen type has its own unique characteristics, functions and locations throughout the 
body [24]. 
 
Collagen types I, II and III are the most abundant in the musculoskeletal system, with 
collagen I being the most common type by far.  In fact, type I collagen constitutes 
approximately 90% of the body's total collagen, being present in skin, bone, dentin, 
sclera, fascia, tendon and ligament [3, 11, 13].  As much as 90% of the collagen of ligaments 
is type I collagen, which is the principal tensile-resistant collagen.  Less that 10% is 
type III collagen, which is found in the loose connective tissue that separates the type I 
collagen bundles.  Collagen types V, VI, X, XII may also be present in small amounts 
[15, 25, 26].  Type II collagen normally does not occur in ligament, it is typically found in 
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cartilage.  However, type II collagen has been identified in the fibrocartilaginous zones 
of some ligament insertions [13]. 
 
1.2.2.1.2  Elastic Fibres  
Ligament may also contain elastic fibres, which allow the tissue to stretch and distend.  
Most ligaments contain less than 5% elastic fibres by dry weight, but a few have higher 
concentrations, and so are known as elastic ligaments, e.g. the nuchal ligament and the 
ligamentum flavum [4, 11].  Elastic fibres are produced by the same cells that produce 
collagen, though they are typically thinner in diameter and have a different structural 
composition to collagen.  They are arranged in a branching pattern to form a three-
dimensional network that is interwoven with the collagen fibres to limit the 
distensibility of the tissue [2, 6].   
 
Elastic fibres are comprised of a central core of elastin with surrounding fibrillin 
microfibrils.  The elastin is rich in glycine and proline like collagen, but is poor in 
hydroxyproline and lacks hydroxylysine [3].  Elastin may form layers or fibres of 
variable thickness.  When not under stress, elastin fibres assume the confirmation of 
random coils.  These coils allow them to undergo a degree of deformation without 
rupturing or tearing, and then return to their original size and shape when unloaded [10, 11].  
The elastin itself is a highly insoluble and stable protein due to its extremely 
hydrophobic nature [11]. 
 
The fibrillin component of elastic fibres is a glycoprotein that forms fine microfibrils.  
These microfibrils are formed first, and then the elastin is deposited onto their surface.  
The absence of these fibrillin microfibrils during elastogenesis results in the 
development of elastin sheets rather than fibres [1, 3].  The synthesis of elastin by 
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fibroblasts parallels that of collagen and both processes may occur simultaneously in the 
cell.  The procollagen and proelastin (the precursor to elastin) molecules remain 
separate throughout the series of synthetic events, due to the activity of signal peptides.  
These are built into the beginning of the polypeptide chains of each molecule [3]. 
 
1.2.2.2 Water 
Approximately 60-80% of the wet weight of most ligaments is water [10, 25].  Water fills 
the spaces between the cells and the macromolecular network of fibres and ground 
substance.  The presence of water in ligament is important for allowing oxygen, 
nutrients and metabolites to diffuse through the extracellular matrix to the ligament 
cells.  This is essential because the cells may lie at some distance from the blood vessels 
and water provides a medium through which cellular communication can occur [10, 27].  
Water is attracted to the extracellular matrix due to the presence of hydrophilic 
molecules called glycosaminoglycans in the ground substance [3].  
 
1.2.2.3 Ground Substance 
Ground substance is the component of the ECM that fills the space between the cells 
and fibres.  It initially appears to be a substance with little morphological structure, but 
in fact contains molecules that are highly structured and complex combinations of 
polysaccharides and proteins.   The consistency of ground substance ranges from fluid 
to calcified, depending on the amount of water present. The ground substance of 
ligament tends to be quite viscous to gelatinous in texture [5, 27].   
 
Ground substance is not usually visible when viewed microscopically, as it is lost in the 
fixation and dehydration processes in routine H&E preparations [2].  Despite its 
outwardly amorphous appearance it serves a number of important roles.  Its molecules 
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attract and hold water which, as mentioned previously, facilitates the diffusion of gases 
and nutrients, and allows cellular communication.  It acts as a barrier to certain large 
molecules such as bacteria while allowing the passage of smaller, water soluble 
molecules [1]. It also contributes to the mechanical properties of the tissue, especially in 
compressive loading and viscoelasticity.  In addition to these roles, the ground 
substance helps to order, support and lubricate the other tissue components [11].  
 
1.2.2.3.1 Proteoglycans  
An important component of ground substance is the non-collagenous molecules called 
proteoglycans.  Proteoglycans contribute only a small portion of the framework of 
ligament, usually less than 1% of the total dry weight, but they play an important role in 
the organisation of collagen fibres and interaction with tissue fluid [10, 22].  In addition, 
proteoglycans interact with the collagen fibres to yield the viscoelastic properties of the 
ligament [12] and are involved in the lubrication of ligaments [25].  
 
Proteoglycans represent a special class of glycoproteins that are heavily glycosylated.  
They can be very large macromolecules comprising a core protein to which one or more 
glycosaminoglycan side chains are covalently bound [2, 12].  Glycosaminoglycans (GAGs) 
are long chained polysaccharides of repeating disaccharide units.  They are so named 
for the hexosamine sugar glycosamine, which is present in each disaccharide [3, 11].  
GAGs possess a high number of negative charges that repel one another, therefore 
enabling the proteoglycans they form to extend through a greater volume than if they 
were uncharged.  This negative charge also allows the GAGs to interact with positively 
charged molecules such as water.  As a result, proteoglycans have a high affinity for 
water, which determines the viscosity of the ECM and maintains the correct 
homeostatic environment for the cells of the ligament tissue [1, 11].   
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GAGs form the major carbohydrate component of all proteoglycans.  Currently a family 
of 7 distinct GAGs are recognised [3].  They are: 
1. Keratan sulfate 
2. Chondroitin 4-sulfate 
3. Chondroitin 6-sulfate 
4. Dermatan sulfate 
5. Hyaluronic acid 
6. Heparan sulfate 
7. Heparin 
 
Of these, keratan sulfate, chondroitin sulfate, dermatan sulfate and hyaluronic acid 
predominate [1, 5].  Keratan sulfate is a GAG that is commonly found in bone, cartilage 
and the cornea, while chondroitin sulfate provides support and adhesiveness in bone, 
cartilage, skin and blood vessels and dermatan sulfate is found in the ground substance 
of tendons, ligaments, heart valves and blood vessels [1].   Hyaluronic acid is a viscous 
slippery substance that binds cells together and lubricates joints.  Unlike the other 
GAGs, hyaluronic acid is not directly associated with the proteoglycan's protein core [2].  
Instead, special link proteins indirectly bind proteoglycan monomers to the hyaluronic 
acid.  It also differs from other GAGs because it is a much longer and more rigid 
molecule, being composed of a carbohydrate chain of thousands of sugars, rather than 
the hundreds (or less) of other GAGs [5]. 
 
Like collagen and elastin fibres, the proteoglycans of ligaments are produced by the 
fibroblasts.  The process involves the synthesis of a protein core by the fibroblast's 
rough ER.  Extension and sulfation of the GAG chains then commence in the smooth 
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ER and are completed and transported in the Golgi apparatus.  The completed chains are 
finally released into the ECM by the fibroblast where they assemble with the protein 
core to form a proteoglycan monomer.  Proteoglycans also contain within their 
structure, a number of binding sites for growth factors such as transforming growth 
factor β (TGF-β).  The binding of such growth factors to proteoglycans leads to either 
their local aggregation or dispersion.  This can in turn inhibit or enhance the movement 
of migrating macromolecules or micro-organisms in the ECM [3].  There are two known 
classes of proteoglycans; small leucine rich proteoglycans, and large aggregating 
proteoglycans. 
 
Small Leucine Rich Proteoglycans (SLRPs) assist in the formation, organisation and 
stability of the ECM, including the formation and diameter of the collagen fibrils during 
fibrillogenesis.  They tend to lie directly on the surface of the collagen fibrils [28, 29].  A 
distinguishing feature of SLRPs is the presence of a central domain containing 6-10 
leucine-rich repeats in their protein core.  It is this domain that is responsible for the 
functional activity of proteoglycans [30-32].  In addition to their role in fibrillogenesis, 
SLRPs also protect the collagen fibrils from degradation by collagenases by limiting 
access to their cleavage site [33].  Four principle SLRPs found in ligament are decorin, 
biglycan, fibromodulin and lumican. 
 
Decorin and biglycan (which have the highest homology) and are both class I SLRPs.  
These proteoglycans contain an N-terminal domain that is usually substituted with 
either one (decorin) or two (biglycan) dermatan/chondroitin sulfate side chains and 10 
leucine-rich repeats [34, 35].  Decorin is the most abundant proteoglycan in the matrix of 
ligament.  It is estimated that it constitutes as much as 90% of the total ligament 
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proteoglycan content [36, 37].  Decorin is involved in several biological functions including 
modulation of cell adhesion, regulation of growth factor activity and inhibition of 
fibroblast proliferation [38-40].  It plays an important role in regulating collagen fibril 
organisation by retarding the rate and degree of collagen fibrillogenesis and delaying 
fibril maturation [41, 42].  It limits the diameter of collagen fibrils produced [40, 43], and as 
the GAGs of decorin extend laterally from adjacent collagen fibrils, it also assists in 
maintaining fibrillar spacing and prevents lateral fusion of fibrils [44].  Decorin 
preferentially binds to collagen types I and II collagen fibrils but can also bind to types 
III, VI and XIV [41].  Collagen fibrils may be linked together through the binding of 
GAG chains of adjacent decorin molecules resulting in a collagen-decorin-decorin-
collagen linkage. While the structure of decorin holds the collagen molecule tightly 
within its concave surface, the interaction between adjacent GAGs is not as strong as 
that between the collagen and decorin’s core protein.  Therefore the bond between 
decorin molecules is possibly the mechanically weakest point between collagen fibrils, 
and may be a breaking point during stretching [44]. 
 
Biglycan is closely related to decorin and the two compete for the same binding site on 
collagen I fibrils [31, 45].  Like decorin, it is involved in matrix organisation and regulation 
of fibrillogenesis, and can interact with a variety of other proteins and growth factors [30, 
37].  Biglycan is normally present in ligament at lower levels than decorin [15, 36], but is 
increased during ACL healing when it contributes to the rate of collagen fibril formation 
[37, 46, 47].  During this time decorin expression may be reduced, suggesting the two SLRPs 
have opposite expression patterns and play contrasting roles in ligament [48].  In addition, 
biglycan plays a role in the events of healing through regulation of cell migration, 
adhesion, signal transduction and proliferation [36, 38].   
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Lumican and fibromodulin are termed class II SLRPs.  Members of this class share an 
identical cysteine-rich region before the leucine rich repeats, and contain clusters of 
tyrosine sulfate residues in contrast to the N-terminal region of class I SLRPs.  They are 
primarily substituted with keratan sulfate chains [34, 35].  Lumican can bind to type I 
collagen and is normally expressed early in fibril development, with expression 
decreasing by 60-70% as fibrillogenesis progresses to the later stages [49].  It regulates 
fibrillogenesis with other SLRPs such as decorin and fibromodulin [31], and modulates 
the assembly of collagens into higher order fibrils [50].  Like decorin, it acts to inhibit 
collagen type I fibrillogenesis, reduces lateral fusion of fibrils, and limits ultimate fibril 
diameter, however the two SLRPs bind to separate site on the collagen fibril surface [43].  
It is a key modulator of ligament strength and enhances collagen fibril stability [51, 52], as 
well as functioning in wound healing and inflammatory responses [50]. 
 
Fibromodulin shares a common binding site with lumican [52, 53]. It is required for the 
maturation of collagen fibrils and it works in co-ordination with lumican in fibril 
assembly [31].  Fibromodulin contains up to four keratan sulfate chains and maintains a 
substantial interaction with the formed fibrils [51].  It has a higher affinity for the binding 
site than lumican and the two SLRPs have differential expression patterns during 
normal ligament development [49, 53, 54].  As fibrillogenesis progresses, lumican decreases 
to barely detectable levels whereas fibromodulin increases significantly indicating a 
more prominent regulatory role during the later stages, and determination of the mature 
fibril’s structural phenotype [43, 53].   
 
Large Aggregating Proteoglycans LAPs - maintain water within the tissue due to their 
long chains of negative charges. In doing so, they contribute to the mechanical 
properties of the tissue such as the ability to withstand compressive loading. The 
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proteoglycans swell as they attract water until they reach their maximum expansion and 
are restrained by the collagen fibril network, filling the regions between the collagen 
fibrils [10].  Ligament however, does not contain appreciable amounts of the huge 
proteoglycan aggregates that are characteristic of cartilage.  This is due to the fact that 
ligament is more subject to tensile forces rather than compressive loading [5, 15].  More 
recently, LAPs have also been identified as acting as a lubricant between collagen fibres 
due to their hydrophilic nature [15].  This class of proteoglycans tends to contain the 
GAGs chondroitin and keratan sulfate.  Aggrecan and versican are two primary 
examples of LAPs. 
 
1.3 THE CRUCIATE LIGAMENTS 
1.3.1  Structure and Function 
The cruciate (meaning crossed) ligaments are the main stabilisers of the knee joint [13].   
Their anatomy and function in humans is shown to be comparable to a number of 
animal species such as dogs [55, 56], sheep [57], goats [58], pigs [59], and rabbits [60].  This 
similarity across species is invaluable as it permits animal models to be utilised in the 
study of knee joint disease in humans, as well as facilitating the crossover of research 
from veterinary and medical disciplines.  
 
The knee joint contains two cruciate ligaments that course between the tibia and the 
femur (Figure 1.9).  They are known as the anterior cruciate ligament (ACL) and 
posterior cruciate ligament (PCL) in humans [13, 61], and the cranial cruciate ligament 
(CCL) and caudal cruciate ligament (CaCL) in animal species such as the dog [55, 56, 62].    
In this discussion it should be assumed that comments relating the ACL and PCL in 
humans also pertain to the CCL and CaCL in animals unless otherwise stated.    
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Both cruciate ligaments are intra-articular but extra-synovial structures as they are 
covered by a mesentery-like fold of synovium that is thought to protect the ligaments 
from the synovial fluid [13, 63, 64].  The PCL is the strongest ligament of the knee joint with 
approximately twice the strength of the ACL, and rupture of this ligament is less 
common [65, 66].  The superior strength of the PCL most likely stems from its larger cross-
sectional area and its extensive femoral attachment [66, 67].  The main function of the PCL 
is to prevent the posterior dislocation of the tibia in relation to the femur [65], also 
Figure 1.9: Anterior view of the knee joint in slight flexion showing the location 
of the cruciate ligaments (red text).  The quadriceps tendon has been cut and 
reflected distally to permit visualisation of the cruciates.  (Image from Marieb, 
2003). 
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referred to as tibial posterior tibial draw [66].  The PCL is made up of two functional fibre 
bundles known as the anterolateral (AL), and the posteromedial (PM), which become 
taught at different angles of knee flexion [67].  The AL bundle attaches to the femur at the 
roof of the femoral intercondylar notch, while the PM bundle attaches to the femoral 
intercondylar notch on the medial side.  Attachment of both bundles to the tibia occurs 
at the posterior intercondylar fossa [55, 66].  
 
Ligaments are attached to bones via direct or indirect insertions (or entheses), with 
direct insertions being the most common.  With indirect insertions, the ligament passes 
obliquely along the surface of the bone.  They tend to cover more bone surface than 
direct insertions and their boundaries are difficult to define [11, 68].  Direct insertions are 
where the ligament seems to pass directly into the bone cortex.  These regions are more 
easily defined and possess four morphologically distinct layers, namely ligament, 
uncalcified fibrocartilage, calcified fibrocartilage and bone.  There is a gradual 
transition through these layers at direct insertions.  The cruciate ligaments of the knee 
attach to the bone via direct insertion [13, 68, 69].  Ligaments transfer force to and from the 
skeleton, and distribute the loads applied to them dynamically in order to execute 
movement patterns.  Stress is concentrated in the region where they attach to bone, and 
these areas may be vulnerable to acute or overuse injuries [70].   
 
The ACL is the most significant ligament of interest in this study.  It is the smaller of 
the two cruciate ligaments and is much more prone to injury.  In both humans and dogs, 
ACL injury is well reported to be one of the most common causes of pelvic limb pain 
and joint instability [64, 71].   The ACL crosses the knee joint from the medial aspect of the 
lateral femoral condyle to the anterior aspect of the middle portion of the tibial plateau 
(also referred to as the intercondylar area) [72, 73].  Its main functions are the resistance of 
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anterior translation of the tibia with respect to the femur (anterior draw) and to limit 
hyperextension of the knee joint.  Secondary functions include resistance of internal 
rotation of the tibia during flexion of the knee, and resistance of valgus rotation of the 
tibia.  It also plays a minor role in preventing medial displacement of the tibia along 
with the collateral ligaments [64].   
 
Like the posterior ligament, the ACL is separated into two functional bundles, known as 
the anteromedial (AM) and the posterolateral (PL) based on the anatomic positions of 
the fascicular attachments of the tibial insertions. Observations have shown the fibres of 
the AM bundle originate most anteriorly on the femoral side and insert anteriorly and 
medially at the tibial point of attachment.  Therefore, as the name suggests, the fibres of 
the PL bundle course from the posterior part of the femoral attachment to the posterior 
and lateral aspect of the tibial attachment site.  Furthermore, the two bundles spiral 90 
degrees laterally between their attachments [74].  The AM and PL bundles are thought to 
have reciprocal functions, as the AM bundle is taut during flexion of the knee, and the 
PL bundle is taut in extension [75-77].   From a functional perspective, the AM bundle is 
the primary restraint against anterior tibial translation, while the larger PL bundle serves 
to stabilise the knee against rotary loads when the knee is near full extension [71, 78].     
 
Within these bundles are fascicles of wavy or undulating collagen fibres with a complex 
ultra-structural organisation and abundant elastic system, making it different to most 
other ligaments and tendons [72, 79].  The ACL is primarily comprised of type I collagen 
fibrils, orientated parallel to the longitudinal axis of the ligament, and which are chiefly 
responsible for the ligament’s tensile strength [13].  Type II collagen, although not 
typically found in ligament, is present in the ACL within the fibrocartilaginous regions 
of its tibial and femoral sites of attachment [64].  Type III collagen is found throughout 
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the ACL in the loose connective tissue dividing the type I collagen bundles, and in 
higher concentrations near the ligament’s attachment sites [13, 64].  Collagen types IV and 
VI may also be found in ACL in low concentrations.  Like other ligaments, the ACL 
contains GAGs and glyco-conjugates such as laminin, tenascin and fibronectin, which 
function to attract key elements in normal, healing and growing tissues.  Finally, ACL 
contains elastic components which protect the ligament from damage during times of 
extreme tension throughout normal joint motion [73]. 
 
1.3.2 Blood Supply and Innervation 
Compared to other connective tissues such as skin and bone, ligament is poorly 
vascularised [62].  Major blood supply to the cruciate ligaments comes from branches of 
the middle genicular artery (MGA) which arises from the anterior aspect of the popliteal 
artery [13, 64].  The distal regions of both cruciates are also supplied by branches of the 
middle and lateral inferior geniculate arteries [62, 68].  During its extra-capsular course, the 
MGA is immersed in the fat of the popliteal space.  It then pierces the posterior capsule 
of the joint, passing through an aperture in the oblique popliteal ligament [64, 68].  Within 
the joint the artery branches into the soft tissues lodged in the intercondylar notch such 
as the ACL and PCL.   
 
The cruciate ligaments themselves are covered by a layer of loose connective tissue 
called synovium where the blood vessels penetrate and form an epiligamentous network 
[14].  Anastamoses exist between the extra and intra-ligamentous blood networks where 
the epiligamentous blood vessels penetrate the transversely into the cruciate ligaments 
[62].  The blood vessels penetrate the ligament substance via small diameter vascular 
channels which lie parallel to the collagen bundles [80].  No intra-ligamentous vessels 
transverse the femoral or tibial attachment site of either cruciate ligament [64].   In 
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addition to this vascular contribution, the cruciate ligaments may also receive 
nourishment by passive permeation from the synovial fluid [80, 81].  
 
Blood vessel distribution within the cruciate ligaments is not homogenous [73].  The mid 
section or central core of both the ACL and PCL is generally less vascular than the 
proximal and distal ends [14].  Furthermore, blood supply to the central core of the ACL 
is further compromised by pressure exerted by the PCL as the two ligaments twist upon 
each other during the course of normal joint movement.  Research has shown blood 
supply to the ACL in general tends to be less than the PCL, possibly contributing to the 
poor healing capacity of this ligament [13].   A number of avascular regions have also 
been identified within the cruciate ligaments, including the fibrocartilaginous zones of 
the femoral and tibial insertion sites of the ligaments, as well as a region located in the 
distal zone of fibrocartilage adjacent to the roof of the intercondylar fossa [73].    
 
The nerves supplying the cruciate ligaments come from the saphenous, tibial and 
common peroneal nerves.  The main trunk of the nerve bundle can be found at the 
femoral end of the cruciates where greater numbers of mechanoreceptors are located [62].  
Within the cruciate ligaments the nerves course alongside the blood vessels in the 
interfascicular areolar spaces [62].  Their function is thought to be primarily associated 
with the autonomic nervous regulation of blood supply to the ligaments and in the 
perception of pain signalling injury [82].  Free nerve endings have been discovered in the 
cruciates which are activated by an increase in ligament tension.  This sensory 
mechanism provides the central nervous system with information about proprioception 
and when stimulated, these nerve endings signal to muscles to adjust their tension and 
stabilise the joint, preventing possible injury [83]. 
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1.3.3 Cruciate Ligament Rupture 
The ACL is one of the most frequently injured ligaments of the knee [84, 85].  Together 
with the MCL it accounts for 95% of all multi-ligament injuries in the knee joint, 
leading to significant functional impairment, joint instability and degenerative damage 
[86]. To date, the precise pathophysiology of ligament rupture is not known but is thought 
to be multifactorial, with joint inflammation, mechanical loading, musculature, gender, 
age, ligament microinjury and ischaemia all considered to be contributing factors [87].    
 
1.3.3.1 Inflammation 
Inflammatory changes, involving multiple knee joint structures such as the synovial 
membrane, epiligament and synovial fluid, are typical in patients with ACL rupture [88].  
It is not known whether this inflammation precedes or follows ligament rupture, but it 
has been hypothesised that in dogs it develops in the early phase of cruciate disease [89].  
It is well established that rupture of the cruciate ligaments, in particular the anterior 
ligament, leads to joint instability and subsequent development of osteoarthritis (OA) 
with associated inflammation [90].  Even if the ligament is not completely ruptured, 
degeneration of normal ligament structure causes increased laxity and can lead to OA [89, 
91-94].  While we know in human subjects OA and associated inflammation is a 
consequence of ACL rupture following trauma, less is known about the influence of 
pre-existing inflammation (such as from pre-existing knee OA or synovitis) on the 
development of ligament disease in the absence of trauma.    
 
Cushner et al. (2003) histologically evaluated the ACLs from 19 human knees with OA 
[95].  They found these ACLs showed degenerative changes that were not observed in 
normal control knees.  The authors identify osteophyte formation in the intercondylar 
notch leading to mechanical destruction of the ACL as a possible cause; however the 
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ligaments exhibited widespread histological changes throughout the ligament, not just at 
the intercondylar notch.  This indicates the degenerative changes in the ligament could 
be due in part to some other aspect of the inflammatory process.     
 
Mullaji et al. (2008) again studied the histology of ACLs and PCLs from 45 
osteoarthritic human knee joints and evaluated the frequency of and severity of 
degenerative changes in the ligaments [96].  They found the ACL was severely 
degenerated or absent in knees with more advanced radiologic OA (higher than grade 
3).  The PCL was only moderately affected regardless of the severity of OA.  They 
concluded that OA causes degeneration of both cruciates, with the ACL being more 
severely degenerated than the PCL in OA.  These results were consistent with the 
findings of a similar study performed Allain et al. (2001) [97]. 
 
Hill et al. (2005) evaluated the prevalence of ACL and PCL rupture among human 
subjects with established OA of the knee [91].  Results showed ACL rupture is more 
common among those with symptomatic knee OA, but fewer than half of subjects with 
rupture of this ligament recalled a specific knee injury.  This may suggest chronic 
degeneration of the ligament leading to eventual rupture, or that OA preceded ligament 
rupture.   
 
A number of canine studies have identified immune-mediated responses may play a role 
in CCL degeneration.  Muir et al. (2007) recently hypothesised that chronic synovitis 
induces CCL degeneration and a significant reduction in the tensile strength of the 
ligament. From the results of their study they conclude that inflammation likely 
develops in the early phase of cruciate disease before the development of stifle 
instability.  Their findings suggest that immune responses within the stifle may be 
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involved in the persistent synovitis and associated joint degradation in dogs with 
arthritis and degenerative CCL rupture [89].   Several other studies support the hypothesis 
that inflammation within the synovium in dogs with CCL rupture is at least in part 
immune mediated.  The inflammatory process is thought to weaken ligament collagens 
due to the activity of biochemical factors such as collagenases and gelatinases (known 
as matrix metalloproteinases).  Anti-inflammatory treatment therefore has the potential 
to slow degradation of the ligament and could even prevent ligament rupture [14, 98-100]. 
 
It has been established in both humans and animals that ligament injury does more than 
just affect the articular cartilage.  It also puts strain on other ligaments of the joint 
leading to a breakdown of normal architecture, and can affect other joint components 
such as the menisci, synovium and subchondral bone [86].  Funakoshi et al. (2007) used 
an ovine model to demonstrate that intact ligaments in joints with an injured ACL are 
also impacted by the injury.   In particular, the intra-articular structures such as the PCL 
were more significantly affected than the extra-articular MCL and LCL.  The intact 
ligaments showed an increase in water content and cell density, and collagen fibril 
diameter distribution was significantly altered.  Furthermore, Nelissen et al. (2001) 
showed that intact ligaments, such as the PCL, in human knees with ACL rupture are 
architecturally damaged [101].  As the PCL is rarely ruptured under normal conditions, its 
degeneration could be a result of inflammatory mediators associated with the rupture of 
the ACL and/or subsequent OA, or changes in mechanical loading due to joint 
instability.   
 
1.3.3.2 Mechanical loading 
Degeneration due to repetitive micro-trauma may also be the cause of cruciate rupture.  
Micro-trauma leads to disruption of normal architecture of the ligament such as loss of 
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‘crimp’ and destruction of ligament fascicles [56, 100].  Crimp is an accordion-like wave 
pattern of ligament cells, fibres and matrix, which provides a buffer against mechanical 
loading, so that any rapid or excessive load will stretch out the undulations without 
damaging the tissue (Figure 1.10) [11].  Abnormal loading conditions can arise for a 
number of reasons.  These include excessive weight of the subject [74], the influence of 
surrounding musculature [102, 103], excessive physical activity such as sport [104].   
Although acute ligament injury can occur due to a single overload from trauma, ACL 
rupture usually results from progressive adaptive or degenerative changes within the 
core of the ligament [87].  Ligament degeneration and injury during sporting activity may 
occur via a combination of number of different mechanisms such as internal and 
external tibial torque (with the foot planted and the knee near full extension), straight 
anterior tibial force (e.g. landing after jumping), hyperextension and hyper-flexion, and 
frontal-plane or transverse-plane loading (e.g. during rapid deceleration) [103, 105-108].   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: ACL (Tol Blue 200x) longitudinal section, showing the wave-pattern or crimp in the 
collagen fibres of the ligament.  This stain has a high affinity for the glycosaminoglycans and elastin 
fibres (which stain a darker blue) present in ligament [109]. (Image A. Daniel).  
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Another factor that has been identified as contributing to abnormal loading in dogs is 
the angle of the tibial plateau.  A steeper tibial plateau angle (TPA) is thought to 
increase cranial tibial thrust and contribute to CCL rupture [110-112].  In humans, an 
excessively steep TPA does not ordinarily occur, but can if the patient has undergone an 
open wedge high tibial osteotomy.  This purpose of this procedure is to alter the weight-
bearing axis of the knee joint to relieve pressure on damaged joint surfaces in patients 
with osteoarthritis.   In some patients however, an unintended outcome of this procedure 
is an increase in TPA [113].   As in dogs, the increased TPA can lead to increased cranial 
tibial thrust and result in cruciate rupture [114].   
 
1.3.3.3 Age 
Throughout life, the biomechanical properties of the cruciate ligaments change.  As the 
subject reaches maturation, there is an increase in the quality and quantity of the cross-
linkages and collagen content of the ligaments.   Then with increasing age, the amount 
of cross-linkages and collagen content begins to decrease.  Therefore the risk of cruciate 
rupture may be greater in older subjects, as the ligaments are less capable of 
withstanding mechanical load [115].  
 
1.3.3.4 Gender 
Gender can be another risk factor affecting ligament rupture in both humans and dogs.  
It is well reported in human studies that females have a much higher incidence of ACL 
injury than do males engaged in similar activities [116-119].  A number of theories have 
been suggested to explain why this disparity exists, but as yet the exact reason has not 
been elucidated.  Studies in dogs have revealed a similar predisposition in females [120-
122].  This literature concerning the role of sex hormones on ligament structure and 
function is reviewed in detail in Chapter 4.   
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1.3.4 Cruciate Ligament Healing Capacity 
Healing in the knee joint is ligament specific.  Some ligaments such as the MCL have 
good healing potential whereas others such as the ACL have a very poor chance of 
healing, especially in the case of complete rupture [88, 123].  Ligament healing depends on 
the response of the tissue to injury. The normal stages of healing in ligament can be 
outlined as follows: 
The Bleeding and Inflammatory Phase - lasts for up to 3 days post injury.  Bleeding and 
oedema occur and there is an acute inflammatory response involving 
polymorphonuclear leukocytes, monocytes/macrophages, lymphocytes, mast cells, and 
the release of inflammatory mediators.  Platelets are also activated and growth factors 
such as PDGF are up-regulated.  Blood escaping from the injured blood vessels forms a 
clot at the injury site. Fibrin accumulates within the clot and platelets bind to fibrillar 
collagen providing haemostasis.   The clot provides a framework for vascular and 
fibroblast cell invasion.  Endothelial cells accumulate near the injury site forming new 
capillaries [68, 124-126].   
 
The Repair Phase – lasts from 1 to 2 days up to 6 weeks post injury.  Early in this phase 
the water content of ligament is high.  The rate of new collagen synthesis continues to 
rise until it peaks at around 3 weeks post injury.  Fibroblasts within the wound begin to 
proliferate rapidly and synthesise new matrix.  The clot and any necrotic tissues are 
replaced with a soft, loose, fibrous matrix consisting of water, GAGs and type II 
collagen.  At this stage, any movement such as premature exercise is extremely 
detrimental to the normal orientation of the new collagen fibres, and can result in bulky 
scar tissue and adhesions.  After the 3-week stage, gradual mobilisation of the joint can 
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assist in increasing the tensile of the repairing tissue.  The water and GAG content of 
the ligament decreases and type I collagen replaces the type II collagen [29, 68, 126].  
 
The Remodelling Phase – lasts from approximately 6 weeks to 6 months post injury.  
By this stage the water content of the ligament has returned to normal while the 
collagen content remains slightly increased.  The tissue is still highly cellular with 
limited tensile strength.  As the scar tissue slowly matures, the number of cells 
decreases and the fibrils become orientated in the direction of greatest load.   The 
maturing ligament gradually acquires the properties of normal tissue, however the 
repaired tissue will never regain the tensile strength of uninjured ligament tissue.   
Usually repaired ligament has approximately 50-70% of normal tensile strength [68, 125-127].  
 
Importantly, injuries to extra-capsular structures tend to repair successfully via the 
above stages of healing.  In contrast, intra-capsular structures such as the ACL often fail 
to produce a successful repair response [128].  The exact reason for the poor healing 
capacity of the ACL remains unclear may be due to a number of factors.    One cause 
may be the disruption of any local clot due to the synovial fluid environment and the 
presence of proteases.  This combined with non-contact between the two ends of the 
injured ligament may contribute to the lack of repair [72].  A study by Murray et al. in 
2000 evaluated healing in 23 ruptured human ACLs.  Results revealed no evidence of 
tissue bridging between the femoral and tibial remnants of the ACL at any time after 
rupture.  They observed that the remnants of ACL appeared to retract after rupture thus 
preventing a bridging scar from forming.  They also noted the formation of a layer of 
synovial tissue over the ruptured surface, which may further impede repair of the 
ligament [129]. 
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When Murray et al. (2006) examined the healing of ruptured CCLs in dogs, they too 
found that no stabilised fibrin clot formed between the ligament remnants, even after 
induced bleeding into the joint.  They found that a gap persisted at the rupture site 
despite attempts at suture repair or gross reapproximation of the tissue edges [130]. 
Hayashi et al. (2003) also found a complete lack of bridging scar between the ends of 
ruptured CCL [87].  This may be explained by the activity of collagenases.  Amiel et al. 
(1989) investigated acute ACL injury in a rabbit model and observed a rapid 
degenerative process within the ligament, with loss of cellularity and matrix 
organisation.  This was associated with a significant increase in collagenase activity and 
a decrease in total collagen content, which may explain the rapid degeneration of the 
remnants of the injured ligament and the persistence of a gap that cannot be bridged [131].  
Muir et al. (2006) reported similar findings in a canine model of CCL rupture [100].   
 
Other explanations for the poor healing capacity of ACL relate to differences in 
collagen synthesis and cell migration to the injury site.  Wiig et al. (1991) compared the 
levels of procollagen type I mRNA in normal and healing MCL and ACL in rabbits [132].  
Results showed that procollagen mRNA levels were significantly higher in MCL than 
ACL, which may contribute to the differences in the healing capacities of these 
ligaments.  Chen et al. (2002) reported similar findings in their study of fibroblast cells 
from rabbit ACL and MCL [133].  Although they found ACL and MCL cells exhibited 
similar morphology, there were significant differences in cellular growth and the 
synthesis of collagen.  Studies by Nagineni et al. (1992) and Geiger et al. (1994), also 
studied cultured cells from explants of ACL and MCL [134, 135].  Results from both studies 
revealed that ACL cells demonstrated a much lower migration potential than MCL cells. 
The poor ability of ACL cells to migrate to the site of injury again may contribute to the 
reduced healing potential of the ACL.   
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1.4  STUDY OVERVIEW 
From this literature review, it is clear that little is known about changes in ligaments in 
OA, and what influences ligament cell metabolism.  The ligament of major interest in 
humans is the ACL, which is a major stabiliser of the knee joint, and is commonly 
injured.   Ligament damage associated with trauma can contribute to OA through 
destabilisation of the joint and subsequent abnormal wear and tear, but the role of 
ligament degeneration in the pathogenesis of OA in the absence of trauma remains 
unclear.     
 
In addition, current literature suggests there is an association between OA and the 
decline in oestrogen levels at menopause.   It is uncertain whether changes in hormone 
levels primarily affect articular cartilage, or whether the degeneration of other joint 
tissues which are oestrogen-responsive, such as cruciate ligaments, may contribute 
significantly to the pathogenesis of OA.  In a recent review of literature on the role of 
hormones in the modulation of connective tissues and the associated risk of knee OA, 
Boyen et al. (2013) highlighted that numerous gaps exist in our knowledge in this area 
[136].  They identified a lack of research into sex-based differences in knee osteoarthritis 
involving age-appropriate female models, and that many studies fail to recognise the 
importance of sexual heterogeneity in the hormonal control of knee connective tissues.   
An important objective of this study was to expand on current knowledge in this area.   
 
The overall aim of this thesis was to investigate the influence of ovariectomy and/or the 
presence of concurrent OA on the fibrillar structure of collagen within the anterior 
cruciate ligament.   Chapter 2 outlines the research tools and methods used in both main 
studies (Chapters 3 & 4), and also describes a preliminary trial which was conducted to 
 
 
39
determine if there were any significant molecular differences between the anterior and 
posterior cruciate ligaments, and whether or not the results of ACL testing would be 
representative of both cruciate ligaments.   
 
Chapter 3 presents the results of a study of the effect of OA separately on the structure 
and gene expression in ACL using a bilateral meniscectomy model of OA.  Chapter 4 
investigates the effect of oestrogen deficiency on ACL tissue, using an ovariectomy 
model to simulate menopause.   It also looks at the effect of oestrogen deficiency in 
combination with OA (combined meniscectomy and ovariectomy), simulating the knee 
joint of a postmenopausal subject with OA. 
 
The major hypotheses examined in Chapters 3 & 4 are listed here, and are repeated at 
the conclusion of the introduction of each chapter. 
 
Chapter 3:   THE INFLUENCE OF MENISCECTOMY ON THE ANTERIOR 
   CRUCIATE LIGAMENTS OF SHEEP 
 
 
Hypothesis 1: that osteoarthritis (meniscectomy) alters gene expression and collagen 
fibril structure and organisation in ACL.  
 
Hypothesis 2:  animals with worse osteoarthritic changes have more severe ligament 
derangement.   
 
 
 
Chapter 4:   THE INFLUENCE OF OVARIECTOMY ON THE ANTERIOR 
  CRUCIATE LIGAMENTS IN NORMAL AND    
  OSTEOARTHRITIC (MENISCECTOMISED) SHEEP 
 
 
Hypothesis 3: that the decrease in ovarian hormone levels associated with menopause 
(ovariectomy) alters the normal composition and organisation of cruciate ligament 
tissue, in particular collagen fibril structure, which has the potential to influence the 
mechanical properties of the ligament, as observed in other connective tissue types 
post-menopause.     
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Hypothesis 4: that the combined effects of ovariectomy and meniscectomy have an even 
greater influence on ligament composition and structure than either meniscectomy or 
ovariectomy alone, and that these changes reflect those of postmenopausal women with 
concurrent osteoarthritis. 
 
 
Finally, Chapter 5 provides an overview of the results of this project, by reviewing each 
of the four hypotheses and whether each was proved/supported or not.   Avenues for 
possible further investigation are also suggested.  
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CHAPTER	2	
	
	
	METHODS	AND	MATERIALS	
	
 
 
2.1 EXPERIMENTAL GROUPS 
All animal experiments were approved by the Murdoch University Animal Ethics 
Committee and conducted in accordance with the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes - 7th Edition.  Animals were selected 
for uniformity of size, conformation, soundness of health and for absence of lameness.  
On introduction to the Murdoch University farm, the sheep were ear tagged for 
identification, and vaccinated against clostridial diseases and Corynebacterium 
pseudotuberculosis [Glanvac 6, CSL Australia].  All sheep were also treated 
prophylactically for endo- and ectoparasites [Ivomec Liquid for sheep (ivermectin), 
MSD Agvet, Australia; Vanquish (alphamethrin 50g/L), SmithKline Beecham, 
Australia] and to prevent footrot [Footrite (zinc sulphate 224g/L), Hardman, Australia].  
All sheep were kept on the same pasture at the Murdoch University farm with 
supplementary feed given when necessary.   
 
2.1.1 Preliminary Study  
12 size-matched, four year old ewes were randomly separated into two groups of six 
sheep.  The first group underwent ovariectomy (OVX1) and the second served as non-
operated control group (NOC1).  Six months (26 weeks) post surgery, both groups were 
sacrificed and samples of both ACL and PCL were harvested for PCR analysis of gene 
expression.  The purpose of this preliminary study was to test the PCR protocols and 
primers, and to assess whether there were any differences in gene expression between the 
anterior and posterior cruciate ligaments. 
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It is evident that study groups OVX1 & NOC1 are similar to groups I & K described in 
the main study (2.1.2).   It was necessary to replicate these groups in the main study for 
three reasons.   Firstly, to confirm that the results obtained in the preliminary study were 
repeatable.  Secondly, for all samples in a study to be directly comparable, they had to be 
batch processed all at the same time.  This removes any influence that slight differences 
in processing or reagents may introduce; therefore it was necessary to repeat the OVX 
and NOC groups in the main study.    Finally, the main study was conducted over a 
longer experimental period than the preliminary study (36 weeks vs. 24 weeks) in order 
to determine whether any outcomes increased or decreased over time.  The results of the 
preliminary study are presented in Chapter 4 along with those of the main study. 
 
Sheep tag numbers: 
 
OVX1 439 445 448 453 1049 1060 
NOC1 409 414 432 433 437 442 
 
Table 2.1: Ear tag numbers of the sheep assigned to each treatment group; OVX1 and NOC1. 
 
2.1.2 Main Study  
This larger study involved a total of 24 size-matched, four year old ewes.  They were 
randomly assigned to four experimental groups (see table 2.2), consisting of six sheep 
each.  
 
Sheep tag numbers: 
 
Group H 03 08 10 21 27 58 
Group I 69 70 71 72 77 94 
Group J 68 76 78 79 95 / 
Group K 45 52 60 63 91 92 
 
 
Table 2.2: Ear tag numbers of the sheep assigned to each treatment group in the main study.  One sheep 
died prematurely of bloat during the course of the experiment (groups J).  This individual was therefore 
excluded from the study. 
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The four experimental groups were assigned the following treatment protocols: 
H. Ovariectomised, meniscectomised, sacrificed at 36 weeks. 
I. Non-operated control 
J Meniscectomised only, sacrificed at 36 weeks. 
K. Ovariectomised only, sacrificed at 36 weeks. 
 
 
 
Treatment Group Sacrificed 36 weeks Focus of Study 
OVX:                           (May 07) 
MENX:                        (May 07) H (Feb 08) 
Testing the effect of 
OVX & MENX. 
No OVX                            - 
No MENX                         - I  
Sacrificed (Mar 08) 
NOC group 
No OVX                            - 
MENX:                        (June 07) J (Mar 08) 
Testing the effect 
of MENX. 
OVX:                           (Nov 06) 
No MENX                         - K (Aug 07) 
Testing the effect 
of OVX. 
 
Table 2.3: Summary of main study, 24 sheep were divided into 6 treatment groups as indicated,H,I,J,K. 
OVX = Ovariectomised, MENX = Meniscectomised, NOC = non-operated control.   
 
 
2.2 SURGICAL PROCEDURES 
2.2.1  Anaesthesia  
All surgical procedures were performed under general anaesthesia in aseptic conditions 
in a surgical setting. Food and water was withheld from the evening prior to surgery.  
Immediately prior to surgery, general anaesthesia (GA) was induced using intravenous 
injection of diazepam (5mg/ml) /ketamine (100mg/ml), [Pamlin, Parnell Labs Aust Pty 
Ltd] [Ketamine, as ketamine hydrochloride, Parnell Labs Aust Pty Ltd], 50:50 mixture 
administered at 1ml/10kg and maintained with 2% inhaled Isoflurane (1ml/ml) [I.S.O. 
VCA Veterinary Companies of Aust Pty Ltd] delivered via a Fluotec 3 vaporiser, and a 
circle circuit with a size 11 endotracheal tube.  Analgesia was provided with carprofen 
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anti-inflammatory injection (50mg/ml) at 3mg/kg, [Tergive, Parnell Labs Aust Pty Ltd] 
and 1ml of morphine sulfate (10mg/ml), given prior to recovery.  Post-operative 
analgesia was maintained for the first three days post surgery with morphine sulfate 
and/or carprofen injection as required. 
 
2.2.2 Meniscectomy 
Bilateral medial meniscectomy was performed on groups B, C, G, H & J, under general 
anaesthesia in a sterile surgical setting.  Both knee joints were clipped free of wool and 
aseptically prepared using alternating swabs of 2% Chlorhexidine surgical skin cleanser 
[Tasman Chemicals Pty Ltd, Aust] and 70% alcohol.  The surgical approach was the 
same for both knees, with a medial skin incision made over the joint allowing access to 
the medial meniscus.  The medial meniscus was removed using a combination of 
scalpel (#15 blade) and a meniscotome, which allowed the meniscal ligaments to be cut 
without damaging the joint surface.  The joint was then flushed with sterile saline and 
closed by routine surgical methods using absorbable suture; 3/0 polydioxanone [PDS II, 
Ethicon, USA] for the retinacular and facial layers, and 3/0 poliglecaprone [Monocryl, 
Ethicon, USA] for the skin layers.  Both joints were treated in an identical manner.  A 
prophylactic intravenous injection of 1g cephazolin [as cephazolin sodium, Hospira 
Australia Pty Ltd] diluted in 10ml sterile saline was administered during surgery.  The 
sheep were housed indoors, in pens with non-slip flooring, for an observation period of 
three days post surgery before being returned to pasture.    
 
2.2.3 Ovariectomy 
Ovariectomy was performed on sheep in groups H & K in the main study, and in group 
OVX1 in the preliminary study.  Surgery was again performed under general 
anaesthesia in aseptic conditions in a sterile surgical setting. Food and water was 
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withheld from the evening prior to surgery.  The sheep were ovariectomised via a 5cm 
ventral midline coeliotomy through the linea alba, placed approximately 5cm forward of 
the cranial border of the mammary gland.  Both ovaries were located and externalised 
from the body cavity, the ovarian pedicle clamped and then ligated using 3/0 
polydioxanone [PDS II, Ethicon, USA], and all ovarian tissue was removed.  The uterus 
was left intact.  The incision was closed using 3/0 polydioxanone for the linea alba, 3/0 
poliglecaprone [Monocryl, Ethicon, USA] for the subcutaneous tissues and the skin.  
The skin sutures were dissolvable and placed intradermally, thus avoiding the need for 
suture removal.  Recovery from anaesthesia was monitored for two days post surgery, 
with the sheep housed in pens inside the barn, after which they were released back onto 
the pasture.    
 
2.3 SACRIFICE AND TISSUE COLLECTION 
2.3.1 Preliminary Study 
After six months the sheep were sacrificed by intravenous injection of 20ml of 
pentobarbitone sodium (300mg/ml) [Valabarb, Jurox Pty Ltd, Australia] and the right 
anterior (cranial) and posterior (caudal) cruciate ligaments were immediately harvested 
and snap frozen in liquid nitrogen.  Tissues were processed for RT-PCR analysis only.   
 
2.3.2 Main Study 
 
At the time of sacrifice for all groups, the sheep were killed by intravenous injection of 
20ml of pentobarbitone sodium (300mg/ml) [Valabarb, Jurox Pty Ltd, Australia].  Both 
the left and right femorotibial joints were immediately dissected and the anterior (cranial) 
cruciate ligaments harvested under aseptic conditions.  The ligaments were dissected free 
of all other tissues and separated from the joint.  The more fibrocartilaginous segments of 
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ligament near the origins and insertions were not included.  Of the harvested ligament, the 
proximal 2/3 of tissue was snap frozen in liquid nitrogen and stored at -80 degrees C.  The 
remaining distal 1/3 of the ligament tissue was fixed in 10% neutral buffered formalin for 
48 hours, before being transferred to 70% ethanol for storage.  Frozen tissue from the 
proximal 2/3 of the ligament was processed for RT-PCR analysis & biochemistry, and 
formalin-fixed tissue from the distal 1/3 of the ligament was processed for histology and 
electron microscopy.  The articular surfaces of the femur and tibia were photographed for 
morphological assessment and samples of cartilage and synovium taken for histological 
analysis.  This was done to confirm the presence of OA in the meniscectomised sheep.     
 
 
2.4 MOLECULAR BIOLOGY 
All details of the methods used, and the reagents & equipment required for the 
homogenisation of the ligament, extraction of RNA, and reverse transcription of RNA 
to cDNA are provided in the following: 
 
2.4.1 Tissue Homogenisation 
 
2.4.1.1 Equipment Required: 
 
 Sterile Petri dishes 
 Single-sided razor blades 
 Tissue forceps 
 RNAse-free 1.5ml tubes 
 Dewar flask with liquid nitrogen 
 Dry ice 
 Stainless steel plate 
 Gloves 
 Kim wipes 
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 Absorbent pads 
 Tube rack  
 1000ul pipette with sterile, RNase-free filter tips 
 UltraSpec RNA Isolation Reagent (Fisher Biotec BL-10200/WS) 
 RNase AWAYTM Reagent  (Invitrogen SKU# 10328-001) 
 Mikro-dismembrator laboratory ball mill (with 3ml Teflon chambers, o-rings 
and stainless steel ball bearings) 
 Polystyrene tray (Esky lid) 
 2 x 250ml Glass beakers with milli-Q water  
 Electronic scale (3 decimal places) 
 
2.4.1.2 Preparations for Tissue Homogenisation: 
 
 Ensure gloves are worn at all times to prevent contamination by RNases.   
 Using RNase AWAY, wipe over bench-tops and soak the forceps, Teflon 
chambers, o-rings, ball bearings and Petri dishes.  Then rinse in distilled water 
and pat dry with Kim wipes. 
 Fill polystyrene tray with dry ice and place metal plate on top to cool. 
 Fill one beaker with pure milli-Q water and the other with RNase AWAY Place 
absorbent pads beside beakers. 
 Place mikro-dismembrator on a hard, stable surface and plug in to power. 
 Fill Dewar flask with liquid nitrogen and add samples to be homogenised. This 
will keep the tissue frozen prior to processing. 
 Place Petri dish on scale and tare. 
 Label the 1.5ml tube with group, tag #, tissue type and date. 
 
2.4.1.3 Homogenising the Tissue: 
 
 Place the ball bearing and o-ring in the lid of the Teflon chamber. 
 Ensure the UltraSpec is well mixed as it can separate during storage. Pipette 1ml 
of UltraSpec into the bottom of the chamber. 
 Weigh out 10020mg of ligament or cartilage for homogenisation.  This is the 
appropriate amount of tissue for 1ml of UltraSpec and for adequate RNA yield.  
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 If the tissue requires chopping, place a Petri dish on the cold metal plate and cut 
the tissue samples using a single sided razor blade.  A Kim-wipe placed over the 
tissue sample while chopping will prevent it flicking out of the Petri dish.   It is 
essential to work quickly and keep the tissue frozen at all times. 
 Drop the frozen tissue into the chamber with the UltraSpec, place on the lid, 
insert into the mikro-dismembrator and shake at 1800 rpm for 90 seconds.   
 Remove the ball bearing and immediately wipe with a Kim-wipe and rinse in 
beaker with milli-Q water as UltraSpec corrodes metal. 
 Using a new pipette tip, collect the homogenate and place in a labelled 1.5ml tube. 
 Wipe the chamber, o-ring and lid clean with a Kim-wipe and place them, along 
with the ball bearing, into in the RNase AWAY.  After a few minutes rinse again 
in milli-Q water and allow to drain on an absorbent pad.   Pat dry with Kim wipe 
before use again.    Repeat procedure between each sample.   
 Let tubes with homogenate sit at room temperature for 30-45minutes before 
storing at -80°C.   
 
2.4.2 RNA Extraction 
2.4.2.1 Equipment Required: 
 
 Qiagen RNeasy Mini Kit spin columns 
 Qiagen RNase-Free DNase Set 
 Molecular Biology (Analytical) Grade Ethanol 70% 
 Pure RNase-free water 
 Chloroform 
 RNAse-free 1.5ml tubes 
 Incubator or water bath at 37C. 
 Centrifuge 
 Tube rack 
 Gloves 
 Ice  
 Kim wipes 
 RNase AWAYTM Reagent  (Invitrogen SKU# 10328-001) 
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2.4.2.2 Preparations for RNA Extraction: 
 
 Ensure gloves are worn at all times to prevent contamination by RNases.   
 Using RNase AWAY, wipe over bench-tops and surface of centrifuge.  
 Thaw frozen tubes containing tissue/UltraSpec homogenate at room 
temperature.  The maximum capacity of the centrifuge is 24 samples. 
 Label a set RNAse-free 1.5ml tubes to match the homogenate tubes. 
 Label a set of collection tubes from Qiagen kit to match original samples. 
 Label a set of spin columns from Qiagen kit to match original samples. 
 
2.4.2.3 Retrieving the Aqueous Phase: 
 
 Add 300ul of chloroform/ml UltraSpec to each tube and vortex for 15 seconds. 
 Allow tubes to stand at room temperature for 3-5 minutes. 
 Spin tubes at 12,000 rpm for 15 minutes (room temperature). 
 Transfer the aqueous phase to the pre-labelled 1.5ml tubes using a separate 
pipette tip for each sample.  Recovery should be about 600ul per ml UltraSpec.   
 Discard the tubes with the pink phenol phase in the contaminated waste. 
 Add equal volumes of 70% ethanol to each aqueous phase. 
 Seal lids and mix gently by inversion. 
 Tubes may sit at room temperature for up to 30mins at this stage. 
 
2.4.2.4 Loading the Spin Columns: 
 
 Ensure spin columns have their collections tubes underneath them at all times 
during extraction process.  Failure to do so will likely cause contamination of 
the final RNA preparation.   
 Load 600ul of the aqueous/EtOH phase onto spin column membrane.  This step 
should be performed in a tube rack not the centrifuge to prevent contamination 
of this instrument.   If the total volume of the aqueous/EtOH phase exceeds 
600ul, the remainder is loaded at a later stage. 
 Transfer the spin columns with collection tubes to centrifuge and spin at 12,000 
rpm for 15 seconds. 
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 Empty each collection tube into waste container and place back under spin 
column.   
 Load any remaining aqueous/EtOH phase into appropriate spin column and spin 
again at 12,000 rpm for 15 seconds.   
 Empty each collection tube into waste container and place back under spin 
column. 
 
2.4.2.5 Washing the Spin Columns: 
 
 Load 350ul of RW1 (from kit) into each spin column and let sit for 5 minutes. 
 Spin at 12,000 rpm for 15 seconds. 
 Empty and discard collection tube. 
 Place a new collection tube underneath spin column. 
 Remove DNase set from freezer and make up a master mix containing 10ul 
DNase and 70ul DNase buffer (from kit) per sample.  For every 10 spin columns 
make up enough master mix for 11.  This will allow for pipette wastage.   
 Add 80ul of the DNase/buffer master mix to each spin column using a new tip 
for each sample.   
 Spin at 12,000 rpm for 15 seconds to saturate the column membrane with 
DNase. Then re-apply the DNase/buffer mix from the collection tube onto the 
spin column again using a new tip per sample.  Ensure the DNase is applied 
directly onto the column membrane.   
 Incubate at 37C for 1 hour. 
 After the incubation period, spin again at 12,000 rpm for 15 seconds. 
 Load another 350ul of RW1 (from kit) into each spin column. 
 Spin at 12,000 rpm for 15 seconds. 
 Empty each collection tube into waste container and place back under spin 
column. 
 Load 500ul of RPE buffer (from kit) into each spin column. 
 Spin at 12,000 rpm for 15 seconds. 
 Empty each collection tube into waste container and place back under spin 
column. 
 Load another 500ul of RPE buffer into each spin column. 
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 Spin at 12,000 rpm for 15 seconds. 
 Empty each collection tube into waste container and place back under spin 
column. 
 Spin at 12,000 rpm for a further 2 minutes to evaporate the EtOH and dry the 
column.   
 Empty and discard the collection tubes. 
 Transfer the spin columns to the pre-labelled 1.5ml tubes supplied with the kit. 
   
2.4.2.6 Eluting the RNA: 
 
 Depending on the expected yield, load 30-100ul of RNase free water into each 
column.  For this study 32ul of water was loaded into each column. 
 A new pipette tip should be used for each sample to prevent cross-
contamination.  
 Ensure the water is placed directly onto the column membrane.   
 Incubate the tubes at room temperature for 10-15 minutes. 
 Spin at 12,000 rpm for 1 minute.   
 Discard spin columns. 
 Place tubes containing eluted RNA on ice. 
 Measure the RNA yield using the Nanodrop ND1000 spectrophotometer (in 
SABC).  This spectrophotometer requires only 1ul of sample to quantify RNA 
content.   
 Freeze tubes at -80C if not continuing to reverse transcription stage. 
 
 
2.4.3 Reverse Transcription of RNA to cDNA 
2.4.3.1 Equipment Required: 
 Qiagen Omniscript RT kit 
 Bioline Random Hexamer Primers 50ng/ul 
 Promega RNasin® Plus RNase Inhibitor 40units/ul 
 1000ul, 200ul, 20ul pipette with sterile, RNase-free filter tips 
 RNAse-free 1.5ml tubes 
 RNAse-free water 
 
 
52
 Incubator and water bath or heating block. 
 Centrifuge 
 Tube rack 
 Ice 
 Gloves 
 Kim wipes 
 RNase AWAYTM Reagent  (Invitrogen SKU# 10328-001) 
 
2.4.3.2 Preparations for Reverse Transcription of RNA: 
 
 Ensure gloves are worn at all times to prevent contamination by RNases.   
 Using RNase AWAY, wipe over bench-tops. 
 Label a set of tubes to match RNA sample. 
 Check incubator is set to 37C. 
 Check water bath or heating block is set to 93C. 
 Dilute RNase inhibitor to 10U/ul using 1xRT buffer. 
 The amount of RNA to be reverse transcribed must be the same for all samples. 
 All samples must be Reverse transcribed at the same time.   
 Total RT volume is 40ul = 10ul master mix + RNA and water up to 30ul. 
 Determine the volume of sample required for 1ug of RNA (volume required to 
yield 1ug must be less than 30ul). 
 Calculate the volume of water (if any) required for total volume to = 30ul. 
 Check stocks of all reagents required for the RT master mix.  For 50 reactions 
the master mix volumes required are as follows: 
 
 
 200ul 10x RT Buffer (supplied in Omniscript kit) 
 100ul dNTP (supplied in Omniscript kit) 
 100ul random hexamer primers 
 50ul RT enzyme (supplied in Omniscript kit) 
 50ul RNase inhibitor 10U/ul 
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2.4.3.3 Procedure for Reverse Transcription of RNA: 
 
 Pipette the appropriate amounts of RNA/water into each pre-labelled tube as per 
calculations. 
 In a separate tube, make up RT master mix as previously described.  Ensure 
contents of the tube are well mixed.  Store on ice until required. 
 Using a new tip for each sample, pipette 10ul of RT master mix into each 
sample tube containing RNA/water. 
 Spin samples quickly in the centrifuge (12,000 rpm for 15secs). 
 Incubate samples for 1 hour at 37C. 
 Then incubate samples for 5 minutes in a water bath or heating block at 93C. 
 Following this incubation, cool samples quickly on ice for 5 minutes. 
 For real time PCR analysis add 150ul of water per ug of original RNA to each 
sample.  This gives a total volume of 190ul of cDNA for analysis. 
 cDNA samples are stored at 4C while in use, and at -20C or -80C long term. 
 
 
2.4.4 Real Time PCR Analysis 
2.4.4.1 Equipment Required: 
 
 Bioline ImmoMix™ reaction mix 
 Primers – forward and reverse 
 Sybrgreen I working dilution 10x 
 cDNA 
 Molecular Biology RNase-free water grade water 
 RNAse-free 1.5ml tubes 
 RNAse-free 25ul Rotor Gene strip tubes 
 1000ul, 200ul, 20ul pipette with sterile, RNase-free filter tips 
 Rotor-Gene 6000 PCR analyser 
 Tube rack 
 Ice 
 Gloves 
 Kim wipes 
 RNase AWAYTM Reagent  (Invitrogen SKU# 10328-001) 
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2.4.4.2 Experimental Procedure: 
 
 Ensure gloves are worn at all times to prevent contamination by RNases.   
 Using RNase AWAY, wipe over bench-tops. 
 If frozen thaw cDNA samples.  Make a pooled sample by taking a small volume 
from each cDNA sample.  Using this pooled sample created a set of cDNA 
standards (4 fold dilutions labelled, 1:10, 1:40, 1:160 and 1:640). 
 Stock Sybrgreen I at a concentration of 10,000x must be diluted to the correct 
working dilution.  Make 1ml of 1000x solution by adding 1ul stock to 1000ul 
molecular biology grade water.  Protect from light by wrapping tube in foil.  
Any remaining working dilution can be stored in the -20 freezer but should be 
discarded after 2 days. 
 Dilute primers in molecular biol grade water to a working dilution of 10uM. 
 Total PCR volume is 25ul = 20ul PCR master mix + 5ul cDNA or standards. 
 Create a PCR master mix by combining ImmoMix, Sybrgreen, forward and 
reverse primers, and water according to the following ratio per sample: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Combine PCR master mix by gentle inversion and spin down for 10 seconds.  
 Calculate how many tubes you will need.  Use 1 per sample and 2 per standard 
with 2 non-template controls (NTC). 
 Place the correct number of tubes in rack and carefully pipette 20ul of PCR 
master mix into each.  Avoid bubbles and place solution well within tube to 
allow room for the cDNA.  
 The same tip can be used to pipette out the master mix. 
Water   3.50ul 
ImmoMix 12.50ul 
Sybrgreen   2.50ul 
Forward primer 0.75ul 
Reverse primer 0.75ul 
Total volume 20.00ul 
Table 2.4: PCR master mix ingredients totalling 20ul, for a final PCR 
volume of 25ul with standards or sample added. 
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 Make sure the standards and cDNA are homogenous and all at the base of the 
tube, especially if they were frozen.  If there is condensation in the tubes, mix by 
inversion and spin down. 
 Add 5ul of cDNA, standard or NTC to appropriate tube.  Use a new pipette tip 
for each addition (including replicates). 
 Pipette the standards first (starting with the highest standard), as the machine 
uses the first tube to automatically set the gain.   
 Cap the tubes tightly.  No need to mix or invert the tubes. 
 Load the tubes into the rotor in the correct order and fill any vacant spaces with 
empty balance tubes.   
 Place the locking ring firmly on rotor and insert the rotor into machine, lining up 
pin correctly. Close lid. 
 Using Rotor-Gene software, set annealing temperature (according to primer 
used), times and cycle number.  Check gain (usually 8-9) and start run.   
 
Appendix 1 shows an example of a quantitation report and melt curve analysis 
generated by the rotor-gene software, including the run settings used.  Appendix 2 is a 
list of all primer sequences used in this study and their annealing temperatures. 
 
 
 
2.5 BIOCHEMICAL ANALYSIS 
Total sulfated glycosaminoglycan (S-GAG) and collagen content was assayed using 
separate protocols.  For SGAG a dimethylmethylene blue dye binding technique was 
used (Farndale method).  Collagen was analysed using a papain digest in combination 
with a dimethylaminobenzaldehyde reagent for colour formation.  Details of these 
protocols and the equipment used is provided below.   
 
2.5.1 Sulfated Glycosaminoglycan (S-GAG) 
2.5.1.1 Equipment Required:  
 
 Microcentrifuge tubes 
 Pipette tips (VistaLab, Ovation) 
 Single pipette (20ul, 200ul, 1000ul) 
 Multichannel pipette  (VistaLab, Ovation 12 channel, 5-250ul) 
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 Analytical balance 
 96 well micro-titre plates (Sarstedt, Round Bottom Wells, single use) 
 Microcentrifuge 
 Tube racks 
 pH meter 
 Micro-titre plate reader (Opsys MR manufacturer Dynex Technologies USA, 
distributor DKSH Australia Pty Ltd) 
 Computer software (Microsoft Excel 2007) 
 Papain 
 Milli-Q H2O 
 Sodium Formate 
 Formic Acid 
 1,9 Dimethylmethylene Blue 
 Glycine 
 NaCl 
 0.1M HCl 
 Chondroitin Sulfate 
 
2.5.1.2 Tissue Preparation: Papain Digest 
 
 Freeze dry all tissue samples prior to weighing. 
 Accurately weigh out 5-10mg (dry weight) of each tissue sample and put into a 
1.5ml screw top tube.   
 Set incubator to 100ºC and prepare papain digestion buffer as follow for 
1000ml. 
 Dissolve 3.72g of EDTA disodium salt in enough PBS to make up to 1000ml 
then adjust pH to 7.4.  This pre-papain buffer can be stored on the shelf until 
required.  Immediately before use add 0.79g L-cysteine HCL and readjust pH to 
7.4.  For each ml of buffer add 2ul of papain suspension.   If smaller volumes of 
papain digestion buffer are required, scale volumes accordingly.   
 Add 1ml of prepared papain digestion buffer per 5-10mg of tissue sample.   
 Place samples into a sealed container with milli-Q soaked gauze to maintain 
humidity.  Cartilage samples should be incubated overnight (16 hours) and 
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checked to ensure complete digestion has taken place.  Ligament samples may 
take up to 3 days, with daily checking to assess if digestion is complete.   
 Digests may be frozen at -80ºC for some time prior to assaying.   
 Prior to use, frozen digest must be thawed, vortexed vigorously to resuspend the 
precipitated material, then centrifuged at high speed for 2-5 minutes.  The clear 
supernatant should be used for analysis. 
 
2.5.1.3 Experimental Procedure: 
 
A. 0.2% Sodium Formate pH 3.0 
1.00g of Sodium Formate dissolved in 200ml of Milli-Q H2O and pH adjusted to 3.0 
using Formic acid.  Transfer solution into 500ml volumetric flask; fill to the 500ml 
mark with Milli-Q H2O. 
 
B: Farndale Reagent  
Dissolve 3.2mg of 1,9 Dimethylmethylene Blue (DMMB) (Sigma Chemical Co) in 
19ml of 0.1M HCl, add 608mg of Glycine and 474mg of NaCl.  Make up to 200ml with 
Milli-Q H2O and adjust the pH to 3.0.  Protect the reagent from light in an amber bottle 
or cover with aluminium foil and store at room temperature.  Under these conditions the 
reagent lasts for up to 3 months. 
 
C: Standard Solutions 
Prepare a stock solution of Chondroitin Sulfate (ChS) (Sigma Chemical Co) by 
dissolving 10.0mg of ChS in 10ml of Milli-Q H2O.   
200ul of this stock ChS solution is placed in a 1.5ml microcentrifuge tube and 800ul of 
0.2% Sodium Formate pH 3.0 is added.   
A standard curve is prepared using the following ChS dilutions in triplicate in a 96 well 
plate.   
 
CSA conc. (ug/well) Working CSA solution (ul) 0.2% Na Formate (ul) 
0.0 0.0 20.0 
0.4 2.0 18.0 
0.8 4.0 16.0 
1.2 6.0 14.0 
1.6 8.0 12.0 
2.0 10.0 10.0 
2.4 12.0 8.0 
2.8 14.0 6.0 
 Table 2.5: Chondroitin Sulfate standard curve dilutions for a 96 well plate. 
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D: Sample Preparation 
If tissue digests are frozen allow samples to defrost at room temperature then vortex 
vigorously to resuspend precipitated material then spin sharply for 2-5min in a 
microcentrifuge at full speed. This ensures the cloudy/insoluble material will settle at 
the bottom and the clear supernatant containing the soluble S-GAGs will read correctly 
on the plate reader.  Prepare a 1:10 dilution of the clear supernatant in a labelled 
microcentrifuge tube using Milli-Q H2O.  This solution may be further diluted in 0.2% 
Na Formate (1:10, 1:20, 1:100 etc) depending on the anticipated S-GAG content of the 
samples.   
 
E: Generation of the Chromophore 
In triplicate, pipette 10ul of each of the dilutions of unknowns (as prepared above) into 
each well followed by 10ul of 2.0% Na Formate pH 3.0.  To each well (standards and 
unknowns) add 200ul of the prepared Farndale reagent using the multichannel pipette.  
Immediately read the absorbance at 540nm using the micro-titre plate reader.   
 
Calculate the S-GAG content of each unknown sample from the standard curve using 
the absorbance and the plate reader software.  Convert values expressed as ug/well to 
ug/ml and calculate the % GAG contained in the unknown samples from these values 
using the appropriate dilution conversions. Ref: Farndale RW, Buttle DJ, Barrett AJ, 
Improved quantitation and discrimination of sulfated glycosaminoglycans by use of 
dimethylmethylene blue. Biochim Biophys Acta., 1986. 883(2): p. 173-7 1986 [137]). 
 
2.5.2 Collagen 
 
2.5.2.1 Equipment Required:  
 
 Microcentrifuge tubes 
 Pipette tips (VistaLab, Ovation) 
 Single pipette (20ul, 200ul, 1000ul) 
 Multichannel pipette  (VistaLab, Ovation 12 channel, 5-250ul) 
 Analytical balance 
 96 well micro-titre plates (Sarstedt, Round Bottom Wells, single use) 
 Adhesive plate covers (temp safe up to 110ºC) 
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 Microcentrifuge 
 Tube racks 
 Micro-titre plate reader (Opsys MR manufacturer Dynex Technologies USA, 
distributor DKSH Australia Pty Ltd) 
 Computer software (Microsoft Excel 2007) 
 Milli-Q H2O  
 pH meter. 
 Citric acid monohydrate 
 Glacial acetic acid 
 Sodium acetate trihydrate 
 Sodium hydroxide 
 Hydrated chloramine T 
 N-propanol 
 NaCl salt 
 P-dimethylaminobenzaldehyde 
 60% perchloric acid 
 6M hydrochloric acid solution 
 6M sodium hydroxide solution 
 Hydroxyproline 
 
2.5.2.2 Tissue Preparation: Acid Digest 
 
 Take 200ul of papain digest and pipette into a screw-top 1.5ml tube. 
 Place tubes into incubator oven at 90°C overnight without the lids to allow 
samples to dry.     
 When completely dry, add 100ul of 6M HCl and seal tubes tightly with a lined 
screw cap. 
 Place tubes in 110°C oven for 16 hours (overnight).  Samples may become 
discoloured (brown) after acid digestion. 
 Allow tubes to cool to room temperature then add 100ul of 6M NaOH to the 
hydrolysate and mix well. 
 Allow tubes to stand on bench to settle. 
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2.5.2.3 Experimental Procedure: 
 
A. Stock Buffer 
Combine 5.0g of citric acid monohydrate, 1.2ml of glacial acetic acid, 12.0g sodium 
acetate trihydrate and 3.4g of sodium hydroxide in 100ml of aqueous solution (pH 
approx 5.75). 
 
B. Assay buffer 
Prepare assay buffer by diluting the stock buffer tenfold with Milli-Q water. 
 
C. Chloramine T reagent 
Dissolve 1.41g of chloramine T (hydrated form) in 20.7 ml of Milli-Q water.  Add 26ml 
of n-propanol and 53.3ml of stock buffer.  This makes 100ml of reagent.  To make up 
enough reagent for one plate use: 0.282g chloramine T, 4.14ml Milli-Q water, 5.2ml n-
propanol and 10.6ml of collagen assay buffer.  Prepare reagent on the day required. 
 
D. Dimethylaminobenzaldehyde (DMAB) reagent 
Suspend 1.5g of p-dimethylaminobenzaldehyde in 6.0ml of n-propanol, followed by the 
slow addition of 2.6ml of 60% perchloric acid.  This reagent must be freshly prepared. 
 
E. Standard Curve: 
Prepare a set of standards using 0 - 3.5ug of hydroxyproline (use 0 - 35ul of a 10mg 
OH-pro/100ml solution made up with Milli-Q water).   
The following table outlines the volumes of each standard required per well.  For each 
assay, standards are pipetted out in triplicate so volumes will need to be multiplied by 
3.5 (allowing for wastage) to produce a full standard curve for each plate.  The total 
volume of each standard = 40ul per well. 
 
OH-pro conc. (ug/well)     OH-pro solution (ul)  Milli-Q water (ul)
0.0 0.0 40.0 
0.5 5.0 35.0 
1.0 10.0 16.0 
1.5 15.0 14.0 
2.0 20.0 12.0 
2.5 25.0 10.0 
3.0 30.0 8.0 
3.5 35.0 6.0 
 
 Table 2.6: Hydroxyproline standard curve volumes.
 
 
61
F: Generation of the Chromophore 
Pipette 40ul of each standard out in triplicate.  To each standard add 10ul of 3M NaCl to 
bring the total volume of each standard to 50ul.  Dilute unknown samples as required 
and pipette out 50ul in triplicate.   
 
Add 50ul of assay buffer to all wells followed by 50ul of freshly prepared chloramine T 
reagent using a multi-channel pipette.  Shake the plate and allow to stand for 20 
minutes.   
 
During the 20 minute waiting period the DMAB colour reagent is freshly prepared.  50 
ul of DMAB is added to each well, the plate is shaken again, sealed with an adhesive 
plate cover and incubated at 60°C for 15 minutes.  After the incubation period allow 
plate to sit at room temperature for a further 15 minutes, then read at 562nm. 
NB during determination of the collagen content of the unknowns, a conversion factor 
of 7.4 for OH-pro must be incorporated into the calculations.  Appendix 3 shows an 
analysis report produced by the Opsys MR micro-titre plate reader, from which the 
statistical analysis was generated. 
 
 
 
2.6 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
For examination using TEM, the ligament was processed in the following way: 
 
2.6.1 Processing of Biological Tissue:  
 Transfer small (1mm x 3mm) cut tissue samples into sample vials. 
 Fix tissue in 5% glutaraldehyde overnight at 4°C.   
 Replace glutaraldehyde with enough 1% Dalton’s chrome OsO4 to cover the 
tissue well.  This step should be performed in a fume hood. 
 Shake bottles to increase tissue exposure and keep in refrigerator for 
approximately 1½ hours.  Shake at regular intervals during exposure time. 
 Wash tissue in several changes of 90% alcohol over 5 minutes. 
 Wash in 95% alcohol for 5 minutes. 
 Wash in 3 changes of absolute alcohol over 10 minutes. 
 Wash in 2 changes of propylene oxide over 10 minutes. 
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 Leave in 60:40 solution of propylene oxide/epoxy (Epon) resin for 1 hour. 
 Leave in epoxy resin overnight on a rotator with lids off at room temperature.  
 Embed tissue in capsules using fresh epoxy resin and bake at 60°C for 24 hours 
until hardened. 
 Trim blocks to a rhomboid shape using a razor blade to expose tissue. 
 Cut thin sections at approximately 0.5µ thickness and place onto a 200 mesh 
copper grid.   
 Stain grids, first with uranyl acetate then with lead citrate. 
 
2.6.2 Image Analysis 
 
 
 Examine grids under transmission electron microscope.  Two images are 
captured of each tissue sample at 37000x from different regions of the grid.  All 
grids are examined blind.  Images are recorded on negatives, developed then 
printed in the darkroom.   
 Hard copy images from the microscope are then digitally scanned as JPEG 
images.  The digital images are modified using Adobe Photoshop CS to enable 
analysis using Image J64 (National Institutes of Health, USA, 
http://rsb.info.nih.gov/ij/).  An example of a modified image is shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: A) an original TEM image of ACL showing collagen fibrils in transverse 
section.  B) the same image after Adobe Photoshop CS  modification for image analysis 
by Image J64.  
A B
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Figure 2.2: Adjusting the threshold in the Image J64 image analysis program to establish which 
pixels of the TEM image will be analysed. 
 
Figure 2.3: After applying the threshold, the dimensions of the collagen fibrils are clearly 
recognisable, and measurements can be obtained for individual surface area and Feret diameter 
(diameter at the widest point).   
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2.7 SCANNING ELECTRON MICROSCOPY (SEM) 
Small cubes (approx 4mm3) of formalin fixed ACL tissue were cut with the fibril 
bundles in cross-section using a scalpel.  2 samples were taken from each test group. 
Samples were washed in several changes of alcohol at 30%, 50%, 70%, 80%, 90%, 
95%, and 100%, and then washed in 50:50 super-dry:amylacetate for 30 minutes.  
Samples were then washed in 2 changes of amylacetate over 2 hours after which they 
were placed in the critical point dryer for several hours.  Following tissue processing, 
the samples were mounted with the cut surface of the tissue facing up, on a metal pin-
type SEM specimen stub using double sided carbon adhesive tape.  The base of each 
stub was labelled with the specimen number and then placed in a Balzers Union SCD 
020 sputtering device, in which each sample was coated with gold/palladium for a 
period of 2 minutes.  Once coated, the samples were viewed using a Phillips XL-20 
scanning electron microscope and TIF. images captured on computer at a magnification 
of 170x and 2000x.  
 
 
2.8 GROSS MORPHOLOGICAL ASSESSMENT 
 
After sacrifice, each joint was removed and dissected free of surrounding soft tissues 
such as muscles and tendons (shown below).   
 
 
 
 
 
 
Figure 2.4:  Removal of surrounding structures and separation of the femorotibial joint.  
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At this time, samples of cruciate ligament and synovium were harvested for further 
examination.   Both the femoral and tibial articular surfaces were visibly assessed for 
signs of cartilage degradation and the presence of osteophytes, in order to confirm the 
presence or absence of osteoarthritis.  Prior to cartilage sample collection, both articular 
surfaces were digitally photographed and separately scored for cartilage damage and 
osteophyte formation by a single blinded operator.  Each surface is assigned a score of 0 
to 3 for osteophyte formation and 0 to 4 for morphological cartilage changes according 
to the following grading system: 
 
 
 
Gross articular cartilage damage – score each separately  Score  
Assessment of joint margin of: Femoral articular surface  
 Tibial articular surface  
   
   
Normal  0 
Surface roughening  1 
Fibrillation and fissures  2 
Small erosions down to subchondral bone (<5mm)  3 
Large erosions down to subchondral bone (>5mm)  4 
Add to give cartilage damage score  0-8 
 
Osteophyte development – score each separately  Score  
Assessment of joint margin of: Femoral articular surface  
 Tibial articular surface  
   
   
Normal  0 
Mild osteophyte development (<2mm outgrowth or 
<20% of joint margin) 
 1 
Moderate osteophyte development (2-4mm outgrowth 
or 20-50% of joint margin) 
 2 
Large osteophyte development (>4mm outgrowth or 
>50% of joint margin) 
 3 
Add to give osteophyte score  0-6 
Table  2.8: Macroscopic scoring of cartilage (reproduced with permission, Little et al, 2010). 
Table 2.7: Macroscopic scoring of osteophytes (reproduced with permission, Little et al, 2010). 
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An average score was calculated for osteophytes and cartilage degradation for both joint 
surfaces for each group.    
 
 
 
 
 
 
 A B
 C D
 
 
 
Figure 2.5:  Photographs demonstrating the morphological appearance of both joint 
surfaces at either extreme of the cartilage integrity scale.  A= Grade 0 femoral 
surface; B= Grade 0 tibial surface; C= Grade 4 femoral surface; D= Grade 4 tibial 
surface.  Note the Grade 0 surfaces exhibit normal architecture with no signs of 
disruption to the smooth and glossy articular cartilage.  This is compared to the 
Grade 4 surfaces which show large areas of cartilage degradation with deep lesions 
and fissures (arrows). Note the scale at the bottom of each photo is 1mm for small 
graduations.      
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2.9 HISTOLOGY 
Details of the protocol for the processing of ligament for histological section, and the 
special stains used are outlined below.     
 
2.9.1 Processing of Ligament Tissue 
 
 Fix the ligament samples in 10% neutral buffered formalin for 48 hours, using 
10-20 times the amount of fixative to tissue. 
 Soften ligament in 10% formic acid/2.5% formalin for 48 hours. 
 Transfer to 70% ethanol (tissue can be stored indefinitely in 70% alcohol). 
 Trim tissue samples to fit cassettes. 
 Tissue must spend at least 24 hours in 70% ethanol. 
 Soak in 80% ethanol for 5 hours. 
 Soak in 95% ethanol for 5 hours. 
 Soak in 100% ethanol for 3 hours. 
 Change 100% ethanol and soak for further 3 hours. 
 Change 100% ethanol and soak for further 3 hours. 
 Change 100% ethanol and soak for further 3 hours. 
 Soak in methyl benzoate for 3 days.  (Note methyl benzoate is noxious and must 
be used in sealable containers in a fume hood at all times). 
 Change methyl benzoate and soak for 3 days. 
 Change methyl benzoate and soak for 3 weeks. 
 Rinse with 3 changes of chloroform - 15 min each. 
 Wax infiltration with Paraplast XTRA for 4 days under vacuum, with 2 wax 
changes per day.  
 Wax embedding in Paraplast Plain. 
 To cut the block, position it so that the cutting edge of the blade is parallel to the 
direction of the ligament fibres.  
 Soften blocks for at least 30 min in 5% formic acid/45% ethanol/50% glycerol 
on a cold plate. 
 Rinse in cold water then keep on cold plate. 
 Cut sections at 5 microns on a microtome with Feather blades N35. 
 Float sections on water bath filled with milli-Q water at 50 degrees C. 
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 Attach sections to SuperFrost Ultra Plus slides (Menzel) and immediately place 
slide in incubator at 85 degrees C. 
 After 30 min, reduce temperature to 55 degrees C and leave overnight.  
  Cut two sections for each sample, one for standard haematoxylin & eosin 
(H&E) staining and one for special staining with toluidine blue (Tol Blue). 
(Method - S. Smith, Raymond Purves Bone and Joint Research Laboratory, Royal 
North Shore Hospital, Sydney). 
 
2.9.2 Special Stains – Toluidine Blue 
 Add sections to 70% ethanol for 15 min. 
 Stain in 0.04% Toluidine Blue O (C152040)/0.1M sodium acetate buffer pH 4.0 
for 10 min. 
 Rinse quickly in tap water. 
 Stain in 0.1% Fast Green FGF (C142053) for 2 min. 
 Rinse quickly in tap water. 
 Dehydrate quickly in 99% isopropyl alcohol, 2 changes, and clear in 2 changes 
of xylene. 
 Mount with Eukitt's mounting medium.  
 
(Modified from two methods in Getzy, L.L.M., Charles J.; Goldberg, Victor M.; 
Moskowitz, Roland W., Factors Influencing Metachromatic Staining in Paraffin-
Embedded Sections of Rabbit and Human Articular Cartilage: A Comparison of the 
Safranin O and Toluidine Blue O Techniques Journal of Histotechnology, 1982. 
5(3): p. pp. 111-116(6) [138].  
  
2.9.3 Processing of Cartilage Tissue 
After gross morphological assessment, histological slides were prepared from each of 
the four regions: MFC, LFC, MTP and LTP.  The following method was used to 
prepare the sections. 
 Obtain osteochondral slices (approximately 3mm thick) from each region by 
bandsaw cuts in the medio-lateral plane, perpendicular to the articular surface. 
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 Cuts should be positioned in the femoral condyles at the point of tibial contact in 
normal stance, and in the tibial plateaux at the level of the intercondylar 
eminences. 
 Fix bone slices in 10% neutral buffered formalin for 48 hours, then decalcify in 
10% formic acid / 5% formaldehyde for seven days. 
 Specimens are then washed and dehydrated in increasing alcohol concentrations 
from 70-100%.   
 Double-embed slices in methyl benzoate/celloidin and paraffin wax, and cut 
4μm sections using a rotary microtome. 
 Adhere slices to glass slides (Superfrost Plus, Menzel Gläcer, USA), and 
deparaffinised in 70% alcohol for 15 minutes. 
 Stain in 0.04% toluidine blue / 0.1M sodium acetate buffer (10 minutes), then 
0.1% fast green (2 minutes), dehydrate in isopropanol then xylene then apply 
coverslip.    
 
2.9.4 Processing of Synovial Membrane   
Synovial specimens were fixed in 10% neutral buffered formalin for 24 hours, washed 
and dehydrated in increasing alcohol concentrations from 70-100%.   They were then 
cleared in chloroform, infiltrated and embedded in paraffin wax.   4μm sections were 
cut using a rotary microtome, adhered to glass slides (Superfrost Plus, Menzel Gläcer, 
USA), and stained with haematoxylin and eosin (H&E).      
 
2.9.5 Histopathology 
The histological sections of synovium and cartilage were scored according to the 
following scoring systems. 
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Criteria Score Observation 
Intimal hyperplasia 0 1-2 layers only 
 1 3-4 layers, focal  
 2 >  5 layers, focal 
 3 >  5 layers, diffuse 
Lymphocytic/plasmacytic infiltration 0 None 
 1  One focus of infiltration 
 2 2-5 foci of infiltration 
 3 Diffuse infiltration or > 5 foci 
Subintimal fibrosis (loose connective 
tissue areas only) 
0 None 
 1 Light focal collagenous staining up to 30%  
 2 Heavy focal or total light diffuse 
collagenous staining 
 3 Heavy diffuse collagenous staining 
Vascularity 0 0-2 vascular elements per 100x field 
 1 3-4 vascular elements per 100x field 
 2 5-8 vascular elements per 100x field 
 3 >8 vascular elements per 100x field 
Aggregate score (joint) 0-12 Sum of the scores obtained for the four 
criteria above 
 
 
Table 2.9:  Microscopic scoring of ovine synovial histopathology (reproduced with permission) [139]. 
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Structure (score the worst area in field of view)    
Normal 0 
Slight surface irregularities (surface barely disturbed) 1 
Moderate surface irregularities (surface roughened) 2 
Severe surface irregularities (disruption, fissuring/fibrillation to < 10% depth) 3 
Fissures to transitional zone (1/3 depth) 4 
Fissures to radial zone (2/3 depth) 5 
Fissures to calcified zone (full depth) 6 
Erosion or severe fibrillation to mid zone (1/3 depth) 7 
Erosion or severe fibrillation to deep zone (2/3 depth) 8 
Erosion or severe fibrillation to calcified zone (full depth) 9 
Erosion or severe fibrillation to subchondral bone 10 
Chondrocyte density (“average” score for whole field of view in non-calcified 
cartilage) 
 
Normal 0 
Increase or slight decrease 1 
Moderate decrease 2 
Severe decrease 3 
No cells 4 
Cell cloning (score the whole field of view)  
Normal 0 
Several doublets 1 
Many doublets 2 
Doublets and triplets 3 
Multiple cell nests or No cells in section 4 
Interterritorial Toluidine blue (score the worst area in field of view working 
from AC surface down) 
 
Normal 0 
Decreased staining to mid zone (1/3 depth) 1 
Decreased staining to deep zone (2/3 depth) 2 
Decreased staining to calcified zone (full depth) 3 
No staining 4 
Tidemark/calcified cartilage/subchondral bone (score the worst area in field 
of view) 
 
Intact subchondral bone plate + single tidemark 0 
Intact subchondral bone plate + duplicated tidemark 1 
Blood vessels penetrate through subchondral bone plate to calcified cartilage 2 
Tidemark penetrated by blood vessels 3 
 
Table 2.10:  Microscopic scoring of ovine cartilage (modified Mankin system).  See Figure 2.6 for 
representative examples of each score. (reproduced with permission) [140] 
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Figure 2.6: Representative toluidine blue/fast green stained sections of cartilage from sheep with 
meniscectomy-induced OA, to demonstrate the features associated with the pathology scores for the 
different parameters outlined in Table 2.9.  A higher magnification image is included for cell cloning to 
demonstrate doublets, triplets and multiple cell nests (clusters). Reproduced with permission M. Cake[140]. 
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2.10 STATISTICAL METHODS 
 
Cartilage and Synovium 
Cartilage and synovium samples for all treatment groups were scored by a single 
blinded reader and the results collated.  Statistical analysis for treatment effect was 
performed using Kruskal-Wallis nonparametric analysis and for specific between group 
comparisons using Mann Whitney U nonparametric analysis with p<0.05 considered 
significant.  
 
Ligament  
Measurements of ACL fibril diameter, fibril area, fibril density and number of fibrils for 
each group were carried out using an image analysis program (Image J64, National 
Institutes of Health, USA, http://rsb.info.nih.gov/ij/), and the data collated using an 
Excel spreadsheet (Microsoft Office Excel 2007).  Statistical analysis for treatment 
effect was performed using a one-way analysis of variance (ANOVA) across treatment 
groups, with Fisher’s protected least significant difference (PLSD) pairwise 
comparisons tests to compare treatment group means.  For molecular and biochemical 
analysis, result reports were generated by device software programmes (Rotor-Gene 
Real-time Analysis Software 6.1© Corbett Research, and Revelation Quicklink Assays 
Statistics DLL Version 4.24 respectively).   Gross morphology scoring was again 
performed by a single blinded reader and the results presented in an Excel spreadsheet.  
For each method of investigation, statistical analysis for treatment effect was performed 
using a paired, one-tailed, T-test.  A significance level of p<0.05 was applied.     
 
The association of OA score with decorin and elastin concentrations, and fibril 
diameter, within the MENX treatment group was explored using simple regression. The 
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R square was used as a measure of association with R square greater than 0.80 
considered strong association. SAS 9.3 (SAS Institute, Cary, NC). 
 
In all analyses, the left and right joints of each sheep were treated as independent events 
rather than repeated measures of the same event.  From a pure statistical standpoint, this 
could be regarded as a weakness in the statistical methodology used in these studies.  
This decision was made for the following reasons: 
1. Meniscectomy (MENX) represents a significant surgical insult to the joint.  
Although ovine MENX is recognized as providing a repeatable model of OA, 
the response to surgery within an individual joint does vary in severity.  The 
magnitude of this variation was considered to be greater than that caused by 
genetic variation between individual sheep, which supports the view that the 
data from each joint can be regarded as individual events. 
 
2. Large animal experimental models require large budgets, and are associated with 
significant animal welfare issues.  Minimising the number of animals used is an 
economic as well as a welfare issue.  To minimize the number of animals in 
these experiments, bilateral surgery was performed, providing the possibility of 
two joints for analysis per animal.  Unilateral surgery decreases the tissue 
available for analysis and provides no advantage in reduction of animal numbers 
by providing an internal control to replace a separate control group. The 
contralateral limb cannot be considered a non-operated control due to the effects 
of abnormal loading in response to surgery on the contralateral limb (ref). 
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3. Three different treatment effects were examined in these studies – MENX, OVX 
and the combined effect of MENX+OVX.  Having resolved that left and right 
joints could be regarded as individual events due to variation in surgical 
response, the structure of the studies required that the joints from the OVX alone 
groups were treated likewise for the purpose of statistical analysis. 
 
4. The ACL tissue from each joint was analysed using biochemical and molecular 
techniques, as well as for structural analysis (histopathology, TEM and SEM), 
requiring significant amounts of tissue that are only available from a large 
animal model, which then creates the conflicts outlined above. 
 
The impact of this potential weakness in statistical methodology on the interpretation of 
the results of these experiments will be discussed in Chapter 5. 
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CHAPTER	3	
	
	
	THE	INFLUENCE	OF	MENISCECTOMY	ON	THE	ANTERIOR	CRUCIATE	
LIGAMENTS	OF	SHEEP	
 
 
 
3.1 INTRODUCTION 
3.1.1 The Structure of Cartilage 
Cartilage is a tissue of mesenchymal origin and is found at numerous sites throughout 
the body.  Cartilaginous tissues are classified histologically as being elastic, fibro-
cartilaginous or hyaline depending on their molecular composition [141-143].  Here the 
focus will be placed on a specialised type of hyaline cartilage known as articular 
cartilage, which is found covering the articular surfaces of synovial joints.  It functions 
to provide a smooth, low-friction, gliding surface for the articulating bones of the joint, 
and enables the joint to withstand compressive loads.  This shock absorbing ability 
minimises peak pressures on the subchondral bone, preventing wear of the joint's 
underlying structures under normal conditions [142, 144]. 
 
3.1.1.1 Chondrocytes 
Structurally articular cartilage is a dynamic, highly organized tissue, comprised of a 
single cell type, the chondrocyte, located within an extracellular matrix (ECM) [145-147]. 
Chondrocytes make up 1-5% of the wet weight of cartilage and are only sparsely spread 
throughout the ECM, generally with no cell-to-cell contact.  These spheroid-shaped 
cells are responsible for the synthesis and maintenance of the matrix infrastructure [142, 
145].  As cartilage is an aneural, alymphatic and avascular tissue, the chondrocytes 
receive their nutrition and hormones by diffusion through the ECM from the synovial 
fluid, and survive on a low oxygen concentration via anaerobic metabolism.  The 
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metabolic function of these cells is influenced by mechanical loading forces placed on 
the joint [142, 145, 147].   
 
3.1.1.2 Extracellular Matrix 
The ECM itself is comprised of a complex network of collagen fibres, elastin, 
hyaluronic acid, proteoglycans (mostly aggrecan and some other small leucine-rich 
proteoglycans), cartilage link proteins, fibronectin and water [142, 144, 146].  65-80% of the 
wet weight of cartilage is water, depending on the depth from the articular surface.  This 
high water content facilitates the transport of nutrients through the matrix and is a 
medium for lubrication, thus creating a low-friction gliding surface.  The water content 
is fixed within the tissue and allows deformation of the cartilage in response to 
compressive loading, therefore protecting the underlying joint surfaces from trauma [141, 
142, 148].  
 
3.1.1.3 Collagen 
The tensile strength of articular cartilage is provided by its collagen content, which 
forms 10-20% of the tissue’s wet weight.  Type II collagen is the principle type present 
and forms a major component (90-95%) of the macrofibrilar framework of the ECM.  
Collagens III, VI, IX, X, XI, XII and XIV are all present in much lower amounts and 
also contribute to the structure of the mature matrix.  These minor collagens help to 
organise and stabilise the larger collagen II fibril network [142, 143, 147, 149]. 
 
3.1.1.4 Proteoglycans 
Another major component of the ECM are the proteoglycans, which are synthesised and 
secreted into the matrix by chondrocytes [142, 147].  Proteoglycans are protein 
polysaccharide molecules which comprise 10-20% of the tissues wet weight.  They are a 
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family of glycoconjugates with a central core protein to which one or more 
glycosaminoglycan (GAG) side chains are covalently bonded [141, 142].  There are two 
major classes of proteoglycans, large aggregating proteoglycans (LAPs) and small 
leucine-rich proteoglycans (SLRPs).  The principle LAP present is aggrecan which is 
forms large aggregates in the ECM [150, 151].  These aggregates are comprised of numerous 
monomers that are non-covalently bound to a hyaluronic acid (HA) chain and stabilised 
by small glycoprotein link proteins [144, 148, 150, 151].   
 
Aggrecan molecules consist of a core protein of ~2300 amino acids.  At one end is an 
amino-terminal globular domain (G1) which is responsible for its interaction with the 
HA chain.  This is followed by a short interglobular domain which separates G1 from 
an additional globular domain (G2).  A third carboxy-terminal globular domain (G3) is 
separated from G2 by a keratan sulfate (KS) attachment domain, and two chondroitin 
sulfate (CS) attachment domains.  Up to 100 covalently attached KS or CS chains may 
be present in these three GAG attachment domains resembling a bottle-brush-like 
configuration (Figure 3.1) [146, 147, 150].   
 
When fully ionized the GAG chains attribute a charge negative density of ~9000 
negative charges/aggrecan to each aggrecan molecule.  This high density of fixed 
negative charges draws water into the tissue, therefore yielding a high osmotic pressure 
which is responsible for more than 50% of the compressive modulus of articular 
cartilage [144, 146, 150, 151].   
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Other LAPs present in articular cartilage include versican and perlecan but these are 
expressed at much lower levels.  Like aggrecan, versican has the ability to bind with HA 
and is involved in the modulation of cell proliferation, adhesion and migration, and 
plays a role in early joint morphogenesis [152, 153].  Perlecan is usually found in the 
basement membrane of tissues, however as cartilage is devoid of a basement membrane, 
its role here is unclear [150].     
 
A number of different SLRPs may be found in cartilage tissue such as decorin, 
biglycan, fibromodulin and lumican. Their function depends on their core protein and 
the type of GAG side chains present.  The core protein of the SLRP allows it to interact 
with the collagen fibrils that form the tissue framework, enabling them to perform a 
Figure 3.1: Schematic representation of the structure of aggrecan and its interaction with 
hyaluronate (hyaluronic acid), and the link protein.  (KS), keratan sulfate chains attached 
at the KS attachment domain; (CS), chondroitin sulfate chains attached at the two CS 
attachment domains; (G1), amino-terminal globular domain; (G2), additional globular 
domain; (G3), carboxy-terminal globular domain.  (Image modified from Heinegard & 
Oldberg, 1989). 
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number of functions such as regulation of fibril diameter during fibrillogenesis, and 
assisting in fibril-fibril interactions in the ECM.  They may also limit the access of 
collagenases to their cleavage sites on the collagen molecules therefore protecting them 
from degradation [141].   
  
3.1.1.5 Ultrastructure 
Articular cartilage can be further classified into four morphologically distinct zones [68] 
(Figure 3.2).  Each zone is characterised by variation in the organisation of the collagen 
network, and by differences in the amounts and types of proteoglycans present [142, 143, 145, 147].   
 
1. The Superficial Zone: is the thinnest of all the zones, 10-20% of the total cartilage 
volume, and is located closest to the surface.  The chondrocytes present here are 
flattened or disc-shaped [145], and are covered by a thin film of synovial fluid which acts 
to lubricate the gliding surface [147, 148].  This zone contains high levels of collagen 
(primarily types II and IX) which are packed tightly and arranged parallel to the 
articular surface.  The high levels of collagen give this layer the greatest tensile strength, 
enabling it to resist the sheer, tensile and compressive forces of the articular surface.  
Relatively low levels of GAG are present at this level [154].  
 
2. The Transitional Zone: is immediately deep to the superficial zone and represents 40-
60% of the total cartilage volume.  This level has a lower type II collagen content, 
however the collagen fibrils are thicker, and the amount of GAG increases [147, 154].  The 
chondrocytes become more spherical in shape and lower in density.  In this zone the 
collagen fibrils are arranged more obliquely to further resist compressive forces [145, 147].   
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3. The Deep Zone: is deep to the transitional zone and represents ~30% of the total 
cartilage volume.  It provides the greatest resistance to compressive forces, with the 
collagen fibrils arranged perpendicular to the articular surface.  Collagen levels in this 
region are the lowest while GAG levels are the highest.  The spherical chondrocytes are 
aligned in columns parallel to the collagen fibres [147, 154].    
 
4. The Calcified Cartilage Zone: this zone is distinguished from the deep zone by a line 
known as the 'tide mark' and it contains high levels of type X collagen as the cartilage 
integrates with the subchondral bone.  In this zone the cell population is very low and 
the chondrocytes are hypertrophic [147, 154]. 
 
 
 
 
 
 
[68] 
 
 
 
 
 
 
 
 
Figure 3.2: cross sectional diagram of the normal structure of articular cartilage outlining: 
A, the cellular organisation in the different zones of articular cartilage; B, the orientation 
of collagen fibres throughout the various cartilage zones.  (Image modified from 
Buckwalter et al,1994).  
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3.1.2 Osteoarthritis 
Osteoarthritis (OA) is the most common form of arthritis and is a leading cause of 
chronic disability, particularly in the hips, knees and hands of human sufferers [155-158].  
Current estimates by the World Health Organisation state that the OA is a cause of 
disability in at least 10% of the population over the age of 60 years [155, 159].  Furthermore, 
the disorder is not limited to human populations, with all animals that fuse epiphyses of 
synovial joints, both primate and non-primate, being capable of developing OA.  While 
this fact greatly increases the scope of the problem, it also provides us with the 
opportunity to increase our understanding of the pathophysiology of the disorder 
through the study of animal models [156].   
 
 3.1.2.1 Pathophysiology 
OA is characterised by focal areas of articular cartilage loss within the synovial joints 
that may progress to fibrillation of the cartilage matrix (especially in weight bearing 
zones), fissure appearance, ulceration and eventually full thickness loss of the joint 
surface (Figures 3.3 and 3.4) [157, 159-161].  
 
 
 
 
 
 
 
 
 
Figure 3.3: A schematic representation of the progression of OA. A), Healthy cartilage 
demonstrating the intact superficial layer with a smooth lubricated surface; B), Early stage 
OA with loss of the superficial layer and exposure of the transition layer, resulting in 
surface irregularities such as deamination, fibrillation, fissures and erosions; C), Late stage 
OA with the appearance of deep erosions and sclerosis of the subchondral bone.  (Image 
from Tummala et al 2011).  
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Associated with the loss of cartilage, is remodelling of the calcified cartilage zone (also 
known as the tidemark), which becomes less distinct on histological section and is 
characterised by infiltration of blood vessels in the later stages of OA.  In addition, 
sclerosis of the subchondral bone occurs, with disordered bone remodelling (particularly 
in non-weight bearing regions) which may result in microfractures as OA progresses [162].  
Figure 3.4: A, a histological section (Tol Blue) of normal sheep articular 
cartilage showing normal ultrastructure.  Note the evenly distributed 
chondrocytes, homogeneous proteoglycan staining and smooth, even surface 
layer; B, an osteoarthritic section of sheep articular cartilage showing disruption 
of normal structure, with loss of blue staining reflecting depletion of 
proteoglycans.  Note the focal loss of cellularity, the uneven cartilage thickness 
and the distinct areas of fibrillation (Image courtesy M. Cake). 
A 
B 
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Another hallmark of OA is the onset of chondrocyte cloning, where usually solitary 
chondrocytes appear in clusters as a result of increased focal mitotic activity (Figure 
3.5).  These proliferating chondrocytes associated with erosive lesions have been found 
to contain unstable DNA with tetraploidy [162].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.5: Histological section of cartilage from an osteoarthritic 
 human  knee  showing  proliferation  of  chondrocytes  in clusters,  
 also known as cloning (see arrows and enlarged inset). (Image  
 from Pauli et al., Osteoarthritis and Cartilage, 20, 2012) [163]. 
 
 
Cartilage breakdown is accompanied by hypertrophy of the bone (osteophyte formation 
and subchondral bone sclerosis), and may include inflammation of the joint capsule and 
synovial membrane [157, 159-161].  In addition, there is a decrease in the concentration and 
viscosity of the synovial fluid of patients with OA, which may reduce joint lubrication 
and decrease the capacity to withstand compressive force [164].   
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The most prominent symptom in most people with OA is joint pain, ranging from mild 
to severe, and it is the most important determinant of the degree of disability in patients.  
Other general features of OA include limited joint movement, crepitus, joint effusion 
and distension of the joint capsule, wasting of the muscles that act across the affected 
joint, instability of the joint and in severe cases joint locking [157, 165, 166].  
 
3.1.2.2 Epidemiology  
The cause of OA is likely to be multifactorial, with the joint having a limited capacity to 
react to various insults, the OA lesion may reflect a common end point [160, 161, 167].  The 
OA process is thought to involve a complex interaction between cells and soluble 
mediators such as cytokines, growth factors, inflammatory mediators, matrix-
metalloproteinases and chondrodegradative enzymes [164].  Pro-inflammatory enzymes 
such as IL-β and TNF-α, also have a significant influence on OA.  They act to increase 
MMP synthesis and reduce the production of the major physiological inhibitors of these 
enzymes.  They may also inhibit the synthesis of matrix constituents such as collagen 
and proteoglycans [161, 168]. 
 
OA can be classified as primary (idiopathic) or may be secondary as a consequence of 
trauma, surgery, infection or some other disease process [155, 164].  There are a host of risk 
factors that have been identified which potentially increase the likelihood of developing 
OA.  These include age, gender, obesity, occupation, nutrition, genetics, ethnicity, 
anatomical abnormalities, proprioception, injury, bone density and muscle weakness [156, 
166, 167, 169].  Of these, age, gender and injury are among the most detrimental. 
 Age - reduces the joint's ability to protect itself from biomechanical stress due to 
thinning of the non-calcified cartilage, increased joint laxity, aberrant joint 
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loading, oxidative damage, wear and tear and accumulated past injuries [155-157, 167, 
170].  In addition, proteoglycan content falls sharply with advancing age and may 
decrease by up to 50% [166, 171]. 
 Gender - the incidence of OA in women and men is similar until about the age 
of 50 yrs.  Thereafter the disease becomes more prevalent, severe and 
generalised in women, particularly involving the hands and knees [158].  The 
incidence of OA in older women post-menopause exceeds the expected increase 
in prevalence that would occur simply from increasing age [167, 169, 172-175].  
Oestrogen affects joint tissues directly via oestrogen receptors which have been 
found on human articular chondrocytes, or indirectly by secondary messengers 
[172], and potentially influences collagen, cytokines, MMPs and may be beneficial 
by improving tissue metabolism [176-178].  Studies suggest ovarian hormone 
replacement therapy may have a protective effect on joints and decrease the 
development OA [172, 176, 179-183] 
 Injury - this is of particular significance in the knee joint. There is a very high 
prevalence of OA, with pain and functional limitation, following anterior 
cruciate ligament (ACL) rupture or meniscal damage, either due to sport injury 
or some other trauma [184-188].  Injury to these structures predisposes the subject to 
OA due to disruption of normal joint biomechanics and instability of the joint.  
This results in aberrant wear on the articular surfaces and can cause further 
degeneration of other joint structures.  ACL reconstruction surgery and 
techniques aim to restore long term function and joint-stability in order to 
prevent OA development.  It is difficult however to reproduce 100% normal 
joint function after injury and studies have demonstrated that degenerative 
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changes often progress over time, even in patients with a good surgical outcome.  
This suggests that OA development is not preventable after joint insult [189-193]. 
 
3.1.2.3 Diagnosis 
Radiographic, symptomatic and self-reported (via questionnaire) are the most common 
terms used in the diagnosis of OA, with most epidemiological studies using one or a 
combination of these [159].  Radiography is the often the first-line diagnostic tool in OA, 
but it is insensitive to change and doesn't depict the soft tissue changes sufficiently [194, 
195], and has limited ability to detect OA in the early stages [196].  Furthermore, 
radiographic findings do not always correlate with clinical symptoms [197, 198].  Several 
grading systems have been developed such as the Kellgren-Lawrence, Brandt and 
Ahlback based on the presence or absence of features such as osteophytes and joint 
space narrowing [199, 200].  There is dispute however, among researchers, about whether 
there is some inconsistency in the interpretation of these scales between studies [171, 198], 
and others conclude a more sensitive method of imaging such as magnetic resonance 
imaging (MRI) should be utilised [187, 194, 195].  In general a diagnosis of osteoarthritis is 
made when there is a combination of radiographic changes and the presence of clinical 
pain [197]. 
 
3.1.2.4 Treatment 
OA remains an irreversible disease with main treatment goals being the reduction of 
pain and the maintenance, if not improvement of joint mobility [199].  There are a number 
of pharmacologic and non-pharmacologic treatments available.  Non-pharmacologic 
options should, where possible, be the first step in the treatment of the disorder.  These 
include specific exercises to improve muscle strength and improve joint stability, 
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modification of lifestyle to reduce joint loading and the discontinuation of exacerbating 
activities.  Other suggestions may include weight loss in obese patients, improving 
posture, the wearing of supportive splints or braces and the use of orthotics etc [166].  
 
If these treatments do not ameliorate symptoms, pharmacologic options may need to be 
utilised.  These include acetaminophen, topically and orally administered non-steroidal 
anti-inflammatory drugs, COX-2 inhibitors, and intra-articular injection of long-acting 
steroids.  A new group of drugs known as symptomatic slow-acting drugs in OA 
(SYSADOAs) including chondroitin sulfate, diacereine, glucosamine sulfate, 
avocado/soybean unsaponifiables and hyaluronic acid have demonstrated improvement 
in pain and physical function with very low toxicity [166, 197, 201].   
 
The final option available is surgery and in most cases should be reserved until other 
options have proven ineffective.  Surgical options include arthroscopy to remove 
damaged articular cartilage, tidal irrigation to remove fibrin and debris, osteotomy to 
remove osteophytes and total joint replacement (usually in the knee and hip) [166, 197].   
 
3.1.3 The Role of Ligament in OA 
As previously discussed, there is strong evidence that ligament damage (commonly 
ACL rupture), may result in OA of a joint rendered unstable by the disruption of normal 
joint biomechanics [93].  In fact, surgical transection of the ACL (the Pond-Nuki 
technique) is a commonly utilised model to induce OA in animals for the purpose of 
research [202].  While the cause of OA in these instances is clear, occurring as a 
consequence of significant ACL disruption, there are often times when the initiating 
factors are unknown.  It may also be that the characteristic bone and cartilage changes 
 
 
89
commonly associated with OA are features of the later stages of the disease, with other 
less detectible changes occurring earlier in other joint structures such as the ligaments 
[203].  The exact role of ligament in the aetiology of idiopathic OA is still unclear, but has 
been the focus of a number of animal and human studies in recent years. 
 
3.1.3.1 Animal Studies  
Being that age is a significant risk factor for OA, one of the earlier animal studies 
utilised a rabbit model to determine the effect of age on the tensile properties of medial 
collateral ligament (MCL).  Results indicated that the tensile strength of the MCL 
increased steadily until maturation and after a brief plateau, began to decline as age 
increased.  If ligament tensile strength decreases with advancing age, this could 
potentially have a detrimental effect on normal knee biomechanics in older subjects, 
predisposing them to OA [204].   
 
Anderson-MacKenzie et al. (1999) [203] proposed that biochemical cruciate ligament 
alteration may play a role in early primary, idiopathic OA.  Using an STR/ORT mouse 
model of spontaneous OA, they discovered that active collagen metabolism in the 
cruciate ligament was up-regulated in the STR/ORT strain.  They determined that active 
collagen remodelling was occurring in the STR/ORT ligament due to the higher levels 
of MMP-2 (responsible for ligament catabolism), and the presence of higher levels of 
keto-imine immature collagen crosslinks (evidence of ligament anabolism) compared to 
controls. In addition, levels of MMP-9 were not significantly higher in the STR/ORT 
ligament compared to controls suggesting that the remodelling is not being mediated by 
inflammation.  These changes, which were associated with significantly weaker ACLs 
in the STR/ORT strain, were detected before radiological signs of OA developed, 
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suggesting that biomechanical cruciate ligament alteration may be an important factor in 
early osteoarthritis.     
 
Studies using the Dunkin-Hartley (DH) guinea pig model of spontaneous OA have also 
detected changes in ligament metabolism prior to the onset of cartilage changes.  Young 
et al. (2002) [205], examined the posterior cruciate ligaments (PCLs) in DH guinea pigs, 
finding aberrant synthesis of cartilage-like matrix in the mid-ligament prior to the 
appearance of OA (cartilage and bone changes).  Deposition of type II collagen in 
ligament is usually restricted to the ligamentous attachment sites; therefore it is 
reasonable to expect that the abnormal presence of fibrocartilage in mid-ligament would 
alter the mechanical properties of the ligament, reducing its elasticity.  As the cruciate 
ligaments are the main interconnecting and stabilising elements of the knee joint, 
changes in their composition and biomechanical function could lead to instability and 
predispose the joint to OA.   
 
Quasnichka et al. (2005) [92], also used the DH guinea pig OA model to examine the 
structure and metabolism of the cruciate ligaments, revealing the DH strain had 
significantly laxer ACLs than the control strain.  This increased laxity was linked to 
uncontrolled collagen turnover.  In a subsequent study, Quasnichka et al. (2006) [206] 
found the DH strain had again significantly increased ACL laxity than the control strain 
at all experimental time-points.  This increased laxity was again associated with 
increased remodelling of the cruciate ligaments, based on markers of collagen turnover, 
and it occurred prior to bone and cartilage pathology, demonstrating the fundamental 
role of ligament in the aetiology of OA.   
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Comerford et al. (2005) [25] presented further evidence of abnormal ligament metabolism 
influencing joint stability.  They compared ACLs from Labradors (a breed predisposed 
to cruciate rupture) with Greyhounds (not predisposed) and found differences in the 
metabolism of the collagenous matrix (specifically increased collagen turn-over).  In 
addition, they discovered anterior-posterior (AP) laxity was significantly greater in the 
Labrador knee joints and their ACLs tended to be weaker (lower ultimate tensile 
strength).  Inferior mechanical properties of the ACL and increased joint laxity could 
increase the potential for non-contact ligament rupture, and eventual knee OA [207]. 
 
3.1.3.2 Human Studies 
Like animal based studies, human research into the aetiology of OA has identified 
changes in ligament as a potential causative factor.  Silman et al. (1987) [208] revealed 
strong evidence that adolescent women had significantly greater joint mobility than men 
for the lower limb (knee) and fore-arm rotation.  In the knee, this may contribute to the 
female susceptibility to cruciate rupture and compound the risk of OA in older women.  
A predisposition of older females to OA is demonstrated by the findings of Woo et al. 
(1991) [209], which showed the structural properties of the female femur-ACL-tibia 
complex (i.e. linear stiffness, ultimate load, and energy absorbed) all decreased 
significantly with advancing age.  This may explain in part the predisposition of older 
females to OA. 
 
Sharma et al. (1999) [210], further investigated the correlation between age, gender and 
knee laxity, with results also demonstrating that women had a greater knee laxity than 
men (especially valgus-varus), and that ligaments become more compliant with age.  In 
addition, they showed that there was greater laxity in the uninvolved knees of patients 
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with OA versus age matched control subjects without OA, supporting the concept that 
some portion of increased laxity may predate the disease [211].   
 
Multiple authors have investigated the role of increased joint laxity in degenerative joint 
disease, particularly in the knee.  Results identified increased joint laxity (identified and 
measured prior to ACL injury) as a significant risk factor for non-contact ACL injury 
and subsequent development of OA [212-215].  It is possible that even in the absence of 
complete rupture, the ligament may sustain multiple 'micro-injuries' over time which, in 
the long term, could contribute to the degeneration of the ligament structure and loss of 
biomechanical integrity.   
 
In 2010, Zhang et al. [169] stated that knee laxity was also greater in the as yet non-
arthritic knees of patients with idiopathic OA compared to a control group.  Like 
Sharma's 1999 study, this suggests that a portion of the increased laxity in knee OA 
precedes disease development and may exacerbate its progress.  While it is likely that 
ligament plays a key role in knee laxity, muscles and other structures such as the joint 
capsule may also play a part.   
 
Kleinbart et al. (1996) [216] provided more evidence of ligament's involvement in joint 
laxity in humans in their  study of PCLs from arthritic knees of patients at the time of 
total knee arthroplasty (TKA).  They histologically compared the PCLs from severely 
OA affected knees to non-OA control PCLs.  Ligaments were considered histologically 
abnormal and degenerative if loose, mucoid, myxoid, or cystic changes were noted. The 
magnitude of degeneration was defined as normal, slight, mild, moderate, or marked, 
based on the amount of tissue demonstrating change. Of PCLs in the control group, 
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45% were normal, 33% showed slight changes and 22% showed mild changes.  
Interestingly no control PCLs exhibited marked degenerative changes.  PCLs from the 
OA knees were very different, with 63% showing marked degenerative changes (+ 17% 
normal and 20% mild-moderate).  The authors concluded that the PCL is not spared the 
degenerative changes involved in OA of the knee.  It is not possible to ascertain from 
this study whether these changes in the PCLs precede OA or if they are a result of it.  It 
has been well established that damage to the ACL is often involved in the OA process, 
so it would be common to find the ACL in a degenerated state at the time of TKA.  
Acute PCL injury occurs far less frequently and this is one of few studies that have 
examined the fate of the PCL in OA.  Interestingly the PCL was also found to be 
degenerate in the arthritic knee joint, potentially as a result of disruption to normal knee 
biomechanics, exposure to inflammatory mediators or possibly due to abnormal 
ligament metabolism as has been identified in animal models.  Foos et al. (2001) [217], 
cited tissue remodelling within the ACL of females due to abnormal metabolism as a 
contributing factor to their predisposition to rupture. 
 
While there is mounting evidence that increased knee laxity due to compromised 
ligament integrity is common preceding the development of disease and in the early 
stages of joint degeneration, this may change as the disease progresses to the late stages.  
Laxity of the knee in late stage OA may in fact be due to other factors such as loss of 
cartilage and/or bone height, chronic capsuloligamentous stretch or combinations of 
ligamentous, meniscal muscular and capsular pathology [218, 219].  Brage et al. (1994) [220] 
identified differences in knee laxity in early and late stage OA, finding that knees of 
severe OA patients displayed less laxity than normal knees.  This may be due to a 
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combination of factors such as contracture of the ligaments, and pressure of osteophytes 
against joint structures.   
 
More recently, Ragusa & Hill (2011) [221] investigated the role of the elastic fibre system 
in the pathogenesis of OA.  The elastic fibre system gives the knee ligaments their 
elastic property which allows them to withstand stretch and deformation.  Without this 
system in place, ligaments would become lax, and joints unstable.  This study found a 
correlation between the elastic fibre content of ligament and the development of OA.  
The elastic fiber density, measured as the concentration of elastic fibers per unit area, 
was correlated with the severity of OA, which was graded on a 0–16 scale using 
histologic and macroscopic markers. Knees with the highest OA scores exhibited the 
lowest elastic fibre content in the collateral ligaments (medial and lateral).   
 
Much has been written about ligament and OA of the knee, but what of other joints in 
the body?  As previously mentioned the hand is another region prone to development of 
OA.  Several authors have examined the effect of ligament insufficiency and the 
occurrence of hand OA.  Tan et al. (2005) [222], used high resolution MRI to show 
ligamentous and tendon abnormalities were a feature of hand OA at even the earliest 
stages.  These findings were repeated in a subsequent 2006 study from these authors in 
which ligament and tendons showed degenerative changes, while cartilage appeared 
normal and inflammation was minimal [223].  Hunter et al. (2005) [224] provided 
longitudinal radiographic evidence supporting their hypothesis that instability of the 
trapeziometacarpal joint with radial subluxation due to ligament laxity leads to OA of 
the thumb.     
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3.1.4 The Meniscectomy Model of Osteoarthritis 
Osteoarthritis (OA) is a naturally occurring condition in a variety of animal species such 
as mice, guinea pigs, dogs and macaques.  Despite this, it is difficult to establish 
colonies of animals with spontaneous OA that are suitable for experimental studies.  
This is due to the influence of ill-defined environmental factors, the time required to 
collect adequate sample numbers (often years) and the difficulty in matching study 
groups e.g. for age, sex, weight, stage of disease [225].  Therefore in order to examine the 
effect of osteoarthritis on the ligaments of the knee joint, the disease must be 
experimentally induced under controlled conditions.   
 
Transection of the anterior cruciate ligament (ACL) is a well-established technique for 
surgically inducing OA in the knee joint [226-228], but this would render the ligament 
useless for the purposes of this study.  Furthermore, while this method has proven 
effective in other species (such as the dog, rat or rabbit), cruciate ligament transection 
alone appears to induce very limited or mild cartilage damage in sheep [140]. An 
alternative method of inducing OA while leaving the ACL intact is to perform a 
meniscectomy, a procedure that involves surgical removal of the medial or lateral 
meniscus of the knee [225, 229, 230]. 
 
Many studies have successfully utilised the meniscectomy model in small animals such 
as rats, guinea pigs and dogs to produce a progressive pattern of cartilage damage 
similar to that seen in human OA [231, 232].  Small animals such as rodents may be ideal 
when very large study numbers are required, but there are several disadvantages 
associated with some small animal models.  Firstly, dogs, rabbits, rats and mice stand 
with their knees flexed and therefore experience different biomechanical loading to 
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humans [233, 234].  Secondly, as mentioned previously, the amount of tissue available for 
biochemical and histological studies is limited in animals such as rats, mice, guinea pigs 
and rabbits [225, 234].  Thirdly, the short lifespan of rodents may preclude them from use in 
long-term OA studies.  Finally, there is a social stigma associated with the use of small 
animals like dogs, cats and rabbits for research purposes [235].   
 
A number of authors have identified the sheep meniscectomy model as an ideal 
alternative for the study of OA.  Ghadially et al. (1986), Turner et al. (1997) and Burger 
et al. (2007) stated that the anatomy and biomechanics of the sheep knee joint closely 
resemble that of the human knee [57, 233, 236].  Although they are quadrupeds, sheep knee 
joints are relatively extended, much like the knee joint of humans.  The sheep knee may 
be smaller than that of a human, but there are few other anatomical differences between 
the knees of the two species.  Little et al. (1997) and Oakley et al. (2004) concluded that 
the cartilage changes in meniscectomised sheep were analogous to those seen in the 
knee cartilage of humans with OA, and that the ovine meniscectomy model is valid 
means for evaluating the initiation and progression of the disease [237, 238].   
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3.2 AIMS & HYPOTHESES 
 
The evidence presented in Section 3.1 shows the effects of OA on articular cartilage and 
subchondral bone are well documented.  Less is known however about the collateral 
damage OA may impose on other intracapsular joint structures such as the cruciate 
ligaments.  It may be that the inflammatory process associated with OA induces 
deterioration of these major stabilisers of the joint, and therefore may alter normal knee 
biomechanics, further contributing to the disease process.  This aim of this study was to 
show that the meniscectomy model leads to degenerative changes in the knee joint 
which parallel naturally occurring OA, and using this model, investigate the influence 
of OA on the structure and organisation of the anterior cruciate ligament. 
   
Hypothesis 1: that osteoarthritis (meniscectomy) alters gene expression and collagen 
fibril structure and organisation in ACL.  
 
Hypothesis 2:  animals with worse osteoarthritic changes have more severe ligament 
derangement.   
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3.3 RESULTS 
3.3.1  Molecular Biology 
 
 
 
 
EXPRESSION NORMALISED TO TOTAL RNA 
 
TARGET GENE NOC MENX FOLD DIFFERENCE P 
 Mean (CI) Mean (CI)   
Aggrecan        279.3    (0 – 686.2)  130.6    (44.2 – 217.0) 2.14 0.436 
Basic FGF        329.9    (138.2 – 521.6)   164.7    (121.7 – 207.7) 2.00 0.147 
Biglycan        164.3    (93.7 -234.9)   165.3    (100.6 – 230.0) 0.99 0.985 
Collagen type I          65.1    (28.6 – 101.6) 48.4    (37.0 – 59.8) 1.34 0.439 
Collagen type II        355.2    (0 – 728.1) 252.0    (84.2 – 419.8) 1.41 0.649 
Collagen type III          34.8    (22.2 – 47.3) 36.0    (24.7 – 47.3) 0.97 0.888 
CTGF        307.2    (98.8 – 515.5) 131.5    (71.7 – 191.3) 2.34 0.084 
Decorin        395.4    (213.9 – 577.0)   150.1    (109.2 – 191.0) 2.63 0.008 
Elastin        579.5    (301.2 – 857.8)   234.5    (168.5 – 300.5) 2.47 0.042 
Fibromodulin        298.7    (161.1 – 436.2)   209.4    (149.8 – 269.0) 1.43 0.289 
iNOS        338.9    (113.0 – 564.9) 266.9    (90.5 – 443.3) 1.27 0.638 
Lubricin        219.3    (51.9 – 386.7) 100.2    (69.9 – 130.5) 2.19 0.224 
Lumican        200.2    (70.7 – 329.6) 167.8    (81.6 – 254.0) 1.19 0.700 
MMP-1          35.2    (11.7 – 58.8) 123.1    (66.8 – 179.4) 0.29 0.006 
PDGF        138.4    (38.7 – 238.1)   95.5    (64.6 – 126.4) 1.45 0.466 
 
 
 
 
 
 
EXPRESSION NORMALISED TO β-actin 
 
TARGET GENE NOC MENX FOLD DIFFERENCE P 
 Mean (CI) Mean (CI)   
Aggrecan      2.501          (0.6 - 4.4)      2.084          (0.5 - 3.7) 1.20 0.750 
Basic FGF      3.631          (2.4 - 4.9)      2.389          (1.8 - 3.0) 1.52 0.114 
Biglycan      1.766          (1.4 - 2.1)      2.334          (1.4 - 3.2) 0.76 0.234 
Collagen type I      0.701          (0.3 - 1.1)      0.678          (0.5 - 0.8) 1.03 0.927 
Collagen type II      3.539          (0.9 - 6.2)      4.090          (1.0 - 7.2) 0.87 0.793 
Collagen type III      0.393          (0.3 - 0.5)      0.479          (0.4 - 0.6) 0.82 0.288 
CTGF      2.648          (1.9 - 3.4)      1.734          (1.1 - 2.3) 1.53 0.078 
Decorin      4.282          (2.8 - 5.7)      2.132          (1.6 - 2.7) 2.01 0.020 
Elastin      6.280          (3.8 - 8.7)      3.216          (2.6 - 3.8) 1.95 0.042 
Fibromodulin      3.172          (2.5 - 3.8)      3.124          (1.8 - 4.4) 1.02 0.947 
iNOS      3.577          (1.2 - 6.0)      3.744          (1.2 - 6.3) 0.96 0.927 
Lubricin      2.466          (1.2 - 3.7)      1.409          (0.9 - 1.9) 1.75 0.162 
Lumican      2.426          (1.1 - 3.7)      2.178          (1.2 - 3.2) 1.11 0.776 
MMP-1      0.416          (0.2 - 0.7)      1.586          (1.0 - 2.2) 0.26 0.001 
PDGF      1.324          (0.9 - 1.8)      1.323          (0.9 - 1.7) 1.00 0.997 
 
 
 
3.3.1.1  Gene Expression Calculated From Total RNA Results 
Table 3.1: Results for target gene expression in ACL tissue in meniscectomised (MENX) and non-operated 
control (NOC) sheep, shown as value of total RNA.   
Table 3.2: Results for target gene expression in ACL tissue in meniscectomised (MENX) and non-operated 
control (NOC) sheep, with data normalised to β-actin.   
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3.3.1.1  Gene Expression Normalised to Total RNA  
Results showed that decorin expression was significantly reduced in ACLs from MENX 
sheep compared to NOC sheep (P ≤ 0.028), as was expression of elastin (P ≤ 0.042).  
MMP-1 expression was significantly higher in MENX sheep than in NOCs (P ≤ 0.006).  
There was no statistical difference between the NOC and MENX groups for all other 
genes tested.  See Appendix A4.1.2 (page 245) for charted molecular biology results of 
NOC vs. MENX and comparison with other experimental groups in Chapter 4.  A 
number of other genes were tested but only produced a weak signal that could not be 
further analysed.   These genes were MMP-3, MMP-13, TNF-, IL-1 and TGF-.  
 
3.3.1.2  Gene Expression Normalised to β-actin  
When data was normalised to a housekeeping gene (β-actin), results showed expression 
of decorin (P ≤ 0.045) and elastin (P ≤ 0.043) was significantly lower in MENX sheep 
than in NOC sheep, and that expression of MMP-I was significantly higher in MENX 
vs. NOC sheep (P ≤ 0.001).    
 
 
 
3.3.2  Biochemistry 
 
3.3.2.1 Collagen Content 
Total collagen content in the ACL of MENX sheep was not significantly different to the 
ACL of NOC sheep [mean ± SE; MENX 60.58 ± 1.4 vs. NOC 57.16 ± 1.1 % of dry 
weight; P = 0.07].  Full results and charts for all biochemical analyses comparing NOC 
vs. MENX and including comparison with the other experimental groups (Chapter 4) 
are available in Appendix A4.2.1 (page 257).   
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3.3.2.2 Sulfated Glycosaminoglycans (S-GAG) Content 
Results showed the amount of S-GAG in ACL from the MENX group was significantly 
lower than in the ACL of the NOC group, [mean ± SE; MENX 9.35 ± 0.6 vs. NOC 
11.78 ± 0.7 % of dry weight; P = 0.07]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.3  Transmission Electron Microscopy (TEM) 
 
3.3.3.1 Fibril Size and Arrangement 
In NOC sheep, fibrils were of similar size and regularly arranged. The majority of fibrils 
in the NOC ACLs were found to be within a close size range of 100-200nm. By 
contrast, MENX had a significantly smaller average fibril size than NOC [mean fibril 
diameter (nm) ± SE, 128.64 ± 5.14 vs. 151.05 ± 2.28 P = 0.013] and showed a greater size 
range with many small fibrils and a less regular arrangement (Figures 3.7-3.9). 
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Figure 3.6: Results of biochemical analysis of collagen and S-GAG content 
in ACL, comparing meniscectomised and non-operated control groups. 
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Figure 3.7: TEM (37000x) of ACL collagen fibrils.  Image 8666 is a sample representative of the NOC 
group with fibrils that are relatively uniform in size and regularly arranged.  Image 8607 is a sample from 
the MENX group with fibrils that are more variable in size and more erratic in their arrangement.  To 
view all NOC and MENX sample TEM images examined in this study refer to Appendix A4.3 (page 259). 
Figure 3.8: Distribution of collagen fibrils in NOC ACL tissue based on fibril size (diameter in nm). 
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Figure 3.9: Distribution of collagen fibrils in MENX vs. NOC ACL tissue based on fibril size 
(diameter in nm), as determined by TEM analysis.  Note the wider size distribution profile of the 
MENX group. 
Table 3.3: Combined fibril diameter data for sheep ACL.  Mean fibril counts (per two TEM 
fields) for MENX sheep were compared to the NOC sheep for each fibril size range and 
calculated as a percentage of the total count.  
FIBRIL SIZE (nm) 
Mean number of fibrils per two TEM fields, approx. 
5µm2 (% of total in brackets) P  
NOC (n=12) MENX (n=10) 
<100      1.2    (<1%)    63.5   (31%) <0.001 
100-200  154.4    (99%)  133.2   (65%) <0.001 
>200      0.2    (<1%)    6.8   (3%) 0.998 
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Data for fibril density was calculated as a % of total field area.  MENX showed no 
significant difference in fibril density compared to NOC [mean % of field ± SE; MENX 
47.3 ± 1.4 vs. NOC 48.1 ± 1.3]. Charts of all TEM results are provided in Appendix 
A4.3 (page 259). 
 
 
3.3.4   Scanning Electron Microscopy (SEM) 
At a low power of magnification the architecture of the MENX ligament was variable 
with multiple large gaps and what appears to be loose connective tissue between the 
fibre bundles (Figure 3.10).  This was in contrast to the NOC tissue which had fibre 
bundles that were closely packed and more uniform in appearance (Figure 3.11).    At a 
higher power of magnification, the images showed conspicuous electron dense bands on 
the cut surface of the ACL of the MENX sheep (Figure 3.12), which were not readily 
apparent in the NOC sheep (Figure 3.13).  
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Figure 3.10:  SEM (170x) ACL tissue from a MENX sheep viewed in cross-
section.  Note the degree of separation between fibre bundles (arrow heads) 
and loose connective tissue between bundles (arrows). 
Figure 3.11:  SEM (170x) ACL tissue from a NOC sheep viewed in cross-
section.  The fibril bundles within the mid-substance ligament are tightly 
packed with little space between them, and the tissue is uniform in 
appearance (arrow heads). 
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Figure 3.12:  SEM (2000x) ACL tissue from a MENX sheep viewed in 
cross-section.  Note the clearly visible light and dark striations in the tissue. 
 
Figure 3.13:  SEM (2000x) ACL tissue from a NOC sheep viewed in cross-
section.  The tissue is very homogeneous, lacking the clearly striated 
appearance of the MENX sample. 
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3.3.5   Gross Morphology 
 
3.3.5.1  Articular Cartilage OA Scores 
 
REGION NOC MENX P 
Cartilage Mean (CI) Mean (CI)  
FEMUR      0.08          (0 - 0.2)      3.10          (2.9 - 3.3) <0.0001 
TIBIA      0.17          (0 - 0.4)      2.80          (2.2 - 3.4) <0.0001 
WHOLE JOINT      0.13          (0 - 0.3)      2.95          (2.6 - 3.3) <0.0001 
 
 
 
 
  
Table 3.4: Results of macroscopic scoring of ovine knee articular cartilage, comparing 
meniscectomised and non-operated control groups.  
 
 
Figure 3.14: Charted data for macroscopic scoring of articular cartilage, comparing 
meniscectomised and non-operated control groups.  
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3.3.5.2  Osteophytes 
 
REGION NOC MENX P 
Osteophytes Mean (CI) Mean (CI)  
FEMUR      0.08          (0 - 0.2)      1.30          (1.0 - 1.6) <0.0001 
TIBIA      0.08          (0 - 0.2)      1.90          (1.5 - 2.3) <0.0001 
WHOLE JOINT      0.08          (0 - 0.2)      1.60          (1.3 - 1.9) <0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Macroscopic evaluation of joints from the meniscectomised and non-operated control 
groups revealed that the meniscectomised sheep scored higher for cartilage degradation 
and osteophyte formation compared to the controls.  This was evident on both the tibial 
and femoral surfaces, and for the combined joint data.        
Table 3.5: Results of macroscopic scoring of osteophyte formation in ovine knee joints, 
comparing meniscectomised and non-operated control groups.  
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Figure 3.15: Charted data for macroscopic scoring of osteophyte formation, comparing 
meniscectomised and non-operated control groups.  
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3.3.6   Histology 
 
3.3.6.1 Ligament 
 
Haematoxylin & Eosin 
General observations of the NOC and MENX samples showed the two groups were 
comparable in regards to the number of cells present (cellularity) and cell appearance 
(morphology) (Figure 3.16 A&B).  The fibres of the NOC group appeared slightly more 
regular and parallel in their arrangement.   
 
Toluidine Blue  
Tol Blue stain revealed the distribution and density of elastic fibres within the ligament.  
Elastin fibres in the NOC group samples were abundant and evenly distributed 
throughout the ligament sections.   In comparison, the density of elastin in the MENX 
sections was lower and the fibres were more randomly distributed (Figure 3.16 C&D).   
  
A   B 
  C   D 
Figure 3.16:  
 
A and B = H&E 200x 
sections of ACL tissue.  
A, NOC sample showing 
normal cellularity and 
morphology, with 
parallel collagen fibril 
arrangement; B, MENX  
sample demonstrating 
less ordered collagen 
fibril arrangement. 
 
 
 
 
C and D = Tol Blue 200x 
sections of ACL tissue. 
C, NOC sample with 
abundant and evenly 
distributed elastin fibres; 
D, MENX sample with a 
lower density of elastin 
which is less regular in 
its distribution.  All 
histological sections, can 
be viewed in Appendix 
A4.5 (pages 289-296). 
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3.3.6.2 Cartilage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histological examination of cartilage revealed the meniscectomised group scored 
significantly higher than the control group for all markers of OA except tidemark, and 
received a much greater total score than NOC.    This was consistent for the femoral and 
tibial surfaces, and the total joint data.   
FEMORAL AC NOC MENX P 
 Mean (CI) Mean (CI)  
STRUCTURE      1.46          (0.68 - 2.24)      3.17          (2.14 - 4.20)   0.015 
CELL NUMBER      0.79          (0.48 - 1.10)      1.38          (1.00 - 1.75)   0.029 
CLONING      0.46          (0.26 - 0.66)      2.71          (2.27 - 3.15) <0.001 
IT TB      0.79          (0.30 - 1.28)       1.71          (1.28 - 2.13)   0.011 
TIDEMARK      1.04          (0.96 - 1.13)      1.08          (0.97 - 1.20)   0.557 
TOTAL       4.54          (2.93 - 6.15)    10.04          (8.35 - 11.73) <0.001 
TIBIAL AC   
 Mean (CI) Mean (CI)  
STRUCTURE      0.58          (0.06 - 1.11)      5.63          (4.48 - 6.77) <0.001 
CELL NUMBER      0.42          (0.21 - 0.62)      2.42          (2.02 - 2.81) <0.001 
CLONING      0.21          (0.02 - 0.40)      3.42          (3.06 - 3.78) <0.001 
IT TB      0.29          (0.04 - 0.55)       2.96          (2.68 - 3.24) <0.001 
TIDEMARK      1.13          (0.95 - 1.30)      1.13          (1.00 - 1.25)   1.000 
TOTAL       2.63          (1.79 - 3.46)    15.54          (13.79 - 17.29) <0.001 
JOINT  AC    
 Mean (CI) Mean (CI)  
STRUCTURE      2.04          (1.14 - 2.95)      9.00          (6.94 - 11.06) <0.001 
CELL NUMBER      1.21          (0.82 - 1.60)      3.79          (3.18 - 4.40) <0.001 
CLONING      0.67          (0.36 - 0.97)      6.13          (5.51 - 6.74) <0.001 
IT TB      1.08          (0.57 - 1.59)       4.67          (4.21 - 5.12) <0.001 
TIDEMARK      2.17          (1.98 - 2.35)      2.21          (2.06 - 2.35)   0.731 
TOTAL       7.17          (5.44 - 8.89)    25.58          (22.49 - 28.67) <0.001 
Table 3.6: Results of microscopic scoring of OA changes in ovine knee articular cartilage, comparing 
meniscectomised and non-operated control groups.    
Figure 3.17: Chart of total joint data for the meniscectomised and non-operated control groups.  
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3.3.6.2.1 Correlation Between Cartilage Degeneration & Ligament Changes in 
 Individuals 
 
 
  
Figure 3.18: Simple regression analysis plot comparing OA score (total 
joint cartilage structure score) with ACL decorin expression.  
Figure 3.19: Simple regression analysis plot comparing OA score (total 
joint cartilage structure score) with ACL elastin expression.  
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Figure 3.20: Simple regression analysis plot comparing OA score (total 
joint cartilage structure score) with ACL fibril size.  
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3.3.6.3 Synovium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microscopic scoring of synovium from the meniscectomised and NOC groups showed 
they did not differ significantly for any criteria except for fibrosis, in which MENX 
scored higher than NOC.  The aggregate scores for the two groups were not 
considerably different.   
 
SYNOVIUM NOC MENX P 
 Mean (CI) Mean (CI)  
INTIMAL 
HYPERPLASIA 0.83          (0.35 - 1.32)  0.67          (0.42 - 0.92) 0.557 
CELL 
INFILTRATION 0.29          (0.01 - 0.57) 0.29          (0.04 - 0.55) 1.000 
SUBINTIMAL 
FIBROSIS 1.63          (1.26 - 1.99) 2.67          (2.45 - 2.89) <0.001 
 
VASCULARITY 
 
2.96          (2.88 - 3.04) 3.00          (0.00 - 0.00) 0.328 
AGGREGATE 
SCORE 5.71          (4.62 - 6.80) 6.63          (6.13 - 7.12) 0.147 
Table 3.7: Results of microscopic scoring of synovium in ovine knee articular cartilage, comparing 
meniscectomised and non-operated control groups.    
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Figure 3.21: Chart of ovine synovium scores for the meniscectomised and non-operated control 
groups.  
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3.4 DISCUSSION 
The gross morphological assessment of the articular surfaces clearly demonstrates the 
presence of major osteoarthritic changes in the knees of the meniscectomised group, 
which were not observed in the non-operated controls.  The MENX group showed 
significant cartilage degradation and osteophyte formation compared to the NOC sheep, 
which exhibited negligible morphological change.  Histological examination of the 
articular cartilage also revealed greater changes consistent with OA in the knee joints of 
meniscectomised sheep compared to NOC.  Furthermore, examination of the synovial 
membrane showed significantly greater subintimal fibrosis in the knees of MENX 
sheep, a prominent feature of chronic synovitis associated with OA [139].  It is possible 
that other synovial changes such as vascularity and cellular infiltration may have 
occurred in the acute stages of the disease process but were more transitory.  As the 
MENX group was treated identically to the NOC group in all other respects, this 
indicates that meniscectomy was successful in inducing OA. This supports the premise 
that the ligament changes identified within the joints of meniscectomised sheep in this 
study are analogous to those occurring in the joints of individuals with naturally 
occurring osteoarthritis.  
 
Investigation of gene expression in the cruciate ligaments revealed that the 
meniscectomy group did not exhibit many differences in ligament gene expression 
when compared to the NOC group.  One noteworthy difference that was observed 
however was the significantly reduced expression of decorin (the most abundant 
proteoglycan in ligament [15] ) in the ACL samples of the MENX group, which has the 
potential to affect the structure of the tissue considerably.  Decorin is a SLRP involved 
in regulating collagen I fibrillogenesis (the main structural element in ligament) [9, 41], it 
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can interact with a variety of proteins such as growth factors and other collagens such as 
type III [30, 40], and it modulates cell/matrix interactions, thus influencing the metabolism 
and integrity of the ECM [37].  Furthermore, an increase in the expression of MMP-I 
(collagenase I) which primarily degrades type I collagen, could accelerate the 
breakdown of collagen fibrils in the ligament tissue.  As there was no increase in type I 
collagen mRNA expression which would counteract this loss of collagen, the overall 
effect would likely be a decrease in the integrity of the tissue and potentially loss of 
biomechanical function.  It was noted that the ligament itself produced no measurable 
increase in the expression of other key inflammatory mediators such as MMP-3, MMP-
13, TNF- or IL-1, suggesting that the ACL was exposed to cytokines produced by 
other structures within the joint capsule such as synovium.  Finally, a reduction in 
elastin expression, which gives ligament its elastic properties, may decrease the ability 
of the ligament to stretch adequately when subjected to biomechanical forces.  This in 
turn may contribute to an increased risk of ACL rupture or over time contribute to an 
increase in the laxity of the ligament and joint instability.       
 
The results for decorin, elastin and MMP-I outlined above were obtained through 
analysis of the total mRNA data.  Although normalised data revealed similar findings, 
there is some doubt regarding the validity of the normalised results due to highly 
variable mRNA expression in the chosen housekeeping gene across all study groups.  
Theoretically, a chosen housekeeping gene should be a stably expressed reference 
which is representative of the cDNA concentration of the sample groups [239, 240], although 
this is not always the case for all biological specimens [241].  A number of commonly 
used housekeeping genes were tested in this study and none were found to be stably 
expressed in ligament, and were therefore found to be unsuitable as internal references, 
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potentially introducing large unpredictable error into the results analysis.  Results are 
shown as normalised to β-actin which showed the least variation of housekeeping genes 
tested, but was still believed to be too influenced by the effects of the various test 
parameters (e.g. OVX, MENX, O+M) to serve as a suitable housekeeping gene.  
Figures 3.22 and 3.23 display the variable expression of two commonly used 
housekeeping genes across the test groups.  The outcome of normalising all molecular 
biology results to a housekeeping gene (β-actin) is shown graphically in Appendix 
A4.1.2 (page 245).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: mRNA expression of beta actin in ACL 
tissue varied significantly across the study groups.   
Figure 3.23: mRNA expression of GAPDH in ACL tissue 
was also highly variable across the study groups and 
therefore is unsuitable as a housekeeping gene.   
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Based on the simple regression analyses comparing individual OA scores with ligament 
changes (as indicated by ligament fibril size, and decorin & elastin content) it was not 
possible to prove an association between osteoarthritic changes and the severity of 
ligament derangement.  These findings may be influenced however, by the consistent 
manner in which the meniscectomy model induced OA in the MENX sheep.  Because 
this model is so reliable in generating OA, as has been demonstrated by numerous 
studies of knee pathology in sheep and mice [242-247], variation in the cartilage scores of 
individuals in the MENX group was insufficient to correlate with ligament change.   
 
Biochemical analysis of the collagen and S-GAG content of the ACL samples from the 
NOC vs. MENX sheep corresponds to the findings of the RT-PCR analysis.  Results 
showed there was no significant reduction in the collagen content of the MENX sheep 
compared to the NOC sheep, which would fit with the lack of change in the expression 
of collagen types I, II or III.  Decorin is the most abundant SLRP found in ligament, 
therefore if expression is significantly reduced in MENX sheep, it is likely that there 
would be an overall reduction in ligament S-GAG content.  This fits with findings of the 
ACL biochemical analysis which found there was a significant reduction in S-GAG 
content in MENX sheep compared to NOC.   
 
These findings correspond with structural changes observed using TEM.  Calculation of 
fibril density (as a % of the total field) did not reveal any significant difference between 
the MENX and the NOC groups, however this does not reflect the differences seen in 
the size of fibrils and their arrangement.  The fibrils of ACL tissue from NOC sheep 
were uniform in size and arranged in a regular fashion.  This was in contrast to those of 
MENX sheep which had a significantly smaller average fibril size and showed a greater 
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size range with many small fibrils and a less regular arrangement.  Similar findings have 
been made in studies involving decorin deficient mice which exhibited connective 
tissues (such as skin and tendon) with more loosely and irregularly packed fibrillar 
networks and reduced mechanical function [31, 42, 248].  Danielson et al. (1997) [42] 
examined the properties of skin and tendon in decorin deficient mice, finding they 
produced fibrils with abrupt increases and decreases in mass along their axes, therefore 
producing fibres with coarser, cross-sectional outlines that were irregular in size and 
shape.  Furthermore, the fibrils were more haphazard in their arrangement, with 
increased interfibrillar spacing, allowing uncontrolled lateral fusion of collagen fibrils 
and reduced tensile strength of the tissue.  While this current study observed similar 
changes in fibril size and arrangement in the decorin deficient MENX group, we did not 
observe the lateral fusion seen by Danielson et al. (1997). This may be due to the fact 
that the mice in Danielson's study were devoid of decorin (knockout mice), whereas the 
sheep in this study were deficient although not completely lacking in decorin.   
 
Amaye et al. (2002) [49] found decorin deficient mice produced abnormal fibrils in 
tendon and skin with significant variation in the range, mean and distribution profile of 
collagen fibril diameters.  They also found changes in collagen fibril orientation, with 
fibrils adopting a more random organisation instead of the usual parallel orientation of 
wild type mice.  Connective tissues in these decorin deficient mice were more fragile 
with markedly reduced tensile strength.  Similarly, Matheson et al. (2005) [31] examined 
the effect of decorin deficiency in the periodontal ligament of decorin deficient mice, 
and discovered they produced fibril bundles that were heterogeneous in size, with a 
decreased average fibril diameter, and were non-uniform in shape.  Also, the 
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interfibrillar spacing was more variable than in the control mice and the fibrils were 
more disorganised.  
 
In contrast, Birk et al. (1995) [249], demonstrated that fibril growth was associated with a 
significant decrease in fibril associated decorin.  These findings fit with the common 
knowledge that decorin limits the size of collagen fibrils during fibrillogenesis [9, 34, 40, 48], 
therefore it's reasonable to assume a reduction in decorin would result in larger fibrils; 
however this does not correlate with the findings of this study or those mentioned 
previously.  It has been suggested by a number of authors that different SLRPS are able 
to perform similar functions, and that one SLRP may be able to compensate for a 
deficiency in another.  Zhang et al. (2006) [250] noted this in their study of decorin 
deficiency in mouse periodontal ligament and tail tendon.  They discovered decorin 
deficiency was associated with increased protein levels of biglycan, a SLRP that is 
structurally related to decorin and competes for the same binding site [38].  Analysis of 
tendon and ligament showed dysfunctional regulation of fibril growth in the early stages 
of linear and lateral growth from immature fibril intermediates, resulting in premature 
progression of fibrillogenesis and lateral fusion of fibrils, which were abnormally 
arranged and had decreased biomechanical strength.  This shows that while biglycan 
may be able to compensate for a lack of decorin in part, it was unable to delay fibril 
assembly and inhibit fibril maturation until the latter stages of development, two 
functions normally performed by decorin.   
 
Young et al. (2003) [251] also showed that biglycan and decorin are highly homologous 
and co-expressed in various connective tissues.  Results of their study revealed that 
biglycan & decorin double knockout mice had more profoundly disturbed connective 
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tissue than single decorin or biglycan knockout mice which appeared to be tissue 
specific.  The same was observed in biglycan & fibromodulin double knockout mice vs. 
single biglycan or fibromodulin knockout mice, suggesting a compensatory or 
synergistic function amongst these SLRPs in some tissues.  Neame et al. (2000) [43] also 
showed SLRPs can have a synergistic effect in modulating collagen fibrillogenesis in 
their in vitro study of decorin and lumican.  They analysed the effects of these two 
SLRPs, finding individually both were able to limit collagen I fibril diameter, while in 
combination they had an even greater effect on fibril size than either SLRP alone, 
suggesting they act on different binding sites on the fibril.   
 
This compensatory ability demonstrated by SLRPs may explain why this study (and 
others) found smaller rather than larger fibrils in decorin deficient tissues.  This study 
did not show a significant increase in the expression of other SLRPs, however this may 
be due to the levels of decorin being reduced rather than completely absent, and other 
proteoglycans may have been able to compensate without having to greatly increase 
their levels.   
 
While is appears clear that other SLRPs may act to modulate fibril size under decorin 
deficient conditions, they seem less able to compensate for decorin in its other role as a 
stabiliser and organiser of the collagen fibril network [42, 44].  Haphazard fibril 
organisation with increased interfibrillar spacing was common to all previously 
mentioned studies, with a number finding disruption was so severe that adjacent fibrils 
were able to fuse together [42, 250].  This implies that other SLRPs may be able to 
compensate for decorin in some but not all of its functions.   
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Histological comparison of the MENX and NOC sheep showed the collagen fibrils of 
NOC sheep were more regular and parallel in their arrangement.  This reflects the 
findings of the TEM analysis which found collagen fibrils in the MENX sheep were 
irregularly arranged, and again this may be influenced by a deficiency in decorin which 
plays a key role in maintaining the regular arrangement of the collagen network.  In 
addition, while the NOC sheep demonstrated an abundance of elastin fibres, evenly 
distributed throughout the tissue, the MENX sheep showed relatively few elastin fibres 
which were more randomly distributed.  This evidence further suggests a disruption to 
the regular arrangement of the fibre network, and supports the molecular findings that 
showed a significant reduction in the expression of elastin in the MENX sheep.  As 
previously stated, this may compromise the ability of the ligament to stretch in response 
to biomechanical forces and may contribute to ligament degeneration over time.   
 
Of further interest were the unusual electron dense bands seen on the cut surface of the 
MENX ACL samples that were examined in cross-section via scanning electron 
microscopy (SEM 2000x).  These striations were prominent on the MENX samples but 
were not as obvious on the NOC samples (Figures 3.10 - 3.13). It is unclear what causes 
these striations but it is possible they reflect the underlying disruption to normal 
ligament structure and potential loosening of interlamellar structure.  This is supported 
by the lower power (170x mag.) images of the same samples in which the MENX tissue 
appears loosely arranged with large spaces separating the bundles of collagen fibres.  In 
comparison, the fibre bundles in the NOC sample are tightly packed with little or no 
space between them.   
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In conclusion, the significant differences observed in the size and arrangement of 
MENX collagen fibrils demonstrates a disruption in normal ligament structure, which 
may affect the biomechanical properties of the tissue.  The reduced expression of 
decorin may contribute to the altered fibrillar arrangement observed in the MENX 
ligament tissue and the reduction in elastin could negatively influence the ability of the 
tissue to stretch in response to mechanical forces, predisposing it to injury.  
Furthermore, the increased expression of MMP-I may further affect the integrity of the 
tissue by degrading collagen fibrils at a faster than normal rate.    
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CHAPTER	4	
	
	
THE	INFLUENCE	OF	OVARIECTOMY	ON	THE	ANTERIOR	CRUCIATE	
LIGAMENTS	IN	NORMAL	AND	OSTEOARTHRITIC	(MENISCECTOMISED)	
SHEEP	
 
 
 
4.1 INTRODUCTION 
 
4.1.1 The Ovaries 
The ovaries are a pair of ovoid shaped structures located on either side of the uterus and 
connected by the fallopian tubes [252, 253].  Their primary functions in the reproductive 
system are to house and expel the ova, beginning at menarche and continuing until 
menopause, and the production and secretion of hormones [254].  
 
Structurally each ovary is made up of several layers (see Figure 4.1).  The outermost 
layer is the ovarian surface epithelium (formerly known as the germinal epithelium), 
which overlies the tunica albuginea, a tough and fibrous protective layer which covers a 
deeper dense region known as the cortex [253].  Located in the cortex are the primary 
ovarian follicles, each containing an oocyte (a potential or immature ovum).  
Surrounding the oocyte are the follicle cells (granulosa) which secrete oestrogen [252, 255].  
Oestrogen and follicle stimulating hormone (FSH) from the pituitary gland stimulate the 
follicle to mature, at which time it is called the Graafian follicle.  Luteinising hormone 
(LH), also from the pituitary gland, causes the release of the ovum (ovulation) leaving a 
ruptured follicle that subsequently becomes the corpus luteum.   The innermost layer of 
the ovary is known as the medulla and contains blood vessels, lymphatic vessels, and 
nerves [252, 253].   
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4.1.2 The Ovarian Hormones 
The major ovarian hormones are divided in two classes, the steroids (oestrogen and 
progesterone), and the peptides (particularly the inhibins and activins) [256].  The ovaries 
(and the testis in males) secrete cholesterol-derived hormones under the influence of the 
hypothalamo-pituitary axis, although activity of the ovary is cyclical unlike the testis 
which is maintained in a more or less constant state of activity.  The hormonal 
secretions of the ovary vary according to the phase of the menstrual cycle and are 
subject to both negative and positive feedback systems [257].   
 
4.1.2.1 Oestrogen 
Oestrogen is one of the major hormones that controls the development and maintenance 
of the female phenotype, and regulates critical signalling pathways involved in the 
control of cell proliferation and differentiation in reproductive and non-reproductive 
Figure 4.1:  Illustration showing the structure of an ovary and the progression of the 
primordial follicle to ovulated oocyte (Image from Marieb 2003). 
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tissues such as bone, cartilage, and blood vessels [252, 254, 258].  The primary sources of 
oestrogen are the ovaries (a secretory product of the granulosa cells of the ovarian 
follicle) and the placenta of pregnant females, with additional small amounts being 
produced by the adrenal glands and adipose tissue [259].   
 
The ovary requires both LH and FSH to produce sex hormones such as oestrogen.  LH 
stimulates the thecal cells surrounding the follicle to produce androgenic precursors 
(testosterone and androstenedione), which diffuse across the basement membrane to the 
granulosa cell layer.  Here the action of FSH facilitates their aromatisation to oestrogens 
via aromatase [255, 257].  There are three principle types of oestrogen produced, oestradiol, 
oestrone and oestriol [259-261].  Oestradiol (E2) is the predominant oestrogen produced 
during the premenopausal period, and is mainly secreted by the ovaries.  17β oestradiol 
is the most potent and abundant naturally occurring oestrogen in humans and is 
synthesised from testosterone [258, 261].  Oestrone (E1) is the main oestrogen present after 
menopause.  It is weaker than oestradiol and is the least abundant of the three oestrogen 
types.  Oestradiol can be reversibly oxidised to form oestrone, but its major precursor is 
androstenedione.  In post-menopausal women 95% of androstenedione is produced by 
the adrenal glands with only 5% produced by the ovaries.  Androstenedione is 
converted to oestrone in the peripheral adipose tissue [259, 261, 262].  Oestriol (E3) is the 
primary oestrogen during pregnancy and is produced in large quantities by the placenta 
[263].  In some women oestriol is secreted by the ovaries, especially during the luteal 
phase, but this is less common [264].  Both oestradiol and oestrone can be irreversibly 
converted to oestriol which is the weakest of the three oestrogens [258, 261].   
 
Once secreted into the blood, most oestrogen circulates reversibly bound to sex 
hormone-binding globulin (which inhibits its function), with a smaller fraction 
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remaining free or unbound in the serum (as biologically active hormone).  When 
oestrogen reaches its target tissues, free oestrogen penetrates the cell surface and binds 
to specific proteins known as oestrogen receptors [255, 259].   
 
4.1.2.2 Progesterone 
Progesterone, also known as antioestrogenic hormone, is another major steroid-derived 
hormone produced by the ovaries, placenta and adrenal glands [254, 255].  In the ovary, the 
site of production is the corpus luteum tissue after ovulation [259].  If fertilisation occurs, 
the placenta produces progesterone for the duration of the pregnancy, which functions 
to prepare and maintain the uterine wall, and inhibit muscular contractions.  If the egg is 
unfertilised, the ovaries continue to produce progesterone until a few days before 
menstruation [253, 259].  In addition to regulating normal female reproductive function, 
progesterone also plays an important role in non-reproductive tissues such as the 
cardiovascular system, bone, brain, liver, skin, gut and bladder [265, 266].  Progesterone 
receptors have also been identified in ligament [267-270]. 
 
4.1.2.3 Peptide Hormones 
The peptide hormones are secretory products of the ovarian granulosa cell and include 
inhibin, activin and relaxin.  Inhibin and activin are structurally related dimeric protein 
complexes that are functionally diverse with opposing biological effects [271, 272].  These 
proteins were first identified for their role in modulating pituitary FSH secretion 
(inhibin down-regulates and activin stimulates) but there is now evidence of their 
involvement in a local autocrine/paracrine regulatory role in ovarian follicles [273, 274].  
Investigation into the potential role of inhibins and activins in a variety of non-
reproductive tissues is ongoing, but they have been implicated in the regulation of cell 
proliferation and wound healing [275].   
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Relaxin is another peptide hormone produced by the corpus luteum of the ovary.  It is 
produced in the highest amounts during pregnancy, when it stimulates the breakdown of 
collagen in preparation for parturition.  However relaxin is not exclusively a hormone of 
pregnancy, and is also produced in non-pregnant females and males.  Its biological 
effects on the structure of collagen are far reaching, affecting a diverse range of tissues 
[276, 277].  It has been shown to reduce collagen deposition in the airways via stimulation of 
collagen-degrading enzymes (MMPs) and inhibition of TGF-β induced matrix protein 
production [277], and it modulates collagen metabolism in the ECM of ligaments 
throughout the body [276, 278-280].  Researchers have also revealed effects on the 
cardiovascular system [281], on regulation of the activity of mature osteoclasts [282], and 
demonstrated its ability to stimulate healing in ischemic wounds suggesting that relaxin 
may also have angiogenic effects [283].  
 
4.1.3 The Influence of Sex Hormones on Ligament  
4.1.3.1 Hormone Receptors 
In order for a hormone to stimulate a biological response in a target tissue, the tissue 
must possess specific hormone receptors.  Therefore an important step in determining 
whether the sex hormones affect ligament is establishing the presence of the appropriate 
receptors in that tissue.  Researchers have identified the expression of oestrogen and 
progesterone receptors in ligaments such as the human periodontal ligament [270, 284, 285], 
and the uterosacral ligament of women [267, 286, 287], but it was Liu et al. (1996) [268] who 
first identified the presence of oestrogen and progesterone receptors in the human ACL.  
Using immunohistochemistry, they localised these hormone receptors to the 
synoviocytes in the synovial lining, fibroblasts in the ACL stroma, and cells in the 
blood vessel walls of the ligament.  This establishes that the ACL is responsive to the 
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female sex hormones, and that these hormones may have an effect on its structure and 
composition.  
 
Sciore et al. (1998) [269] further investigated the presence of female sex hormone 
receptors in human and rabbit knee ligaments using RT-PCR.  Their investigations 
stemmed from existing research showing a higher frequency of knee ligament injury [288, 
289] and joint hyper-mobility in females compared to males [290-292], and that the occurrence 
of degenerative joint osteoarthritis is more common in older females [293].  These 
findings lead Sciore et al. (1998) to hypothesise that the connective tissue components 
may be regulated differently in males and females, and that these tissues may be 
responsive to oestrogen and progesterone.  Results of their study confirmed that 
oestrogen and progesterone receptor transcripts are expressed in ligament tissue in both 
humans and rabbits, therefore suggesting that ligament is a hormone-responsive tissue.  
Sciore et al. concluded that the rapid induction and reversal of the depression in 
oestrogen receptor transcript levels observed in their study in response to changing 
hormone concentrations, likely indicates that they serve an important function in 
ligament tissue. 
 
As outlined previously, relaxin is another ovarian hormone believed to play a major role 
in modulating collagen metabolism in the ECM of ligaments.  In pregnant women it is 
well known that relaxin contributes to loosening of the pelvic ligaments and cervical 
changes that occur before childbirth [294-296], however less is known of its effects on other 
ligaments in non-pregnant females and males.  In 2003, two research groups postulated 
that relaxin may play a role in the female predisposition for non-contact ACL injury, 
and sought to establish the presence of relaxin receptors in the ACL.  Dragoo et al. 
(2003) [297] tested for the presence of relaxin receptors in the remnants of ruptured ACLs 
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of men and women undergoing reconstructive surgery.  They discovered all female 
ACLs showed specific relaxin binding, suggesting the presence of relaxin receptors in 
the ACL of the female subjects.  This binding exhibited hormone specificity as it was 
only noted with relaxin, and not with relaxin's structural homolog, insulin.  In contrast, 
there was no binding of relaxin in the ACL tissues taken from male subjects.  As serum 
relaxin levels in non-pregnant females range from 20-150 pg/ml [298-300], they concluded 
that women expressing relaxin receptors with higher relaxin levels may be at increased 
risk of ACL injury due to increased exposure to this collagenolytic hormone. 
 
The same year, Galey et al. (2003) [301] also investigated the presence of relaxin 
receptors in ACL specimens from eight female and four male reconstruction patients 
using immunohistology techniques.  All 12 ACL samples stained positive for relaxin 
binding, although staining was more intense in female subjects.  Their data suggests that 
relaxin binding to the ACL is specific, indicative of a receptor-mediated event.   
 
The effect of testosterone on the female ACL was also investigated by Lovering et al. 
(2005) [302].  The findings of their study identified the presence of androgen receptors on 
the ACL of female subjects suggesting that it is an androgen responsive tissue, however 
testosterone fluctuations did not correlate with changes in ACL stiffness.  This indicates 
that ACL stiffness is likely influenced by another sex hormone, or a combination of 
hormones. 
 
4.1.3.2 Animal Studies   
Animal research may be conducted to further knowledge about that species or may 
serve as a model for human disease.  A number of research groups have made use of 
animal models to explore the influence of differing ovarian hormone concentrations on 
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ligament, including during pregnancy, through variation in the oestrus cycle and after 
ovariectomy.  There are multiple benefits to using animal models, especially in respect 
to controlling experimental parameters, minimising environmental influences, and 
obtaining adequately matched study groups.  Conversely, for the animal model to be 
valid in human research, it must bear adequate relevance to the anatomy and physiology 
of the human disease process.   
 
As with human populations, there is evidence that gender may play a part in ligament 
injury in animals.  Several studies investigating the epidemiology of cranial cruciate 
rupture (equivalent to human ACL) in canine populations have identified female gender 
among the significant risk factors [120, 121, 303-305].  A recent study of dogs in the United 
Kingdom by Adams et al. (2011) [306] found that females were twice as likely to suffer 
cranial cruciate rupture compared to males.  Yet another study by Harasen (1995) [307] 
reported a considerable 70% of their study population of dogs with cranial cruciate 
rupture were female.  In the absence of any known differences in other risk factors, this 
suggests that the female hormonal state influences susceptibility to injury, presumably 
through modulation of structure or cellular function.  
 
During animal pregnancy, the levels of sex hormones such as oestrogen, progesterone 
and relaxin increase steadily until shortly before birth, paralleling that of humans [308-312].  
Several authors have used animal models to investigate the increase in joint laxity 
known to occur in pregnancy [313].  In 1998, Hart et al. [314] used a rabbit model to 
examine the effect of pregnancy on gene expression in knee ligaments (specifically the 
ACL and MCL).  Results of their study demonstrated that hormonal fluctuations 
occurring during pregnancy resulted in changes in the patterns of gene expression in 
knee ligaments.  Messenger RNA (mRNA) transcripts for both collagen types tested (I 
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& III) were depressed in RNA isolated from the MCL.  Likewise transcripts for 
collagen type III were significantly depressed in ACL, however in contrast to the MCL, 
transcripts for collagen type I were not depressed.  Expression for proteoglycans was 
more variable, with biglycan depressed and decorin increased in MCL, while ACL 
exhibited no alteration in transcript levels.  With regard to proteinase expression, MCL 
showed an increase in MMP-1 (collagenase) expression but not its inhibitor TIMP-1.  
ACL showed no difference in MMP-1 or TIMP-1 expression compared to non-pregnant 
controls.  These results suggest that the response of knee ligaments to pregnancy at the 
mRNA level is complex and may be ligament specific.  Further investigation is required 
to confirm that these mRNA changes translate to biochemical alterations at a tissue 
level.   
 
Hart et al. (1998b) [315] conducted a similar study, again investigating the effect of the 
mRNA changes in knee ligaments induced by pregnancy in a rabbit model.  Results of 
this subsequent study showed that mRNA for collagen types I & III were depressed in 
both MCL and ACL during pregnancy.  Expression of mRNA for biglycan, decorin and 
TIMP-1 was also significantly depressed in MCL and ACL.  Transcript levels for 
collagenase remained unchanged compared to non-pregnant controls. While these 
results vary to some degree from those of their previous study, they still indicate that the 
relationship between increased ligament laxity and molecular changes during pregnancy 
is complex and may warrant further study.  
 
Ohtera et al. (2002) [316] examined the effect of pregnancy on joint contracture in the rat 
knee. During pregnancy oestrogen and relaxin levels are elevated which affects 
fibroblast function [290],  which in turn is associated with altered soft tissue structure and 
increased joint laxity, particularly due to the effect of oestrogen in reducing type I 
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collagen synthesis and fibroblast proliferation [317].  Furthermore, relaxin also decreases 
the synthesis and secretion of interstitial collagen, while increasing the expression of 
MMP procollagenase and decreasing TIMP production by fibroblasts [318, 319].  Given 
evidence supporting the influence of female hormones on ligament laxity, Ohtera et al. 
hypothesised that the hormonal changes occurring during pregnancy could have a 
therapeutic role in preventing joint contracture.  Results of their study demonstrated a 
trend towards reduced contracture in the knee joints of pregnant subjects compared to 
non-pregnant subjects, however these findings were not statistically significant.  The 
authors identified a number of limitations in this study which may have influenced the 
results and so suggest further research should be conducted in this area in order to draw 
more accurate conclusions.  
 
Further evidence to suggest an increase in female sex-hormone levels alters the 
properties of knee ligament is provided by Liu et al. (1997) [317].  Having previously 
identified the presence of oestrogen and progesterone receptors in fibroblasts of human 
ACL, they investigated the affect of oestradiol on the proliferation of fibroblasts and 
collagen synthesis in rabbit ACL.  After confirming the presence of oestrogen receptors 
in rabbit ACL fibroblasts, they exposed cultured ACL fibroblasts to increasing 
concentrations of oestrogen for a period of 2 weeks.  Results revealed collagen 
synthesis and fibroblast proliferation were significantly reduced with increased 
oestradiol concentration.  The authors propose that these alterations in ACL cellular 
metabolism may lead to changes in ligament composition, therefore rendering it more 
susceptible to injury. 
 
Slauterbeck et al. (1999) [320] investigated the effect of oestrogen levels on the failure 
load of the ACL in rabbits.  Based on evidence that female athletes tear their ACL more 
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frequently than male athletes [288], they hypothesised that increasing the level of 
circulating serum oestrogen would decrease the load at failure for rabbit ACL.  Their 
study involved two groups of ovariectomised (OVX) rabbits, one group treated with 
oestrogen and the other a non-treated control group.  While results showed that 
specimens treated with oestrogen had a significantly reduced load at failure compared 
with the non-treated controls, suggesting that oestrogen may influence ligament 
strength, the investigators conclude that further research is required to clearly establish 
the exact mechanism responsible for ACL failure in women.   
 
In a similar study Komatsuda et al. (2006) [321] hypothesised that serum oestrogen levels 
may play some role in the discrepancy in injury rates between the sexes.  Various serum 
oestrogen levels were tested in OVX rabbits using 17 oestradiol. Their findings 
showed a decrease in ultimate tensile strength and linear stiffness occurred in specimens 
with high serum oestrogen levels.  This suggests that high serum levels of oestrogen 
may be one of the factors in the multifactorial pathogenesis of ACL rupture.  In a 
subsequent study from this research group, Hattori et al. (2010) [322] continued 
investigations into the effect of supraphysiologic levels of oestrogen on the tissue 
properties of the ACL.  Again using an OVX rabbit model, they administered various 
doses of 17 oestradiol over a 4-week period, however this study utilised different 
methods to evaluate changes in the ACL.  Scanning acoustic microscopy was used to 
measure tissue sound speed in ligament samples as an indicator of the elastic modulus 
of the tissue.  Results indicated that there was a significant, negative correlation 
between increasing serum oestrogen levels and the elasticity of the tissue.   
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Lee et al. (2004) [323] examined whether mechanical tensile forces affect oestrogen 
regulation of collagen synthesis by porcine ACL fibroblasts in vitro.  Results revealed 
that oestrogen alone stimulated synthesis of collagen types I and III at the mRNA level.  
When oestrogen and mechanical loading were combined, expression of collagen types I 
& III was decreased at all tested oestrogen levels.  This suggests that oestrogen may 
directly regulate ligament structure and function through alteration of collagen 
synthesis, dependent on mechanical loading. 
 
In a subsequent study, Lee et al. (2004b) [324] studied the combined effects of oestrogen 
and mechanical loading on the gene expression of three major ligament components; 
type I collagen, type III collagen and biglycan.  Results revealed that cyclic tensile 
loading alone increased the expression of type I collagen but not type III collagen or 
biglycan.  Oestrogen alone increased the mRNA expression of collagen types I & III but 
not biglycan.  Combined oestrogen and cyclic tensile loading however, inhibited the 
mRNA expression of all three genes.  This suggests that the inhibition of all three 
matrix molecules resulting from a combination of oestrogen and mechanical loading is 
unique to females and may explain the high incidence of ACL injury in females.     
 
Woodhouse et al. (2006) [325] studied the effects of reproductive hormones on the 
strength of rat ACL.  The material properties of ACL in rats with normal oestrus cycles 
were compared with rats administered oral contraceptives.  After 12 oestrus cycles, 
those rats influenced by oral contraceptives displayed greater ACL toughness and had 
significantly lower serum progesterone levels.  The investigators do not believe 
differences in the mechanical characteristics of the two groups were the result of short-
term changes in the ACL structure due to hormone fluctuations, suggesting that this was 
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unlikely due to the short 5-day cycle of rats.  Rather, they believe the differences in 
ACL structure are due to exposure to differing hormone levels over time.  They 
concluded that chronic exogenous hormone treatment in rats, dosed to mimic oral 
contraceptive use in humans, is associated with changes in the mechanical 
characteristics of the ACL.   
 
In contrast to the findings of these studies, a number of other authors dispute the notion 
that changes in sex-hormone levels alter the composition of ligament tissue or fibroblast 
activity.  Seneviratne et al. (2004) [326], examined the effect of various levels of 
oestrogen on ACL fibroblast proliferation and collagen synthesis in vitro in an ovine 
model.  They found no significant difference in ACL fibroblast proliferation or collagen 
synthesis regardless of oestradiol concentration.  They comment that collagen has a low 
turnover in ligament and therefore it is unlikely that a 2 to 3-day per month increase in 
serum oestrogen would result in significant alterations in the material properties of the 
ACL.  Rather, they believe the aetiology of non-contact ACL injury is complex and 
multifactorial in nature.  One suggestion is that oestrogen or relaxin may have an effect 
on the expression and activation of metalloproteinases in ACL tissue.  Despite the 
results of this study, which indicate oestrogen alone does not directly affect fibroblast 
activity, oestrogen cannot be excluded as a contributing factor in ACL injury.  
 
Rau et al. (2003) [327] studied the failure properties of the ACL during the oestrous cycle.  
Their theory was that oestrogen may play a role in the mechanism underlying female 
ACL injury, based on the presence of oestrogen receptors in human and rabbit ACL.  
They examined the mechanical properties of the ACL from the right hind limbs of 60 
female rats.  The rats were divided into four groups according to their stage of the 
oestrus cycle.  Results showed no difference in the mechanical properties of the ACL 
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between the groups, suggesting that fluctuations in the oestrous cycle during the normal 
oestrus cycle do not alter the failure properties of the tissue.  Again this study may 
demonstrate a lack of influence of hormonal fluctuation on the properties of rat ACL, 
but it cannot rule out the presence of the female sex hormones as a contributing factor in 
female ACL injury.     
 
Strickland et al. (2003) [328] hypothesised that although female athletes injure their ACL 
at a much higher rate than males, oestrogen does not directly affect ligament ultimate 
stress and knee laxity.  Using an ovine model, the effect of ovariectomy, ovariectomy 
plus oestrogen implant, and a selective oestrogen agonist (raloxifene) were tested 
against a sham control.  Difference in the ultimate stress between ram and ewe ACL 
was also tested.  From the results of this study they concluded that ultimate stress 
differences do exist between the ACL of rams and ewes, but this decrease in ligament 
strength could not be attributed to the effects of oestrogen or oestrogen receptor agonists 
at physiologic levels.  There are however, aspects of their scientific method which may 
call into question these findings.  Primarily, no explanation is given why the ligament is 
dissected down to a single bundle, which presumably would not represent the true 
biomechanical strength of the ligament.  In addition, the joint angle used during testing 
was not equal to that of normal stance.  Again no explanation was provided as to why 
this was done, raising the question as to whether the results are representational of 
normal (sheep) knee biomechanics.      
 
Warden et al. (2006) [329] tested the viscoelastic and tensile mechanical properties of 
MCL and ACL in male rats administered either oestrogen, or an oestrogen agonist to 
avoid the influence of endogenous oestrogen.  Data indicated that neither oestrogen nor 
pharmacological stimulation of oestrogen receptors has a major direct effect on 
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ligament mechanical properties.  This study is limited however, in that it is unclear 
whether the expression of oestrogen receptors in male ligament is the same as it is in 
female ligament, or whether male oestrogen receptors exhibit the same degree of 
sensitivity as females, which could affect the results.   
 
4.1.3.3 Human Studies 
It is well documented that there is a higher incidence of ligament injury involving the 
knee joints of females compared to males [330-332].  In addition, it is widely reported that 
hormonal fluctuations associated with pregnancy or the menstrual cycle lead to an 
increase in the knee joint laxity [333-337].  This evidence suggests that the female sex 
hormones, in particular oestrogen, may have some influence on the function of knee 
joint structures in women and that this may predispose them to ligament injury.  Pollard 
et al. (2004) [332] investigated whether gender differences in hip and knee joint 
mechanics in male and female athletes would explain the higher incidence of injury in 
females.  They concluded that male and female athletes demonstrate similar hip and 
knee joint mechanics while performing a randomly-cued cutting (side-step) manoeuvre.  
This suggests that basic hormonal differences are a potential cause for the injury 
discrepancy. 
 
Slauterbeck et al. (2001) [338] stated that while the reasons for this discrepancy between 
injury rates in males and females is unknown, possible causative factors include size, 
strength, anatomic, social and hormonal differences.  Their study examined gender 
differences in metalloproteinases (MMPs) and their inhibitors in order to establish 
whether normal tissue remodelling events play a role in ACL injury.  Tissue 
remodelling occurs continuously in normal and repairing tissue, with a balance existing 
between the degradative and biosynthetic arms of tissue remodelling, modulated by 
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MMPs and tissue inhibitors of MMPs (TIMPs).  Gender differences may play a part in 
this control because oestrogen and progesterone regulate the transcription of several 
MMP and TIMP genes.  Result of this study showed that one parameter of tissue 
remodelling, the MMP3/TIMP1 gene expression ratio, is higher in the ACL of women 
than in men.  This provides support for the hypothesis that that tissue remodelling in the 
human ACL varies by gender, and that such gender differences may explain the high 
injury rate in females.   
 
Chandrashekar et al. (2005) [339] examined differences in the mechanical properties of 
ACL tissue in order to elucidate whether the female predisposition to injury was due to 
anatomical, neuromuscular or hormonal differences.  They performed a cadaveric study 
to determine if any difference exists between the tensile properties of the ACL of males 
and females.  When accounting for age and body anthropometric measurements as 
covariates, results revealed the female ACL was found to have lower mechanical 
properties such as strain at failure, stress at failure, strain energy density at failure and 
modulus of elasticity.   Although this study did not identify the cause of the gender 
difference in mechanical properties, it does show that there is variation between males 
and females, and hormonal differences between the sexes cannot be ruled out as an 
influence.   
    
The highest levels of endogenous oestrogen, progesterone and relaxin occur in the 
female body during pregnancy [340-343].  Dumas and Reid (1997) [344] stated that a 
pregnancy-related increase in the laxity of knee joint ligaments may result in joint 
instability, and presumably renders the joint more susceptible to injury.  They assessed 
knee laxity changes in healthy female subjects during pregnancy using a KT-100 
clinical arthrometer, and observed that knee laxity was increased during the second half 
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of pregnancy and significantly decreased by 4 months after birth.  They also tested the 
effect of exercise on the same group of pregnant women and found that increased 
weight-bearing exercise had no additional influence on the laxity of the joint.  
 
Charlton et al. (2001) [339] performed another study examining a correlation between 
endogenous oestradiol in pregnancy and ACL laxity.  In this study patients were 
initially examined during the third trimester of pregnancy, and again post partum.  
Results showed that high serum oestradiol levels present during the third trimester of 
pregnancy correlated with increased ACL laxity.  Laxity was found to significantly 
decrease as serum oestradiol returned to non-pregnant levels.   This evidence supports 
the theory that oestrogen may affect laxity of the ACL in female subjects.  If joint laxity 
predisposes the ACL to injury, then the effects of female hormones such as oestrogen 
may prove a significant factor in the higher incidence of non-contact ACL injury in 
females.  The authors are however, careful not to conclude that oestrogen directly 
affects laxity of the ACL, stating, “…the hormonal milieu in female subjects is 
complex.”  Rather, oestrogen fluctuations may induce changes in ACL collagen and 
elastin composition which in turn leads to changes in the mechanical properties of the 
ligament tissue.  They also identified relaxin, particularly active during pregnancy, as 
also being likely to have an effect on collagen remodelling to reduce soft tissue tension, 
including that of ligaments.  Oestrogen however, is thought to influence relaxin 
regulation.   
 
Many researchers have focussed on investigating oestrogen fluctuations associated with 
the menstrual cycle as a potential cause for the female predisposition to knee joint laxity 
and ACL injury, as it is well reported that non-traumatic ACL injuries are 4-8 times 
greater in women compared to men [288, 345-348].  Wojtys et al. (1998) [336]  postulated that 
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oestrogen has a direct effect on collagen metabolism and behaviour, and investigated 
the association between the menstrual cycle and the occurrence of ACL injury in female 
athletes.  They found a significant correlation between the ovulatory phase of the cycle 
and ACL injury, with statistically more than expected injuries occurring during the 
ovulatory phase, and significantly fewer injuries occurred during the follicular phase.  
Wojtys et al. (1998) infer that the surge of oestrogen just prior to the ovulatory phase 
suggests that the increased incidence of non-contact ACL injury may be hormonally 
induced.  The investigators make reference to previous studies showing oestrogen 
acutely decreases the total collagen content in rat facia, and reduces collagen synthesis 
in rat periodontal tissue [349, 350].   
 
Since the results of this study were published a number of issues have been raised 
regarding its validity.  In a letter to the Editor of the American Journal of Sports 
Medicine, Wolman (1999) [351] outlined three major flaws in this study.  Firstly he stated 
that five of the 28 subjects in the study were taking oral contraceptives which would 
give them a very different hormone profile to the others, and that the ovulatory phase of 
the cycle would not occur in these five women.  The article assumes that women taking 
an oral contraceptive and those who menstruate naturally have a similar cyclical 
hormone profile, which Wolman (1999) believes is wrong.  Secondly, in their study 
Wojtys et al. (1998) assumed a 28-day cycle for all subjects in their chi-square test, 
however they state that cycle lengths for the study group actually ranged from 21 to 32 
days.  We are not told what proportion of subjects had the ideal 28-day cycle.  Those 
subjects that differ from the 28-day ideal will alter the expected frequency, especially 
those with very short cycle lengths, and dramatically change the result of the study.  
Finally the study involved subjects with widely varying ages, namely 11 to 42 years.  
 
 
140
Wolman (1999) stated that hormonal profiles in menstruating women differ across age 
groups, with anovulatory cycles being common in the first few years after menarche and 
approaching menopause.  He believes this group is heterogeneous regarding their 
hormone profiles and should not be considered together in a study drawing conclusions 
on a hormonal basis.  In 2000 McShane et al. [352], in a second letter to the editor, 
detected errors in the statistical analyses of the data proving Wojtys et al. (1998) result 
for the correlation between ovulatory phase and ACL injury was not significant as 
claimed.     
 
Yu et al. (1999) [353] studied the effects of 17 oestradiol on cell proliferation and 
procollagen levels, which serve as an indicator of collagen synthesis in human ACL 
fibroblasts.  They hypothesised that fluctuation in the serum oestrogen levels may in 
turn translate to changes in the metabolism of ACL cells, and consequently may affect 
ligament structure and composition.  Results showed a significant dose dependent effect 
of oestrogen on ACL fibroblasts during the early period of hormone exposure.  Type I 
procollagen synthesis and fibroblast proliferation were significantly reduced with 
increased oestradiol concentrations.  Therefore, cumulative or acute fluctuations in 
serum oestrogen concentrations, such as those occurring during the menstrual cycle, 
may induce changes in ACL fibroblast metabolism.   Yu et al. (1999) conclude that this 
in vitro study highlights the important influence of the female sex hormones (in 
particular oestrogen) on collagen metabolism, and comment that further in vivo studies 
should be undertaken in the future. 
 
Heitz et al. (1999) [354] also examined the correlation between hormonal changes during 
the menstrual cycle and ACL laxity, to determine whether surges of oestrogen and 
progesterone during a normal menstrual cycle affect ACL laxity.  They state that 
 
 
141
increased laxity may increase the risk of ACL injury, but also comment that this may 
also be a protective mechanism allowing the ligament to elongate rather than rupture. 
They do not elaborate however, on why this “protective mechanism” would need to 
fluctuate with hormone changes.  Results of the study showed a significant increase in 
knee joint laxity in subjects throughout the menstrual cycle compared to baseline 
measurements.  They were unable to determine if the increased laxity was greatest 
during a particular phase of the cycle, or if it was due to surges in oestrogen, 
progesterone or a combination of both.  The investigators concluded that further 
research was required to establish whether the circulating hormones simply increase 
joint laxity or if they contribute to the increased incidence of ACL injury in women. 
 
Yu et al. (2001) [335], studied the combined effects of oestrogen and progesterone on cell 
proliferation and procollagen synthesis in human ACL fibroblasts.  Results showed 
fibroblast proliferation and type I procollagen synthesis are significantly reduced with 
increasing oestrogen concentrations.  These effects are mitigated by increasing levels of 
progesterone, which subsequently increases fibroblast proliferation and type I 
procollagen synthesis.  Yu et al. (2001) suggest that cumulative or acute fluctuations in 
these hormones such as those occurring during the female menstrual cycle could result 
in structural and compositional changes.  This in turn could decrease the strength of the 
ligament and render it more susceptible to injury. 
 
In 2002, Slauterbeck et al. [355] examined the predisposition for ACL injury in female 
athletes.  They outline gender differences regarding the ACL; with females having 
increased risk of ACL graft rupture and unsuccessful outcomes post ACL reconstruction 
[356].  They reiterate that a possible explanation for these observations is sex specific 
differences in ligament remodelling.  Based on the premise that as oestrogen and 
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progesterone regulate the expression of tissue remodelling proteins (MMPs and TIMPs), 
they hypothesised that ACL injury would be more likely at a certain time or times in the 
menstrual cycle.  Therefore the aim of their study was to determine whether ACL 
injuries in females occur randomly or correlate with a specific phase of the menstrual 
cycle.  Results showed that a significantly greater number of ACL injuries occurred on 
days 1 and 2 of the menstrual cycle.  In commentary on this article, Kirk (2002), raised 
some doubts on the reliability of the study results.  She stated that the authors relied on 
the subjects to identify the phase of the cycle they believed themselves to be in at the 
time of injury, which can be unreliable.  The authors attempted to correct for this 
problem by using salivary oestrogen and progesterone measurements, however surges in 
hormones can occur at multiple times during the cycle making determination of cycle 
stage using this method difficult [357].   
 
Deie et al. (2002) [358] examined changes in anterior knee joint laxity across different 
stages of the menstrual cycle, and found the anterior displacement values varied 
significantly between the follicular and ovulatory phase, and the follicular and luteal 
phase.   There were no statistical differences in the anterior displacement of knee joints 
in a similar, age-matched group of men.  This lead the investigators to conclude that 
ACL laxity in women might be dependent on the concentration of hormones, with 
further study required to establish whether increased joint laxity is linked to the high 
injury risk in women.   
 
Wojtys et al. (2002) [359] theorised that there was an association between the distribution 
of ACL tears and menstrual cycle phase.  Results of hormone assays indicated that 
women taking part in the study had a significantly greater than expected percentage of 
ACL injuries during the midcycle (ovulatory) phase, and a less than expected 
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percentage occurring during the luteal phase.  It was not clear however, if female 
hormones such as oestrogen act directly on ACL collagen metabolism or via indirect 
action.   
 
Dragoo et al. (2003) [297] investigated the mechanism for increased non-contact ACL 
injuries in women by examining ACL remnants from men and women undergoing 
reconstruction.  Results showed relaxin exhibits specific saturable binding in the female 
ACL where specific relaxin receptors were present.  These receptors were not present in 
men.  Dragoo et al. (2003) suggest that the high incidence of ACL rupture in females 
may be partially explained by the effects of relaxin, which reduces the density and 
organization of collagen bundles, observed using histology and immunohistochemistry 
techniques.  This leads to a marked local decrease in the total collagen content.  Gender 
differences also play a role because the expression of relaxin receptors appears to be 
under the control of oestrogen, and oestrogen priming also increases the response of 
target organs to relaxin.  Furthermore, during the luteal phase when relaxin levels are 
highest, there may be simultaneous binding of oestrogen and relaxin in ACL tissue.  
The investigators found that these hormones have a synergistic effect on the collagen 
degradation in the ACL.  Dragoo et al. conclude that the effects of these hormones 
could increase the risk of ACL rupture in females.   
 
In 2003 Romani et al. [360] investigated the high ratio of ACL rupture in females by 
examining the correlations between the female sex hormones and ACL stiffness in 
healthy females.  They tested ACL stiffness and assessed concentrations of oestradiol, 
oestriol, oestrone and progesterone during the three phases of the menstrual cycle.  
Results indicated that there was a significant correlation between oestradiol, oestrone 
and progesterone and ACL stiffness near ovulation.  ACL stiffness correlated positively 
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with progesterone and negatively with oestradiol concentrations near ovulation.  These 
two hormones appear to have an antagonistic effect on ACL. They conclude that future 
studies should examine the physical properties of the ACL near the ovulatory phase.  
 
Shultz et al. (2004) [361] similarly examined the notion that ACL laxity is affected by 
fluctuating hormones levels associated with the menstrual cycle.  They measured 
changes in knee joint laxity and hormone levels across the menstrual cycle in 25 female 
subjects.  Results showed that changes in knee joint laxity in response to changes in 
serum hormone levels are not immediate, but occur a few days later.  A relationship was 
also evident between hormone concentration and knee laxity.  Oestrogen, progesterone 
and testosterone each contributed to changes in knee laxity across the cycle.  The effects 
of oestrogen and progesterone combined contributed to more of the variance in knee 
laxity that any of the hormones acting alone.  The conclusions made from this study 
were that changes in sex hormones may mediate knee laxity across the menstrual cycle, 
and that the relative contribution of each hormone and the associated time delay is 
highly variable among women.   
 
Shultz et al. (2005) [362] further investigated whether absolute sex hormone 
concentrations (oestrogen, progesterone and testosterone) predict the magnitude of knee 
joint changes.  Results showed that the absolute minimum concentrations of 
progesterone and oestrogen in the early follicular phase are important factors in 
determining the sensitivity of the knee joint to changing hormone levels.  Lower 
oestrogen levels and higher progesterone levels during the early follicular phase 
correlated to women experiencing a greater increase in knee laxity when oestrogen and 
testosterone levels eventually peaked.  The study also revealed that knee laxity changes 
are fairly transient and vary between individuals.  The investigators found it difficult to 
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identify a day or even a range of days that represents the same point in the menstrual 
cycle for all females.  In addition, there was a delay of 3 to 4 days from a change in 
hormone levels to when knee laxity altered.    
 
Shultz et al. (2006) [363] continued the investigation into sex differences in knee joint 
laxity across the menstrual cycle.  In this study they comment that sex differences in 
knee laxity appear to be restricted to adults.  This theory is based on research by Flynn 
et al. (2000) [364], which measured knee laxity in children.  They found no statistical 
difference in knee laxity between girls and boys of a similar age.  Shultz et al. (2006) 
suggest that this leads to the hypothesis that it is the influence of sex hormones that 
begin circulating after puberty that contributes to ACL rupture in women.  The aim of 
this study was to investigate hormonal influences on joint behaviour in males versus 
females across the menstrual cycle.  Results revealed sex differences in knee laxity were 
dependent on the menstrual cycle, with increased laxity coinciding with significant 
increases in oestradiol.  Females were found to have greater knee joint laxity than males 
at all measured stages.  Females were also found to have variable joint laxity at different 
stages of their cycle.  These results suggest sex hormones may be a primary mediator of 
sex-based differences in knee laxity.   
 
Pollard et al. (2006) [333] examined the collective effects of gender, oestrogen and 
exercise on knee laxity,  and showed females exhibited greater knee laxity than males 
across all three stages of the menstrual cycle (follicular, ovulatory and luteal), both pre 
and post exercise.  They did not find that oestrogen fluctuations during the menstrual 
cycle altered knee laxity, rather a general increase in knee laxity was observed in 
females, possibly leading to decreased joint stability and increased ACL injury.   
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Beynnon et al. (2006) [334] collected serum samples and self-reported menstrual history 
information from skiers immediately after ACL injury (within 2 hours).  Skiers were 
found to be three times more likely to rupture their ACL in the preovulatory phase than 
the postovulatory phase. These findings suggest cycle phase may be one of the risk 
factors that influence knee ligament injury in females.  It is still unclear from this study 
whether oestradiol and progesterone act directly on the ACL, or if other hormones 
associated with the menstrual cycle may modulate injury risk.   
 
Zazulak et al. (2006) [365] and Hewitt et al. (2007) [366] reviewed current literature on the 
effects of the menstrual cycle on ACL injury and concluded that women are more 
susceptible to ACL injury during the preovulatory phase of the menstrual cycle.  In 
addition, Hewitt et al. stated that it is difficult to perform a controlled study in which a 
“normal” cycle is clearly defined.  They also outlined the limitations of some studies 
that relied on the use of questionnaires to collect data. 
 
In contrast to many of the afore mentioned studies, which agree to some degree that 
fluctuations in the female sex hormones effect the laxity and injury rate of the female 
ACL, a number of investigators have concluded that fluctuations in these hormones are 
unlikely to effect the mechanical properties of the ligament.  Karageanes et al. (2000) 
[367] studied the knee joints of female athletes over an 8-week period using arthrometry.  
Results showed no statistical difference in knee joint laxity across the three phases of 
the menstrual cycle.  The investigators concluded that no single phase of the menstrual 
cycle clinically affects the female ACL more than another.  This study may suggest that 
fluctuations in the levels of hormones such as oestrogen do not alter joint laxity, 
however it cannot rule out that the presence of the female sex hormones may indeed 
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predispose females to ACL injury.  The fact that laxity doesn’t fluctuate with changing 
hormone levels does not mean that oestrogen plays no part in the aetiology of ACL 
disease in females.    
 
Van Lunen et al. (2003) [368] used an arthrometer to measured the knee joint laxity of 12 
female subjects and correlated the results with reproductive hormone levels across their 
menstrual cycles.   The results indicated that there was no significant difference in knee 
laxity across the menstrual cycle, therefore suggesting that oestrogen fluctuations do not 
directly alter ACL laxity.  Similarly, Belanger et al. (2004) [369] examined the laxity of 
the ACL of 18 females and concluded that ACL laxity is not significantly different 
across the three phases of the menstrual cycle.  However, both of these studies are 
limited by their small sample size and the variation in the menstrual cycles of women.  
 
A study by Beynnon et al. (2005) [370] also failed to show a significant correlation 
between hormone fluctuations during the menstrual cycle and cyclic fluctuations in joint 
laxity.  However this does not rule out the possibility that these hormones contribute to 
the increased risk of injury observed in females.  This same study also found that 
women had significantly greater knee and ankle joint laxity values compared to men.  
The investigators concluded that only a single time-point joint laxity measurement is 
required to assess an individual for injury risk. 
 
Wolman (2009) [331] in a review of knee injuries in females athletes comments that 
results regarding the timing of injury and the phase of the menstrual cycle are 
inconclusive, with different studies each identifying risk during a different phase of the 
cycle.  Often these studies involve subjects taking oral contraceptives, when the effect 
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of oral contraceptives on injury risk is unknown, and many utilise questionnaires to 
determine the subject’s stage of cycle, which may be unreliable.   
  
Changes in tissues other than ligament may also affect knee joint laxity and should not 
be overlooked.  Oestrogen receptors are present within skeletal muscle, leading Bell et 
al. (2011) [371] to hypothesise that muscle stiffness in the hamstrings may limit ACL 
loading.  There is substantial evidence to suggest that muscle strength does not change 
across the menstrual cycle [372-375] but it has been shown that muscle stiffness does 
change during the menstrual cycle [376].  Bell et al. (2011) evaluated the muscle 
properties of the hamstrings and reproductive hormone levels in men and women with 
no history of knee injury.  Male subjects showed no affect of the selected hormones 
(17β oestradiol, free testosterone and progesterone) on muscle properties, while females 
demonstrated a negative correlation between muscle stiffness and 17β oestradiol & free 
testosterone.  Given the low turnover of collagen in normal ligament [326, 377-379] it seems 
improbable that the short-term fluctuations in hormone levels would cause significant 
changes in the material properties of the ACL.  In light of Bell et al.'s results, it may be 
possible that other structures such as muscles may modulate knee joint laxity in 
females, particularly in response to hormone fluctuations.   
 
4.1.3.4 Conclusions   
From this review of current literature on the effects of female sex hormones and 
ligament a number of summations can be made.  It seems clear that oestrogen has an 
influence on the mechanical properties of knee ligament, however it is not clear whether 
it is via direct or indirect action.  Furthermore oestrogen may not act alone in its effects 
on the mechanical properties of ligament. What seems likely is that the aetiology of 
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physiologic changes in knee ligament, leading to an increased risk of knee injury, is 
multifactorial involving sex hormones as well as other molecules such as MMPs and 
their inhibitors which can modulate collagen turnover.  Also a number of challenges 
seemed to arise when conducting studies of the hormonal effects on ligament.  One 
difficulty encountered by a number of studies was identifying the effect of a particular 
hormone amongst the hormonal milieu in vivo.  In addition, conducting a controlled 
study using live subjects is made difficult by the variation in hormone levels and 
hormonal fluctuation of individuals that exists within a group of subjects (inter-subject 
variability).  It is also difficult to isolate the exact same time-point in the menstrual 
cycle of a number of subjects, or even identify what exactly is a “normal” menstrual 
cycle.  To account for the degree of variability that exists, much larger sample groups 
would be appropriate, with adequate controls.  The same limitations in current research 
were also highlighted by Smith et al. (2012), in their recent review of the risk factors for 
anterior cruciate ligament injury involving female hormone levels [380].   
 
This represents a large volume of information available regarding the effects of 
physiologic and supraphysiologic levels of female hormones such as oestrogen on the 
properties of knee joint ligament.  In contrast there is relatively little information of the 
effect of a hormonal deficiency on knee ligament.  Future studies focussing on the 
effects of ovariectomy (or menopause) on the physical properties and metabolism of 
knee joint ligament could clarify the interaction between ligament and the female sex 
hormones.  A study such as this would presumably be less affected by inter-subject and 
cyclic hormonal variability.  It is well known that menopause (for which ovariectomy is 
a common model) affects the metabolism of other connective tissues in the body such as 
cartilage, skin and bone, therefore it is likely that ligament could also be affected in 
some way.  A number of unanswered questions and conflicting opinions remain 
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surrounding the subject of sex hormones and ligament, which compel further research in 
this area.   
 
4.1.4 The Influence of Sex Hormone Deficiency on Connective Tissue 
The female sex hormones, in particular oestrogen, play an important role in the normal 
maintenance and turnover of connective tissues throughout the body.  With age and the 
onset of menopause, a decline and eventually cessation in oestrogen production by the 
ovaries occurs, leading to a number of changes in the structure and integrity of the 
body’s connective tissues.   A number of biological changes signify the menopause 
transition in women.  These include a critically low level of oocytes, disruption of the 
normal menstrual cycle, rising gonadotrophin levels, declining oestrogen levels and a 
host of associated clinical symptoms [381, 382].  
 
4.1.4.1 Effects on Bone 
The decline in endogenous oestrogen is well documented to affect the turnover and 
integrity of bone tissue in postmenopausal women.  The decline in oestrogen levels 
leads to increased bone turnover, resulting in a high rate of bone loss and decreased 
bone mineral density (BMD).  This leads to a condition known as osteoporosis, and 
predisposes sufferers to pathological bone fractures [383-385].  Decreased bone mineral 
density measurements and evidence of increased bone resorption, which can be assessed 
by measurement of the urinary excretion of bone type I collagen degradation products, 
are indicative of osteoporosis [386].  The following evidence exists to support the role of 
oestrogen deficiency in the disease mechanism of osteoporosis.   
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Pacifici et al. (1991) [383] emphasised that the bone-  sparing effect of oestrogen is related 
to an inhibitory effect on bone resorption and importantly, outlined the existence of 
oestrogen receptors in the osteoclasts and osteoblasts of bone.  This is significant 
because it indicates bone is an oestrogen responsive tissue.   
 
Satoh et al. (1993) [387] also demonstrated the importance of oestrogen in the 
maintenance of normal bone structure in their study comparing the BMD of women 
with hysterectomy and unilateral or bilateral oophorectomy (OVX).  In the bilateral 
OVX group accelerated bone changes were obvious immediately following surgery, and 
the rapid bone loss continued throughout the follow-up period.  In contrast, the 
unilateral OVX group exhibited no initial signs of accelerated bone loss post surgery, 
with a slow phase of bone loss during the follow-up period.  Therefore bone loss was 
greater in the bilateral OVX group in which oestrogen had been removed completely.   
 
A prospective study of bone loss in menopausal Australian women was conducted by 
Guthrie et al. in (1998) [388], demonstrating the influence of menopause on bone loss. 
BMD of the hip and lumbar spine was assessed in 224 women; 74 pre-menopausal, 90 
peri-menopausal and 60 post-menopausal.  Results showed BMD loss was accelerated 
during the transition from peri to post-menopause, indicating that menopause and the 
associated oestrogen deficiency is a catalyst for osteoporosis. 
 
In 1999, Meunier et al. [389] again highlighted the important role of oestrogen in 
prevention of osteoporosis.  They studied the effect of raloxifene, a selective oestrogen 
receptor modulator, on the bone density of post-menopausal women.  Post-menopausal 
women were tested because they are at high risk of osteoporosis, with an estimated 23% 
of post-menopausal women over 50 yrs being affected.  Results showed raloxifene 
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increased bone density and decreased bone turnover, therefore may prove an effective 
treatment for osteoporosis in post-menopausal women.  This conclusion was reiterated 
by Ringa (2000) [390], who stated that osteoporosis is directly associated with hormonal 
changes at menopause, and that hormone replacement therapy is proven to be effective 
in the prevention of bone loss. 
 
A study by Picard et al. (2000) [391] assessed the bone density of the lumbar spine in 141 
women pre-menopause, and again 10 years later post-menopause.  Multiple regression 
analyses of bone mineral density results and information gained from questionnaires 
revealed bone density pre-menopause, time without oestrogen, weight and vitamin D 
intake were the only significant predictors of present bone mass or bone loss.  This 
study emphasises the importance of good bone mass prior to menopause, and the early 
commencement of oestrogen replacement therapy to minimise bone loss in the years 
post-menopause, therefore reducing the risk of osteoporosis.    
 
In order to assess the influence of other hormones on bone density, Guthrie et al. (2004) 
[392] performed a study of 159 Australian born women during the menopause transition.  
They tested the association of a number of hormones with bone loss at the lumbar spine 
and femoral neck.  In addition to oestrogen, free testosterone, sex-hormone binding 
globulin and dehydroepiandrosterone were also tested.  Results showed oestrogen was 
the only hormone tested to have a significant effect on BMD during the menopause 
transition.    
 
Zecchin et al. (2004) [393] examined the association between osteoporosis and oestrogen 
deficiency, utilising the post-dental extraction healing process as a model for the 
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disease.  Their study focussed on the essential role of MMPs play in the remodelling of 
the bone extracellular matrix after tooth extraction.  They compared the healing process 
in 2 groups of rats; ovariectomised to simulate menopause versus sham operated 
controls.  The OVX animals showed a significant delay in the healing process.  This 
was attributed to a decrease in the gelatinolytic activities and expression of MMPs and 
collagen types I & III, which was observed in the OVX group.  Therefore it can be 
concluded form this study that the absence of oestrogen contributes to delayed healing 
by interfering with bone extracellular matrix turnover.   
 
In 2005, Jochems et al. [394] studied the link between rheumatoid arthritis (RA) and 
osteoporosis.  In postmenopausal RA, osteoporosis is caused both by the deficiency in 
oestrogen and the inflammation associated with the arthritis.  Statistically, the peak 
incidence of RA in women occurs around the time of menopause, with 50% of sufferers 
having generalised osteoporosis.  In this study, non-arthritic OVX mice were compared 
to OVX and RA induced mice. At completion of the trial period, the OVX group 
showed trabecular BMD reduction of 22%, whereas the OVX and RA group showed 
BMD reduction of 58%. This study proves interesting because it examines the 
compounding effect inflammation has on osteoporosis.  A similar situation may exist in 
the knee joint, where inflammation associated with osteoarthritis may compound 
degeneration of ligament tissue.  
  
Akhter et al. (2007) [395] examined the effect of menopause on the structure of trabecular 
bone.  Their study focussed on the excessive remodelling of bone that results from 
oestrogen deficiency in postmenopausal women.  This results in a deficit of bone which 
compromises bone structure, and is characteristic of osteoporosis.  They showed that 
measuring the activation frequency of new bone remodelling sites is a more powerful 
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predictor of bone strength and bone fragility fractures than BMD alone.  Their study 
showed that at the onset of menopause, the remodelling rate of bone increases to twice 
the rate of that pre-menopause, highlighting the important role oestrogen plays in the 
regulation of normal bone turnover. 
 
Mas et al. (2007) [396] demonstrated that OVX is associated with systemic bone loss in a 
baboon model.  Their study showed bone loss following acute oestrogen deficiency 
takes up to 5 years to plateau, with the maximal deleterious effect on bone density 
occurring in the first 12 months.  Another 2007 study conducted by van Essen et al. [385] 
suggested that increased osteocyte apoptosis, as a result of oestrogen deficiency, could 
play a role in the decreased bone strength and bone mass seen in postmenopausal 
osteoporosis.  Furthermore, a study by Taxel et al. (2008) [397], suggests that oestrogen 
deficiency at menopause causes an increase in osteoclast formation and activation, 
therefore leading to excessive bone resorption and osteoporosis.   
 
4.1.4.2 Effects on Cartilage 
The evidence provided by the studies listed in Section 4.1.4.1 supports a clear link 
between oestrogen deficiency and bone loss.   Similarly, current research also supports a 
link between the degeneration of articular cartilage associated with osteoarthritis (OA), 
and the decline in oestrogen levels at menopause [398-401].  Statistically, the prevalence of 
OA in women and men is similar until the age of 50 years, when it becomes more 
prevalent, more severe and more generalised in women [167, 169, 173].  The increased 
prevalence of arthritic symptoms coincides with the onset of menopause, and with joint 
symptoms being experienced by up to 50% of women with menopausal symptoms, 
hormonal changes are the likely modulators of the disease [172, 181, 233, 402].  Spector & 
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Campion (1989) [398]  quoted population studies that showed the incidence of OA in 
women over the age of 70 was even higher at 90%.    
 
Oestrogen receptors have been isolated in human articular chondrocytes, indicating 
cartilage is an oestrogen responsive tissue [233, 402, 403].  These oestrogen changes are 
thought to play a role in triggering the initial changes in cartilage proteoglycans, either 
directly or indirectly via cytokines.  Furthermore, studies have shown less severe OA 
symptoms occur in individuals treated with oestrogen replacement therapy [172, 399, 402, 404-406].    
 
Evidence to support the correlation between menopause and OA is provided by a 
number of previous studies.  Dai et al. (2005) [403] investigated oestrogen receptor 
expression in cartilage, and osteoarthritis induced by OVX in a guinea pig model.  Two 
groups were studied, ovariectomised to simulate menopause, and sham operated control.   
Results showed that oestrogen receptor expression in joint cartilage in the OVX group 
was significantly lower than in the control group at the same time-point post surgery.   
In addition, examination of joint articular cartilages using scanning electron microscopy 
and transmission electron microscopy revealed severe degenerative lesions in the OVX 
group, but not in the control group, at 12 weeks post-op.  This suggests that bilateral 
OVX in the guinea pig leads to development of severe OA, and this is likely to be 
related to lower serum oestrogen levels and a reduction in oestrogen receptor 
expression.   
 
Song et al. (2004) [406] studied the protective effect of hormone replacement therapy 
(HRT) in postmenopausal women with OA.  A group of 64 women with radiographic 
evidence and symptoms of knee OA were randomly divided in two groups, those 
receiving HRT, and those receive a placebo control.  A significant reduction in 
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symptoms such as tenderness around the knee, pain during walking and morning 
stiffness was observed in the in the HRT group compared to the control group after 1 
month.  The improvement in symptoms was still significantly greater in the HRT group 
compared to the control group after 6 months.  This indicates that HRT (combined 
oestrogen and progestin) can provide relief from OA symptoms in postmenopausal 
women.   
 
Claassen et al. (2005) [401] state that OA is aggravated in menopausal women, and the 
likely cause is  a change in serum oestrogen levels.  They studied the effect of oestradiol 
on cultured articular chondrocytes.  They postulated that oestrogen protects 
chondrocytes cells from oxidative stress induced by oxygen free radicals. Results of 
their study supported this hypothesis, indicating that oestradiol protects articular 
chondrocytes from oxygen free radical damage, and that decreased oestrogen levels 
contribute to menopausal OA.   
 
Christgau et al. (2005) [400] investigated the  association between post-menopausal OA 
and oestrogen deficiency by studying the effects of OVX on cartilage erosion in rats.  
Histology and analysis of cartilage-specific type II collagen degradation products were 
utilised to assess cartilage erosion.  Results showed OVX rats had significantly 
increased urinary excretion of type II collagen degradation products compared to 
controls.   This subsequently manifested as increased surface erosion of knee articular 
cartilage in the OVX group compared to controls.  This leads to the conclusion that 
oestrogen-deficiency induced changes in type II collagen are correlated with cartilage 
surface erosion and postmenopausal OA.  Ma et al. (2007) [407] also demonstrated the 
role of sex hormones in cartilage degradation and progression of OA using a murine 
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model.  OVX females developed significantly more severe OA than control females 
following transection of the meniscotibial ligament of the medial meniscus (a technique 
used to accelerate OA development).  This result led the investigators to conclude that 
ovarian hormones decrease the severity of OA in females [404].   
 
Wluka et al. (2001) [399] tested the hypothesis that oestrogen replacement therapy, 
administered for a period of 5 years or more, is associated with increased cartilage in the 
knee joints of postmenopausal women.  Two test groups of postmenopausal women 
over the age of 50 years were examined, those administered oestrogen supplementation 
and those without.  The study showed women on long-term oestrogen replacement 
therapy had increased knee cartilage thickness compared to controls, therefore 
indicating that oestrogen may prevent cartilage loss in women.  Similarly, a study by 
Ham et al. (2002) [404] demonstrated significantly less severe cartilage lesions developed 
in the knee joints of OVX cynomolgus monkeys administered oestrogen replacement 
therapy compared to those receiving no treatment.   
 
Hoegh-Andersen et al. (2003) [408] examined the validity of an OVX rat model in the 
assessment of postmenopausal OA, with the aim to assess the influence of OVX on the 
degradation and turnover of cartilage.  Urinary excretion of collagen degradation 
products was measured, and histological analyses of articular cartilage were performed 
to assess cartilage metabolism and erosion.  Results showed surface erosion of cartilage 
was more severe in the knees of OVX rats than the sham controls, and that OVX also 
significantly increased the excretion of type I and type II collagen degradation products.  
The study also showed that administration of oestrogen or a selective oestrogen receptor 
modulator inhibits the degradative effects of OVX on cartilage.   
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In 2006, Sowers et al. [178] aimed to establish a correlation between endogenous 
oestrogen and an increased risk of knee OA in women.   In their study they examined 
the serum oestrogen levels and incidence of knee OA and concluded that there was a 
significant correlation between lower baseline serum oestradiol levels and development 
of knee OA.   
 
Cake et al. (2005) [409] examined the effect of OVX on the structure of articular cartilage 
in an ovine model.  Two groups of ewes were tested, an OVX group and a non-operated 
control group, using dynamic biomechanical indentation testing and histology to assess 
articular cartilage.  This study concluded that oestrogen depletion associated with OVX 
resulted in thinning of the femoro-tibial cartilage. Biomechanical and histological 
examination of the cartilage also revealed changes indicating the structural organization 
of the cartilage tissue was altered.  In addition, the study suggests an observed up-
regulation in cartilage iNOS could be responsible for the matrix changes.   
 
Finally, Oestergaard et al. (2006) [410] investigated the influence of oestrogen 
supplementation on type II collagen turnover and integrity in the articular cartilage of 
OVX rats.  The results indicated that oestrogen mitigates the degradation of type II 
collagen and related alterations in cartilage structure, therefore suggesting oestrogen 
replacement therapy may prove beneficial in the prevention of OA post menopause.  
The investigators also deduced from their research that the protective effect of oestrogen 
is related to a direct inhibition of the catabolic function of chondrocytes.   
 
As in bone, there appears to be a large volume of evidence to support the theory that 
oestrogen deficiency has significant effects on the structure and metabolism of articular 
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cartilage, and this may predispose women to the development of OA in the years post-
menopause.   
 
4.1.4.3 Effects on Other Connective Tissues 
In addition to bone and articular cartilage, other connective tissues such as the skin, 
uterus, urogenital system, intervertebral disks and blood vessel walls are also adversely 
affected by the decline in oestrogen accompanying menopause in women.  The skin is 
comprised of two primary layers, the epidermis containing keratin producing cells, and 
the underlying dermis containing collagen and elastin fibres.  Collagen makes up the 
main mass of the dermis, with collagen types I, II, III, V, XI all being present in skin.  
The collagen is produced by dermal fibroblasts, which have been shown to contain 
oestrogen receptors on their surface.  This indicates that skin dermis is also an oestrogen 
responsive tissue [411, 412].  Oestrogen has been shown to have a profound effect on the 
structure of skin, and this is particularly evident in postmenopausal females [413].  A 
decline in oestrogen levels occurring with the onset of menopause leads to a reduction 
in skin thickness and collagen content.  As the skin atrophies, it becomes wrinkled and 
fragile, is easily bruised, and exhibits delayed wound healing.  The skin also tends to 
become dry, itchy and flaky due to loss of water content [414-416].   
 
The effects on skin brought about by declining oestrogen levels can be arrested and 
even reversed by the administration of oestrogen replacement therapy [411, 416]. Studies 
have demonstrated that oestrogen replacement therapy can increase skin thickness by 
10-20% [414].  Replacing depleted oestrogen increases the dermal content of GAGs and 
collagen, and improves the hydroscopic properties of the dermis, which likely occurs 
via enhanced synthesis of HA.  It is postulated that oestrogen increases the rate of 
collagen production by altering the degree of polymerisation of the GAGS in the 
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extracellular matrix.  In addition, collagen fibrils have been found to be less fragmented in 
the dermis of women taking hormone replacement therapy compared to non-users [411].   
 
Degeneration in the intervertebral discs (IVDs) of the spine is also linked to declining 
oestrogen levels at menopause.  Garnero et al. (2004) [417] investigated the link between 
IVD degeneration and the increased urinary excretion of type II collagen degradation 
products in postmenopausal women, with results showing a positive correlation exists.   
 
Gambacciani et al. (2007) [418] further evaluated the effect of menopause on IVD height 
in 464 normal menopausal women, between the 12th thoracic and 4th lumbar vertebrae.  
In postmenopausal women, data showed a significant correlation between years since 
menopause (i.e. years without oestrogen) and IVD height, but no correlation between 
age and IVD height.  In conclusion they stated that IVD height shows a progressive 
decrease after menopause, in particular during the first 10 years, suggesting oestrogen 
decline may rapidly alter the metabolism of IVD connective tissue.  
 
Menopause is also associated with late onset of visceral prolapse and urinary 
incontinence due to weakening of connective tissues.  Reay-Jones et al. (2003) [419] 
assessed the resilience of the uterosacral ligament in order to establish a link between 
menopause and uterine mobility and/or uterocervical prolapse.  Results showed that a 
decrease in pelvic connective tissue resilience was related to menopause, and may 
progress to pelvic visceral collapse.  In addition, Lang et al. (2003) [420] reported serum 
oestrogen levels and the number of oestrogen receptors present were significantly lower 
in the uterine ligaments of women with pelvic organ collapse. 
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Dyer et al. (1980) [349] also indicated a link between oestrogen and uterine collagen in 
OVX rats.  They examined the effect of 17 oestradiol on uterine collagen synthesis in 
two groups, OVX versus OVX plus oestradiol supplementation.  The oestradiol treated 
group showed a 2 to 3-fold increase in newly-synthesised collagen, and a 8-fold 
increase in insoluble collagen in the uterine connective tissue when compared to the 
non-treated group.  Results showed oestradiol stimulates the synthesis of both type I and 
type II collagens.   
 
Galea & Brincat, (2000) [411] showed that the female urinary and genital tracts are both 
oestrogen sensitive, and undergo changes following menopause.  With the withdrawal 
of oestrogen, the vagina becomes less vascularised, the tissue is thinned and inflamed, 
and the cervix atrophies and retracts.  The genital atrophy that accompanies menopause 
is associated with dyspareunia and urinary incontinence.  An estimated 40% of women 
over the age of 60 years suffer from incontinence to some degree, with oestrogen being 
key to the modulation of urogenital symptoms.  This is supported by the role oestrogen 
deficiency plays in the onset of symptoms, and by the fact that oestrogen replacement 
therapy can mitigate these symptoms by increasing synthesis of collagen types I & II, 
and reducing incontinence by increasing urethral resistance [411, 421].   
 
Oestrogen can also influence the cardiovascular system.  Di Carlo et al. (2007) [422] 
showed that postmenopausal oestrogen deficiency increases arterial vascular tone via 
alterations in the neuropeptide content of the arterial walls.  This can have negative 
effects, such as hypertension, on the cardiovascular system.  Derby (2000) [423] 
hypothesised that the depletion of ovarian hormones with menopause is associated with 
increased cardiovascular disease, and that the risk is reduced with hormone replacement 
therapy.  Results of their study showed post-menopausal women exhibited more severe 
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arteriosclerosis, which impedes blood flow, when compared to those post-menopausal 
women who took oestrogen replacement therapy.  Oestrogen receptors are present in the 
vessels of the cardiovascular system and therefore oestrogen may influence the blood 
flow within these vessels.  It is thought that oestrogen inhibits arteriosclerosis via action 
on the structure of vascular connective tissue. For example, oestrogen inhibits smooth 
muscle cell proliferation, thus helping maintain normal vessel wall thickness and 
function. 
 
4.1.4.4  Effects on Ligament 
In contrast to the numerous studies examining the effect of oestrogen fluctuation on 
human knee ligaments (reviewed in Section 4.1.3), little is known about the effect of 
menopause on the ligaments of human synovial joints, in particular the knee.  It is 
known that aging is linked to changes in the properties of ligament in the body, which 
are independent of gender.  These include an increase in collagen crosslinking, which is 
postulated to lead to an increase in ligament and tendon stiffness, a reduction in 
collagen fibril diameter, a decrease in ECM turnover (due to a decreased load) and a 
decrease in water content [424-426].  However, studies of the epidemiology of cruciate 
rupture in dogs have yielded some evidence that sterilisation (castration or 
ovariohysterectomy) may predispose them to injury.  Boute et al. (2009) [427] conducted 
a study of the prevalence of cranial cruciate ligament rupture in a group of 94 Labrador 
retrievers.  Of this group with initial cruciate rupture, 32 (34%) were castrated males, 50 
(53.2%) were spayed females, 7 (7.4%) were intact males and 5 (5.3%) were intact 
females.  Of these 94 dogs, 45 (48%) went on to rupture the CCL in the contra-lateral 
limb; 16 (35.5%) castrated males, 23 (51.1%) spayed females, 2 intact males (4.4%) and 
4 (8.9%) intact females.  Sterilised individuals (in particular females) are over-
represented in these figures, indicating an increased risk in this group.  This is possibly 
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due to hormonal effects on the ligament, although other factors such as increased body 
weight cannot be ruled out.   
 
Scavelli et al. (1990) [121] studied the signalment for CCL injury in 25 dogs with partial 
rupture of the CCL.  Of these 25 dogs a larger proportion were female (n = 17), 
compared to male (8), and a majority of the females were sterilised (14).  Again these 
figures demonstrate a particular predisposition for injury in sterilised females.  As there 
was no history of trauma in 23 of the 25 cases, a degenerative or immune mediated 
process may possibly be responsible.  Hayashi et al. (2004) [14] suggest inflammatory 
changes within the joint tissues and increased expression of collagenolytic proteases 
may contribute to the progressive degradation of CCL collagen and lead to progressive 
rupture of the ligament.  
 
Whitehair et al. (1993) [120] carried out a much larger study of 10,769 dogs with CCL 
rupture, comparing them to data from a control population of 591,548 dogs.  For the 
effect of gender, analysis showed females had a significantly higher prevalence than 
males and that sterilisation of either gender increased the prevalence of ACL injury over 
intact dogs.  Furthermore, they found the difference in prevalence between spayed 
females and intact females was statistically greater than the difference between castrated 
males and entire males, suggesting the sex hormones affect the prevalence of ACL 
injury, especially in females.  Similarly, Slauterbeck et al. (2004) [428] conducted a 
retrospective study of 3218 dogs CCL rupture, and Duval et al. (1999) [122] performed a 
smaller study of 201 dogs with CCL rupture.  Both studies found that the frequency of 
injury was significantly higher in sterilised male and female dogs compared with 
sexually intact dogs, with sterilised females demonstrating the highest prevalence 
overall.   
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4.1.5 The Ovine Oestrous Cycle 
Sheep provide a useful model to study the effects of menopause in women, as they 
exhibit similarities in oestrous periodicity, breeding and metabolic rate [429].  Although 
most breeds of ewe are seasonally polyoestrous, with an annual anoestrous period of 1-2 
months, during the remainder of the year oestrogen production is relatively high, with 
levels similar to those of women [430-434].   Sheep have up to 20 oestrus cycles during the 
breeding period of the year [431, 432], with some breeds of sheep such as the Merino (the 
breed used in this study) able to continue to cycle almost year-round [434].   It is thought 
that an ovariectomised animal model with more frequent oestrous cycles than, for 
example, the dog, may prove to be more sensitive to estrogen deficiency [433], and 
therefore more representational of menopause in women. 
 
The oestrous cycle of the sheep lasts 17 days on average, which more closely 
approximates that of women than other animal species such as the rat, with an oestrous 
cycle of just 4 days [430, 431].   Sheep are also reproductively similar to humans in that they 
are generally limited to one offspring at a time.  This is in contrast to other animal 
species commonly used as human models such as rats, mice and dogs, which are far 
more prolific breeders [435].   Furthermore, it has been shown that sheep, like humans, are 
born with a limited number of primordial ovarian follicles that declines throughout the 
life of the animal [430, 435].  Similarly, older ewes experience similar changes to women 
with declining oestrogen levels, including a loss of bone density [432, 434, 436], an increase in 
coronary artery disease [234, 437], changes in temperature regulation (hot flashes) [438, 439] and 
changes in articular cartilage [233, 234, 409]. 
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4.2 AIMS & HYPOTHESES  
 
With so much evidence to support the assumption that a deficiency in oestrogen causes 
significant changes in the structure and integrity of connective tissue throughout the 
body, it seems likely that similar changes could occur in ligaments.  There is much 
written about the effect of variable oestrogen levels on ligaments such as the ACL, but 
there appears to be a deficit in knowledge about the effects of oestrogen loss.  While 
cruciate ligament rupture is thought to be multifactorial with no single factor 
responsible for all aspects of its pathogenesis [62, 440], the female predisposition for injury, 
apparent in both animals and humans, cannot be overlooked.  It is also unclear whether 
the coexistence of other joint conditions such as OA amplifies degeneration of ligament 
tissue such as is the case with arthritis and osteoporosis.  It may be that ligament 
degeneration precedes the onset of OA, with destabilisation of the joint contributing to 
OA development.  With so many types of connective tissues in the body being 
responsive to the same hormone, it could be that the same disease mediators affect 
multiple tissue structures within the same joint.  
 
As previously described, ligament is certainly an oestrogen responsive tissue with much 
research dedicated to investigating the effect of fluctuating oestrogen levels on knee 
biomechanics and ligament function.  Despite this, researchers have failed to come to 
any common conclusions about oestrogen's influence on ligament, with some studies 
utilising questionable methodology to obtain their results.    Furthermore, ligament has 
been largely overlooked in the field of research into the effects of menopause on the 
body, regardless of its important role in the body's biomechanical function. It has also 
been shown that the incidence of OA increases with the onset of menopause, although 
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the pathogenesis remains unclear. The aim of this study was to elucidate what affect a 
deficit in ovarian hormones (menopause) has on the major stabilising ligaments of the 
knee, particularly the commonly injured anterior cruciate ligament, and whether these 
effects (if any) may contribute to the development of OA.  It also examined the effects 
of concurrent OA and menopause on the structure and metabolism of ligament tissue, in 
order to better understand the possible synergistic relationship between these two 
conditions.   
 
 
 
Hypothesis 3: that the decrease in ovarian hormone levels associated with menopause 
(ovariectomy) alters the normal composition and organisation of cruciate ligament 
tissue, in particular collagen fibril structure, which has the potential to influence the 
mechanical properties of the ligament, as observed in other connective tissue types 
post-menopause.     
  
Hypothesis 4: that the combined effects of ovariectomy and meniscectomy have an even 
greater influence on ligament composition and structure than either meniscectomy or 
ovariectomy alone, and that these changes reflect those of postmenopausal women with 
concurrent osteoarthritis.  
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4.3 RESULTS 
 
4.3.1  Molecular Biology 
 
4.3.1.1 Preliminary OVX Study 
 
 
TARGET GENE NOC1   ACL Mean (CI) 
OVX1   ACL 
Mean (CI) 
FOLD 
DIFFERENCE P 
Collagen type I 245.0     (135.4 - 354.6)        93.0     (76.7 - 109.3) 2.6 0.023 
Collagen type II 263.5     (154.7 - 372.3)      212.5     (123.1 - 301.9) 1.2 0.494 
Collagen type III 524.7     (432.0 - 617.4)      250.2     (173.0 - 327.4) 2.1 0.001 
Decorin 582.3     (522.9 - 641.7)      166.2     (133.1 - 199.3) 3.5 <0.001 
Fibromodulin 570.7     (518.0 - 623.4)      201.0     (103.6 - 298.4) 2.8 <0.001 
Biglycan 202.5     (158.8 - 248.2)      231.2     (137.3 - 325.1) 0.9 0.602 
 NOC1   PCL 
Mean (CI) 
OVX1   PCL 
Mean (CI) 
FOLD 
DIFFERENCE P 
Collagen type I      345.8     (243.5 - 448.1)      112.2     (88.9 - 135.5) 3.1 0.001 
Collagen type II      188.6     (9.5 - 367.7)      270.5     (153.7 - 387.3) 0.7 0.471 
Collagen type III      508.5     (370.1 - 646.9)      222.3     (164.9 - 279.7) 2.3 0.004 
Decorin      549.2     (452.6 - 645.8)      278.3     (197.7 - 358.9) 2.0 0.002 
Fibromodulin      556.3     (448.1 - 664.5)      312.0     (207.9 - 416.1) 1.8 0.010 
Biglycan      236.0     (160.1 - 311.9)      258.6     (199.6 - 317.6) 0.9 0.654 
 NOC1   ACL Mean (CI) 
NOC1   PCL 
Mean (CI) 
FOLD 
DIFFERENCE P 
Collagen type I      245.0     (135.4 - 354.6)      345.8     (243.5 - 448.1) 0.9 0.220 
Collagen type II      263.5     (154.7 - 372.3)      188.6     (9.5 - 367.7) 0.7 0.440 
Collagen type III      524.7     (432.0 - 617.4)      508.5     (370.1 - 646.9) 1.4 0.700 
Decorin      582.3     (522.9 - 641.7)      549.2     (452.6 - 645.8) 1.0 0.520 
Fibromodulin      570.7     (518.0 - 623.4)      556.3     (448.1 - 664.5) 1.1 0.810 
Biglycan      202.5     (158.8 - 248.2)      236.0     (160.1 - 311.9) 1.0 0.590 
 OVX1   ACL 
Mean (CI) 
OVX1   PCL 
Mean (CI) 
FOLD 
DIFFERENCE P 
Collagen type I        93.0     (76.7 - 109.3)      112.2     (88.9 - 135.5) 0.9 0.081 
Collagen type II      212.5     (123.1 - 301.9)      270.5     (153.7 - 387.3) 0.8 0.555 
Collagen type III      250.2     (173.0 - 327.4)      222.3     (164.9 - 279.7) 0.8 0.605 
Decorin      166.2     (133.1 - 199.3)      278.3     (197.7 - 358.9) 1.1 0.027 
Fibromodulin      201.0     (103.6 - 298.4)      312.0     (207.9 - 416.1) 0.6 0.123 
Biglycan      231.2     (137.3 - 325.1)      258.6     (199.6 - 317.6) 0.6 0.639 
 
 
 
 
 
 
 
 
Table 4.1: Results of the preliminary study of RNA expression in target genes in ACL and PCL tissue.  
Results are normalised to total RNA.   OVX1 = ovariectomised, NOC1 = non-operated control, ACL = 
anterior cruciate ligament, PCL = posterior cruciate ligament.  Results shown compare treated ACL and 
PCL with their relevant non-operated controls to demonstrate the effect of OVX on ligament gene 
expression.  Comparison is also made between ligament types (ACL and PCL) to determine if any 
difference exists between either the treated groups, or the controls.  
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Results are presented normalised to total RNA.  GAPDH was selected as a housekeeping 
gene, however its expression proved too variable for this purpose.  Type I collagen 
expression for ACL was significantly lower in OVX1 sheep vs. NOC1 sheep (P ≤ 0.023).  
Type I collagen expression in PCL was also significantly lower in OVX1 sheep vs. NOC1 
sheep (P ≤ 0.001).  There was no significant difference between ACL and PCL for type I 
collagen expression in the NOC1 group (P = 0.220) or the OXV1 group (P = 0.081).  See 
Appendix A4.1.1 for charted results (page 241).  
 
No significant difference was found between NOC1 and OVX1 for collagen type II 
expression in ACL (P = 0.494) or PCL (P = 0.471).  There was also no significant 
difference between ACL and PCL for NOC1 (P = 0.440) or OVX1 (P = 0.555). 
 
Type III collagen expression in ACL was significantly lower in OXV1 compared to NOC1 
(P ≤ 0.001), and also for PCL in OVX1 compared to NOC1 (P ≤ 0.004).  No significant 
difference was found between ACL and PCL for NOC1 (P = 0.700) or OVX1 (P = 0.605).  
 
Decorin expression for ACL was significantly lower in OVX1 sheep compared to NOC1 
sheep (P ≤ 0.00001), and also for PCL in OVX1 sheep vs. NOC1 sheep (P ≤ 0.002).  There 
was no significant difference between ACL and PCL for decorin expression in the NOC1 
group (P = 0.520), however expression was significantly lower in ACL compared to PCL 
in the OXV1 sheep (P = 0.027). 
 
Expression of fibromodulin for ACL was significantly lower in OVX1 sheep vs. NOC1 
sheep (P ≤ 0.0001).  Fibromodulin expression in PCL was also significantly lower in OVX1 
sheep vs. NOC1 sheep (P ≤ 0.010).  No significant difference was found for fibromodulin 
expression between ACL and PCL in the NOC1 group (P = 0.810) or the OXV1 group (P 
= 0.123). 
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Biglycan expression was not significantly different for NOC1 vs. OVX1 in ACL (P = 
0.602) or PCL (P = 0.654).  There was also no significant difference between ACL and 
PCL for biglycan expression in NOC1 sheep (P = 0.590) or OVX1 sheep (P = 0.639). 
 
 
4.3.1.2 Main Study 
 
EFFECTS OF OVX  
TARGET GENE NOC Mean (CI) 
OVX 
Mean (CI) 
FOLD 
DIFFERENCE P 
Aggrecan      279.3    (0 – 686.2)         66.2    (32.2 – 100.2) 4.22 0.159 
Basic FGF      329.9    (138.2 – 521.6)      155.3    (110.7 – 200.0) 2.12 0.096 
Biglycan      164.3    (93.7 -234.9)      104.2    (58.5 – 149.9) 1.58 0.175 
Collagen type I        65.1    (28.6 – 101.6)        16.4    (10.0 – 22.9) 3.96 0.017 
Collagen type II      355.2    (0 – 728.1)        23.8    (10.6 – 36.9)  14.95 0.096 
Collagen type III        34.8    (22.2 – 47.3)        14.4     (7.9 – 47.3) 2.41 0.010 
CTGF      307.2    (98.8 – 515.5)      152.7    (91.9 – 213.5) 2.01 0.152 
Decorin      395.4    (213.9 – 577.0)      102.8    (54.6 – 150.9) 3.85 0.001 
Elastin      579.5    (301.2 – 857.8)      236.2    (182.1 – 290.2) 2.45 0.027 
Fibromodulin      298.7    (161.1 – 436.2)        94.7    (67.4 – 122.0) 3.15 0.009 
iNOS      338.9    (113.0 – 564.9)      258.6    (82.8 – 434.4) 1.31 0.588 
Lubricin      219.3    (51.9 – 386.7)      152.9    (114.3 – 191.5) 1.43 0.457 
Lumican      200.2    (70.7 – 329.6)      104.1    (56.7 – 151.4) 1.92 0.186 
MMP-1        35.2    (11.7 – 58.8)        42.4     (0.9 – 83.9) 0.83 0.765 
PDGF      138.4    (38.7 – 238.1)        77.0    (44.3 – 109.7) 1.80 0.264 
 
: 
 
EFFECT OF PRIOR OVX ON OA 
TARGET GENE O+M Mean (CI) 
MENX 
Mean (CI) 
FOLD 
DIFFERENCE P 
Aggrecan      420.6    (181.1 – 660.1)      130.6    (44.2 – 217.0) 3.22 0.069 
Basic FGF      523.3    (372.5 – 674.1)      164.7    (121.7 – 207.7) 3.18 0.001 
Biglycan      749.6    (419.7 – 1079.4)      165.3    (100.6 – 230.0) 4.53 0.798 
Collagen type I      477.0     (219.3 – 734.7)        48.4    (37.0 – 59.8) 9.86 0.008 
Collagen type II    1167.4     (184.0 – 2150.9)      252.0    (84.2 – 419.8) 4.63 0.116 
Collagen type III      466.5     (225.3 – 707.7)        36.0    (24.7 – 47.3) 12.96 0.005 
CTGF      361.8     (215.4 – 508.2)      131.5    (71.7 – 191.3) 2.75 0.015 
Decorin      699.1     (412.4 – 985.8)      150.1    (109.2 – 191.0) 4.66 0.003 
Elastin      667.7     (330.9 – 1004.5)      234.5    (168.5 – 300.5) 2.85 0.035 
Fibromodulin      900.1     (474.5 – 1325.5)      209.4    (149.8 – 269.0) 4.30 0.009 
iNOS      240.0     (91.0 – 389.0)      266.9    (90.5 – 443.3) 0.90 0.820 
Lubricin      217.7    (159.7 – 275.6)      100.2    (69.9 – 130.5) 2.17 0.003 
Lumican      513.9    (261.2 – 766.6)      167.8    (81.6 – 254.0) 3.06 0.029 
MMP-1      224.9    (74.7 – 375.2)      123.1    (66.8 – 179.4) 1.83 0.627 
PDGF      268.4    (164.0 – 372.8)        95.5    (64.6 – 126.4) 2.81 0.010 
 
4.3.1.2.1 Gene Expression Normalised to Total RNA. 
Table 4.2: RNA expression of target genes in ACL tissue, shown as value of total RNA.  NOC = non-
operated control, OVX = ovariectomised.  
Table 4.3: RNA expression of target genes in ACL tissue, shown as value of total RNA.  O+M = 
ovariectomised & meniscectomised, MENX = meniscectomised. 
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4.3.1.2.1 Gene Expression Normalised to Total RNA 
Total RNA results showed that the OXV group had significantly lower expression of 
collagen type I (P ≤ 0.017), collagen type III (P ≤ 0.01), decorin (P ≤ 0.006), fibromodulin 
(P ≤ 0.009), and elastin (P ≤ 0.027) than the NOC group.  Charts comparing gene 
expression for all experimental groups are shown in Appendix A4.1.2 (page 245). 
 
The O+M group showed significantly higher expression of collagen type I (P ≤ 0.005), 
collagen type III (P ≤ 0.002), biglycan (P ≤ 0.002), lumican (P ≤ 0.041) and MMP-I (P 
≤ 0.029) when compared to NOC sheep.   
 
Expression in the OVX sheep was significantly lower than in sheep from the O+M 
group for most genes tested; collagen type I (P ≤ 0.002), collagen type II (P ≤ 0.033), 
collagen type III (P ≤ 0.001), decorin (P ≤ 0.001), biglycan (P ≤ 0.001), fibromodulin 
(P ≤ 0.001), lumican (P ≤ 0.005), elastin (P ≤ 0.021), aggrecan (P ≤ 0.007), MMP-1 (P 
≤ 0.048), basic FGF (P ≤ 0.0001), CTGF (P ≤ 0.017), and PDGF (P ≤ 0.002).     
 
4.3.1.2.2 Compared to MENX Results (Chapter 3) 
Total RNA results comparing MENX and OVX groups showed expression of collagen 
type I (P ≤ 0.0001), collagen type II (P ≤ 0.008), collagen type III (P ≤ 0.003), 
fibromodulin (P ≤ 0.002) and MMP-I (P ≤ 0.034) was significantly lower in OVX sheep 
than MENX. 
 
Expression of collagen type I (P ≤ 0.008), collagen type III (P ≤ 0.005), decorin (P ≤ 
0.003), biglycan (P ≤ 0.005), fibromodulin (P ≤ 0.009), lumican (P ≤ 0.029), lubricin (P 
≤ 0.003), elastin (P ≤ 0.035), basic FGF (P ≤ 0.001), CTGF (P ≤ 0.015) and PDGF (P ≤ 
0.01) was significantly lower in MENX sheep compared to O+M sheep.  
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4.3.2  Biochemistry 
 
4.3.2.1 Collagen  
Results were calculated as a % of the dry weight of tissue.  Results showed total 
collagen in the ACL of OVX sheep was significantly lower than in the NOC sheep 
[mean ± SE, OVX 53.55 ± 1.33 vs. NOC 57.16 ± 1.07, P ≤ 0.03] and O+M sheep [67.30 
± 2.51, P ≤ 0.0001].  Collagen in the O+M group was significantly higher than in the 
NOC group (P = 0.001).   
 
4.3.2.1.1 Compared to MENX Results (Chapter 3) 
The OVX group had significantly less collagen than the MENX group (P = 0.002), 
while the O+M group had significantly higher collagen content than the MENX group 
(P ≤ 0.039).  Appendix A4.2 shows results comparing all experimental groups (page 
257). 
 
4.3.2.2 Sulfated Glycosaminoglycans (S-GAG)  
Results were calculated as a % of the dry weight of tissue. 
Results showed S-GAG content in the ACL of OVX sheep was significantly lower than 
in the NOC sheep [mean ± SE, OVX 9.43 ± 0.40 vs. NOC 11.78.± 0.70, P ≤ 0.02] but 
not O+M sheep [10.11 ± 0.32, P = 0.196]. ACLs from O+M sheep contained 
significantly less S-GAG than those from NOC sheep (P = 0.013).   
 
4.3.2.2.1 Compared to MENX Results (Chapter 3) 
There was no significant difference between the OVX and MENX groups (P = 0.837), 
or the O+M and MENX groups (P = 0.196) for S-GAG content.  
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4.3.3  Transmission Electron Microscopy (TEM) 
 
4.3.3.1 Fibril Size and Arrangement 
NOC fibrils were of similar size and regularly arranged. The majority of fibrils in the 
NOC ACLs were found to be within a close size range of 100-200nm. 
 
OVX fibrils had a significantly smaller average fibril diameter than NOC [96.87 ± 1.79 
vs. 151.05 ± 2.28; P ≤ 0.0001] and a lower fibril size range. The fibrils in the OVX group 
were much more haphazard in their arrangement (Figure 4.3 & 4.4). 
 
The O+M group was not significantly different to NOC for average fibril diameter, 
however this does not reflect the abnormal bimodal distribution with unusually small and 
large fibrils, or the irregular fibril arrangement (Figure 4.5 & 4.6).  See Appendix A4.3 
for graphical presentation of TEM results comparing all experimental groups (page 259) 
and to view all TEM images from each group (pages 264-286).  
Figure 4.2: Results of biochemical analysis of collagen and S-GAG content 
in ACL, comparing OVX, O+M, NOC and MENX groups. 
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Figure 4.4: Chart showing ACL fibril diameter (size) distribution for the OVX group compared to 
the NOC group, as determined using TEM analysis.  Note the shift towards smaller sized fibrils in 
the OVX group. 
Figure 4.3: TEM images (37000x) of ACL collagen fibrils.  Image 8666 is from the NOC group 
displaying uniform sized fibrils that are regularly arranged.  Image 8700 is a typical sample from the 
OVX group with smaller sized fibrils that are variable in their arrangement. 
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Figure 4.6: Distribution of collagen fibrils in O+M vs. NOC ACL tissue based on fibril size 
(diameter in nm), as determined using TEM analysis.  Note the bimodal size distribution in the 
O+M group with many unusually small and large sized fibrils. 
 
 
Figure 4.5: TEM images (37000x) of ACL collagen fibrils, comparing fibril size and arrangement in 
NOC (image 8666) with O+M (image 8584) samples.  Note the abnormal bimodal distribution with 
unusually small and large fibrils in the O+M sheep compared to the more uniform fibrils in the OVX 
sheep. 
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Table 4.4: Combined fibril diameter data for sheep ACL.  Fibril counts for OVX and O+M sheep were 
compared to the NOC sheep for each fibril size range.  P-values are calculated at 5% significance level.  
MENX data is included for comparison. 
FIBRIL 
SIZE 
(nm) 
Mean number of fibrils per two TEM fields, approx. 5µm2 
(% of total in brackets) 
NOC (n=12) OVX (n=12) P (vs NOC) O+M (n=12) P (vs NOC) MENX (n=10) 
<100      1.2  (<1%)   94.8 (48%) <0.001 54.6 (29%) <0.001      1.2  (<1%) 
100-200 154.4  (99%) 102.2 (52%) <0.001 98.6 (53%) <0.001 154.4  (99%) 
>200      0.2   (<1%)     0.3 (<1%) 0.255 33.4 (18%) <0.001      0.2   (<1%) 
Figure 4.7: Comparison of distribution of collagen fibrils in all groups for ACL tissue, based 
on fibril size (diameter in nm), as determined using TEM analysis.  All experimental groups 
displayed a pattern of fibril size distribution that varied greatly from that of the NOC group. 
 
 
 
176
Data for fibril density was calculated as a % of total field.  Results showed OVX had 
significantly lower fibril density than all other groups; NOC [mean % of field ± SE, 
OVX 27.3 ± 0.9% vs. NOC 48.1 ± 1.3%; P ≤ 0.0001], MENX [47.3 ± 1.4%; P ≤ 
0.0001] and O+M [59.9 ± 1.8%; P ≤ 0.0001].  O+M had greater total fibril density than 
all other groups, NOC (P ≤ 0.0001), MENX (P ≤ 0.0001).  
 
4.3.4   Scanning Electron Microscopy (SEM) 
Cross-sectional SEM images were taken of ACL from NOC, OVX and O+M sheep.  
The OVX and O+M images showed structural differences and obvious electron dense 
bands or striations across the cut surface of the tissue that weren’t clearly seen in the 
NOC sheep (Figures 4.8 - 4.14).  Similar striations were observed in MENX ACL tissue 
(Chapter 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8:  SEM (170x) ACL tissue from a NOC sheep viewed in cross-
section.  The fibril bundles within the mid-substance ligament are tightly 
packed with little space between them, and the tissue is uniform in appearance. 
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Figure 4.10:  SEM (2000x) ACL tissue from a NOC sheep viewed in cross-
section.  The tissue is more homogeneous, lacking the striated appearance seen 
in the MENX sample (Chapter 3). 
Figure 4.9:  SEM (170x) ACL tissue from an OVX sheep viewed in cross-
section.  The bundles within the ligament are more open with multiple cracks 
appearing throughout (arrows).   
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Figure 4.11:  SEM (2000x) ACL tissue from an OVX sheep viewed in cross-
section.  The tissue has striated appearance similar to that seen in the MENX 
sheep.   
Figure 4.12:  SEM (3016x) ACL tissue from an OVX sheep.  Viewed at a 
higher power of magnification this striated section of tissue appears to have 
multiple areas of separation between groups of collagen fibres.  
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Figure 4.13:  SEM (2000x above, 170x below) ACL tissue from an O+M sheep viewed in cross-
section.  In this ovariectomised and meniscectomised sample, the spaces between the fibre bundles 
were not as pronounced as in the OVX and MENX only samples, however there were a number of 
areas where the mid-fascicular architecture appeared distracted.  This was not seen in the NOC 
samples.     
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Figure 4.14:  SEM (2000x) ACL tissue from an O+M sheep viewed in cross-
section.  Like the OVX and MENX only samples, the tissue had obvious light 
and dark banding across the cut surface. 
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4.3.5   Gross Morphology 
 
4.3.5.1  Articular Cartilage  
   
 
 
 
 
 
  
REGION NOC MENX OVX O+M 
Cartilage Mean (CI) Mean (CI) Mean (CI) P  (vs. NOC) Mean (CI) 
P 
(vs. NOC)
P 
(vs. MENX)
FEMUR 0.08   (0.0 - 0.2) 3.10   (2.9 - 3.3)    0.08   (0.0 - 0.2) 1.00 3.25   (2.8 - 3.7) <0.0001 0.564 
TIBIA 0.17   (0.0 - 0.4) 2.80   (2.2 - 3.4)    0.50   (0.2 - 0.8) 0.09 3.33   (2.9 - 3.7) <0.0001 0.156 
JOINT 0.13   (0.0 - 0.3) 2.95   (2.6 - 3.3)    0.30   (0.1 - 0.5) 0.10 3.26   (2.9 - 3.5) <0.0001 0.191 
Table 4.5: Results of macroscopic scoring of ovine knee articular cartilage, comparing the non-operated 
control group with the ovariectomised group and the ovariectomised & meniscectomised group. 
 
 
Figure 4.15: Charted data for macroscopic scoring of articular cartilage, comparing the non-
operated control group with the ovariectomised, meniscectomised and the ovariectomised & 
meniscectomised group.   
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4.3.5.2  Osteophytes 
 
 
 
  
REGION NOC MENX OVX O+M 
Cartilage Mean (CI) Mean (CI) Mean (CI) P  (vs. NOC) Mean (CI) 
P 
(vs. NOC) 
P 
(vs. MENX)
FEMUR 0.08   (0.0 - 0.2) 1.30   (1.0 - 1.6) 0.41   (0.1 - 0.7) 0.06 1.58   (1.3 - 1.9) <0.0001 0.201 
TIBIA 0.08   (0.0 - 0.2) 1.90   (1.5 - 2.3)   0.08   (0.0 - 0.3) 1.00 1.67   (1.4 - 1.9) <0.0001 0.386 
JOINT 0.08   (0.0 - 0.2) 1.60   (1.3 - 1.9) 0.26   (0.1 - 0.4) 0.09 1.65   (1.4 - 1.8) <0.0001 0.870 
Figure 4.16: Charted data for macroscopic scoring of osteophyte formation, comparing the non-
operated control group with the ovariectomised, meniscectomised and the ovariectomised & 
meniscectomised group.   
Table 4.6: Results of macroscopic scoring of the presence of osteophytes in ovine knee joints, 
comparing the non-operated control group with the ovariectomised group and the ovariectomised & 
meniscectomised group. 
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4.3.6  Histology 
 
4.3.6.1 Ligament 
 
OVX - Haematoxylin & Eosin  
While the NOC and OVX groups (Figure 4.17 A&C) appeared similar in their 
cellularity, the cells of the NOC samples were arranged in straight lines along the fibre 
bundles, whereas those of the OVX samples were more randomly distributed.   The two 
groups also appeared comparable for cell morphology, although in regions of some 
OVX sections, the cells appeared slightly more rounded due to a more transverse than 
longitudinal orientation when sectioned.  This was also observed in the arrangement of 
collagen fibres of the OVX samples, with some fibre bundles orientated transversely 
while adjacent bundles were longitudinal.  In general, the collagen fibres of the OVX 
samples were more irregular in their arrangement and much less parallel in their 
alignment than the NOC samples.   
 
OVX - Toluidine Blue  
The density of elastin fibres in the OVX samples was reduced compared to the NOC 
samples (Figure 4.17 B&D).  The few darkly stained elastin fibres observed in the OVX 
samples were more haphazard in their distribution than those of NOC samples.   
 
O+M - Haematoxylin & Eosin  
The cellularity of the O+M samples did not appear to differ greatly from that of the 
NOC samples, and they appeared similar in their morphology (Figure 4.17 A&E).  The 
arrangement of collagen fibres in the O+M samples was variable, with some sections 
having fibres that were parallel in their alignment and regularly arranged, while others 
were more random in their organisation.  Like the OVX samples, some sections 
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exhibited fibres that were both longitudinal and transversely orientated, despite being 
sampled from the same region of the ligament and transversely embedded in the block.   
 
O+M - Toluidine Blue  
The density of the elastin fibres in the O+M group was greater than in the OVX only 
group and appeared similar to that of the NOC group, however the elastin fibres were 
less evenly distributed and more irregular in their alignment (Figure 4.17 B&F).   
 
A B 
 
C D 
E F 
 
Figure 4.17:  
 
A and B =  NOC ACL tissue.  
A, H&E 200x sample showing 
normal cellularity and 
morphology, with parallel 
collagen fibril arrangement; B, 
Tol Blue 200x sample 
demonstrating abundant and 
evenly distributed elastin fibres.  
All histological sections can be 
viewed in Appendix A4.5 
(pages 285-292). 
 
 
C and D = OVX ACL tissue. 
C, H&E 200x showing fibre 
bundles that are less regular in 
their arrangement, with some 
bundles orientated transversely 
while adjacent bundles are 
longitudinal; D, Tol Blue 200x 
sample showing the reduced 
density of elastin fibres in the 
OVX tissue, with less regular 
arrangement.  
 
 
 
E and F = O+M ACL tissue. 
E, H&E 200x arrangement of 
collagen fibres was variable 
with some sections having 
fibres that regularly arranged, 
while others were more random 
in their organisation as shown 
here; F, elastin fibre density 
was greater than in the OVX 
only group but was less evenly 
distributed than in NOC 
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4.3.6.2 Cartilage 
 
 
 
 
   
FEMORAL  
CARTILAGE NOC MENX OVX O+M 
 Mean (CI) Mean (CI) Mean (CI) P  (vs. NOC) Mean (CI) 
P 
(vs. NOC)
P 
(vs. MENX)
STRUCTURE 1.46     (0.68 - 2.24)   3.17       (2.14 - 4.20) 0.29    (0.03 - 0.55) 0.079 3.25    (2.14 - 4.36) 0.017 0.440 
CELL NUMBER 0.79     (0.48 - 1.10)   1.38       (1.00 - 1.75) 0.33    (0.19 - 0.47) 0.051 0.92    (0.64 - 1.19) 0.340 0.065 
CLONING 0.46     (0.26 - 0.66)   2.71       (2.27 - 3.15) 0.21    (0.03 - 0.39) 0.280 1.67    (0.98 - 2.35) 0.023 0.052 
IT TB 0.79     (0.30 - 1.28)   1.71       (1.28 - 2.13) 0.50    (0.22 - 0.78) 0.250 1.25    (0.88 - 1.62) 0.100 0.120 
TIDEMARK 1.04     (0.96 - 1.13)   1.08       (0.97 - 1.20) 1.25    (1.13 - 1.36) 0.220 1.38    (1.02 - 1.73) 0.085 0.140 
TOTAL 4.54     (2.93 - 6.15) 10.04       (8.35 - 11.73) 2.58    (2.17 - 2.99) 0.190   8.46    (6.19 - 10.73) 0.024 0.280 
TIBIAL  
CARTILAGE     
 Mean (CI) Mean (CI) Mean (CI) P  (vs. NOC) Mean (CI) 
P 
(vs. NOC)
P 
(vs. MENX)
STRUCTURE 0.58     (0.06 - 1.11)   5.63      (4.48 - 6.77) 1.13    (0.08 - 2.17) 0.360 5.67    (4.57 - 6.77) <0.0001 0.480 
CELL NUMBER 0.42     (0.21 - 0.62)   2.42      (2.02 - 2.81) 0.33    (0.15 - 0.52) 0.440 1.96    (1.55 - 2.37) 0.001 0.140 
CLONING 0.21     (0.02 - 0.40)   3.42      (3.06 - 3.78)  0.21     (0.0 - 0.46) 0.474 3.00    (2.34 - 3.66) <0.0001 0.340 
IT TB 0.29     (0.04 - 0.55)   2.96      (2.68 - 3.24) 0.50    (0.07 - 0.93) 0.380 2.08    (1.52 - 2.65) 0.001 0.033 
TIDEMARK 1.13     (0.95 - 1.30)   1.13      (1.00 - 1.25) 1.38    (1.03 - 1.72) 0.140 1.58    (1.25 - 1.92) 0.018 0.024 
TOTAL 2.63     (1.79 - 3.46) 15.54     (13.79 - 17.29) 3.54    (1.75 - 5.33) 0.460 14.29    (11.64 - 16.96) <0.0001 0.400 
WHOLE 
JOINT     
 Mean (CI) Mean (CI) Mean (CI) P  (vs. NOC) Mean (CI) 
P 
(vs. NOC)
P 
(vs. MENX)
STRUCTURE 2.04     (1.14 - 2.95)   9.00    (6.94 - 11.06) 0.29    (0.03 - 0.55) 0.380   8.92    (7.00 - 10.83) 0.001 0.480 
CELL NUMBER 1.21     (0.82 - 1.60)   3.79    (3.18 - 4.40) 0.33    (0.19 - 0.47) 0.260 2.88    (2.29 - 3.46) 0.013 0.070 
CLONING 0.67     (0.36 - 0.97)   6.13    (5.51 - 6.74) 0.21    (0.03 - 0.39) 0.370 4.67    (3.48 - 5.86) 0.002 0.100 
IT TB 1.08     (0.57 - 1.59)   4.67    (4.21 - 5.12) 0.50    (0.22 - 0.78) 0.460 3.33    (2.60 - 4.07) 0.008 0.029 
TIDEMARK 2.17     (1.98 - 2.35)   2.21    (2.06 - 2.35) 1.25    (1.13 - 1.36) 0.084 2.96    (2.39 - 3.53) 0.009 0.019 
TOTAL 7.17     (5.44 - 8.89) 25.58    (22.49 - 28.67) 2.58    (2.17 - 2.99) 0.370  22.75   (18.57 - 26.93) <0.0001 <0.0001 
Table 4.7: Microscopic scoring of articular cartilage degeneration in ovariectomised joints with and without 
concurrent OA, compared to controls.  
Figure 4.18: Charted data for microscopic scoring of articular cartilage, examining the 
effect of ovariectomy in joints with and without concurrent OA (O+M).  
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4.3.6.3 Synovium 
 
 
 
 
 
 
 
 
 
 
  
SYNOVIUM NOC MENX OVX O+M 
 Mean (CI) Mean (CI) Mean (CI) P  (vs. NOC) Mean (CI) 
P 
(vs. NOC)
P 
(vs. MENX)
INTIMAL HYPERPLASIA 0.83     (0.35 - 1.32) 0.67      (0.42 - 0.92) 0.54    (0.26 - 0.82) - 0.67    (0.39 - 0.95) - - 
CELL INFILTRATION 0.29     (0.01 - 0.57) 0.29      (0.04 - 0.55) 0.25    (0.00 - 0.51) - 0.58    (0.35 - 0.82) - - 
SUBINTIMAL FIBROSIS 1.63     (1.26 - 1.99) 2.67      (2.45 - 2.89) 0.83    (0.49 - 1.18) 0.014 1.71    (1.38 - 2.04) 0.300 0.0017 
VASCULARITY 2.96     (2.88 - 3.04) 3.00      (0.00 - 0.00) 2.08    (1.71 - 2.46) 0.002 3.00    (0.00 - 0.00) 0.400 1.000 
AGGREGATE SCORE 5.71     (4.62 - 6.80) 6.63      (6.13 - 7.12) 3.71    (2.65 - 4.77) 0.014 5.96    (5.39 - 6.53) 0.042 0.130 
Table 4.8: Microscopic scoring of synovial tissue in ovariectomised joints with and without concurrent 
OA, compared to controls.  MENX data is also presented for comparison.   
Figure 4.19: Charted data for microscopic scoring of synovial tissue, examining 
the effect of ovariectomy in joints with and without concurrent OA (O+M).  
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4.4 DISCUSSION 
 
4.4.1 Ovariectomy  
Gross morphological examination of the knee joints of the ovariectomised and NOC 
sheep found no statistical difference between the groups for either cartilage degradation 
or osteophyte formation.  This was also the case when the articular cartilages were 
viewed on histological section.  These findings indicate that ovariectomy alone does not 
appear to have any adverse affect on the cartilaginous surfaces of the knee joint, within 
the experimental time frame of this study.  It was also interesting to note, that the 
synovium of the OVX group actually scored better than the NOC group for fibrosis and 
vascularity.  These findings are in contrast to those of a number of other studies, that 
found ovariectomy induced oestrogen deficiency had a detrimental effect on cartilage, 
synovium and subchondral bone [408, 409, 441-444].  It should be noted that some of these 
studies were performed using small animals such as rats or rabbits, and the disease 
progression may differ in these models.  Furthermore, the findings of the present study 
do not fit with the body of evidence that shows an increase in the incidence of OA in 
females associated with the onset menopause, and may represent an anomaly.  An 
alternative explanation is that the six-month experimental period was not a long enough 
for the development of perceivable arthritic changes in a large animal model following 
the decrease in oestrogen.    
 
Results of the preliminary molecular study showed that ovariectomy altered the 
expression of key structural genes similarly in both the ACL and PCL tissue.   The only 
notable difference between the two ligaments was that ACL exhibited even lower 
decorin expression that PCL in the ovariectomised groups.  As the two ligaments were 
so similar in their expression profiles, it was determined that the main study should 
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focus on further investigating the ACL, which is the more frequently injured [85, 445], and 
macroscopically has been shown to be more severely degenerated than the PCL in OA [96]. 
  
In the ACLs, molecular findings for OVX vs. NOC sheep were comparable in the 
preliminary and main studies, with analysis in both studies showing the same molecular 
changes in OVX ligament, involving some of the main structural components of the 
ECM.  Collagen types I & III were significantly down-regulated, and as these two 
collagens comprise 70-80% of the dry weight of ligament [11, 25] this has the potential to 
significantly alter ACL collagen fibril structure, and effect a change in ACL 
biomechanical function post-menopause.   These findings are consistent with results of 
other studies using an animal OVX model to examine the effects of oestrogen 
deficiency on connective tissues such as bone [393], cartilage [410, 441], and uterine tissue [349].    
 
Furthermore, there was a significant decrease in fibromodulin and decorin, which bind 
to different sites on collagen I fibrils and are involved in regulating the normal 
progression of fibrils through the stages of assembly and growth to maturity [446].  They 
also assist in the organisation of the collagen network, acting to regulate interfibrillar 
spacing and prevent lateral fusion of fibrils [34, 53].  The reduction in fibromodulin 
expression is noteworthy as a lack of fibromodulin has been associated with increase 
osteoarthritis in the knees of mice [54]. Gill and Oldberg (2002) [54] found fibromodulin 
deficient mice have a higher propensity towards degenerative changes in their knee 
joints than comparable wild type animals although this was not attributed to underlying 
ultra-structural or fibril abnormalities within the articular cartilage.  They concluded that 
alterations in ligaments, and possibly other tissues within the knee, are of considerable 
importance in the pathogenesis of the observed articular cartilage degeneration, a 
conclusion supported by this ligament study.  Furthermore, in addition to the reduction 
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in fibromodulin and decorin, results of the main study showed a reduction in the 
expression of elastin (not tested in the preliminary study).  This may decrease the ability 
of the ligament to stretch adequately when subjected to biomechanical forces and in turn 
may contribute to an increased risk of ACL injury.      
 
These molecular findings complement structural changes observed with TEM.  Decorin 
deficiency was shown to promote fibrils which had a greater size range, with a tendency 
towards smaller fibrils, and an irregular fibre arrangement in MENX sheep (Chapter 3).  
In OVX sheep, the deficiency of decorin in combination with decreased fibromodulin 
expression had an even greater effect on ACL collagen fibril structure.  They had a 
significantly smaller average fibril diameter than NOC with a lower fibril size range, 
and were much more haphazard in their arrangement exhibiting increased spacing 
between fibrils.  A number of authors made similar findings in studies of fibromodulin 
deficient mice, discovering fibrils with irregular profiles, increased interfibrillar spacing 
and a greater frequency of small diameter fibrils [49, 50, 52, 53, 446, 447].   
 
In some fibromodulin knockout studies, a deficiency in fibromodulin was associated 
with a significant increase in lumican [53, 446, 447], however this was not observed in the 
OVX sheep.  Interestingly, in contrast to fibromodulin, lumican knockout mice were 
found to produce fibrils that were much larger in size, indicating that these two SLRPs 
work in co-ordination to modulate different phases of fibrillogenesis, while sharing the 
same collagen I binding site [53, 448].  While lumican is expressed in the early development 
period during fibril assembly, fibromodulin is expressed later, promoting the maturation 
of collagen fibrils and their growth from a small to large diameter [50, 52, 447].  Therefore in 
the absence of fibromodulin, there is prevalence of small sized fibrils, reflecting the 
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appearance of the OVX ACL, presumably due to failure to progress through the stages 
of assembly and growth to maturation.  Other studies have also attributed the presence 
of small diameter fibrils in the absence of fibromodulin to a failure of intermediate 
fibrils to mature, and found it resulted in tissue with reduced strength and aberrant 
healing [449, 450]. 
 
In the absence of fibromodulin, an up-regulation of lumican may represent a 
compensatory response which attempts to maintain normal fibrillogenesis, however 
studies have found collagen fibrils still exhibit abnormal morphology [446].  
Fibrillogenesis is a finely regulated process in which each SLRP has a specific role to 
play, and while lumican can fulfil some of the roles of fibromodulin, it has a very 
different overall function [446].  When Hedbom et al. (1993) [451] identified that decorin 
and fibromodulin are structurally related, share some common functions and have a 
similar affinity for collagen I via separate binding sites, it seemed reasonable to assume 
that these two SLRPs may be able to compensate for each other.  This assumption 
however was proven incorrect by Svensson et al. (1999) [446], who showed that decorin 
expression was unchanged in their study of fibromodulin-null mice, and Forslund et al. 
(2002) [452], found that the two proteins failed to substitute for each other in their study of 
tendon mechanics in knockout mice.  Furthermore, Forslund et al. found a lack of both 
fibromodulin and decorin, inhibited fibril maturation in regards to both strength and 
stiffness.   
 
As OVX sheep exhibited a deficiency in both fibromodulin and decorin in ACL tissue, 
and significant structural changes (as observed via TEM), normal biomechanical 
function may be compromised in these ligaments, potentially predisposing them to 
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injury and/or joint instability.  The observation of these ligament changes in the absence 
of cartilage pathology suggests that disruption of the ligaments could be a primary event 
in the pathogenesis of OA.  Further investigation should focus on assessing the physical 
properties of OVX ACL compared to NOC.  In addition, if these molecular changes are 
present in both cruciate ligaments as the preliminary study suggests, the potential for 
disruption of joint stability would be even greater.       
 
At a biochemical level, there was a significant decrease in OVX ACL collagen and S-
GAG content compared to NOC sheep.  This fits with expected results based on the 
molecular findings, and suggests that mRNA expression may correspond to actual 
protein levels, although immunohistochemical analysis is required to confirm this.  
These results do raise an interesting question however.  If OVX sheep exhibit a decrease 
in both S-GAG and collagen content, as well as a decrease in collagen fibril area, what 
remains in the space that exists between fibrils?  One possibility is fibrillin, a glycoprotein 
which is involved in the formation of elastic fibres in connective tissues [453], and which 
has been shown to be abundant in canine cruciate ligaments [454].   Further analysis is 
required to confirm what other substances comprise the extracellular matrix of OVX 
ligament tissue in the absence of collagen and S-GAG.      
 
Normalising Molecular Data to a Housekeeping Gene: As outlined in Chapter 3, there 
is some doubt regarding the suitability of β-actin as a stably expressed housekeeping 
gene to which results could be normalised.  As β-actin showed the least variability of 
the commonly housekeeping genes tested in this study, for completeness normalised 
results are presented in Appendix A4.1.2 (page 245), however they do not fit with 
findings of the biochemical and TEM analysis. 
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4.4.2 Combined Ovariectomy and Meniscectomy  
Macroscopic examination of the articular surfaces of the femur and tibia revealed that 
the O+M joints had greater cartilage erosion and osteophyte formation than the NOC 
group.  The severity was similar to that observed in the MENX group.  When the O+M 
joints were viewed on histological section, similar OA changes were noted.  The femurs 
of the O+M group displayed worsening of the cartilage structure and increased cloning 
and tidemark scores.  The tibial surfaces in O+M joints scored higher for all OA 
parameters, with significantly higher total joints scores overall compared to NOC.  The 
synovial changes were less marked, however the O+M group did receive a higher 
aggregate score than NOC.  These findings indicate that the meniscectomy model was 
successful in inducing OA in the O+M group.   
 
In contrast to the findings of OVX sheep and MENX sheep, the combination of 
ovariectomy and concurrent osteoarthritis (meniscectomy) showed a very different 
pattern of disruption to either treatment alone.  Molecular results for O+M sheep 
showed a significant increase in the expression of collagen types I and III.  This 
combined with the up-regulation of MMP-1 may indicate an increase in collagen 
turnover, and is characteristic of a healing or remodelling response in ligament [455].  In 
support of this, Ireland et al. (2001) [456] found significantly increased expression of type 
I collagen mRNA in degenerate samples of human Achilles tendon tissue, and Jarvinen 
et al. (1997) [457] found increased amounts of type I and III collagen, and proteoglycans 
in tendon samples with chronic tendonitis.  In addition, Provenzano et al. (2005) [9] 
showed sub-failure injury in ligament coincides with up-regulation of proteoglycan and 
type I and III collagen, indicating fibrillogenesis is occurring to remodel the tissue and 
restore its mechanical properties.   Corps et al. (2004) [458] also found an 8-fold increase 
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in the expression of type I collagen in Achilles tendons with tendinopathies, while 
Bramono et al. (2005) [47] found collagens I and III and MMP-I were increased during 
the healing of injured human ACL tissue.      
 
Changes in proteoglycan expression were also very different in O+M sheep than in 
either MENX or OVX when compared to NOC, with analysis showing a significant 
increase in lumican and biglycan expression.  Lumican is responsible for regulating the 
assembly of collagens into higher order fibrils [50] and its expression is found to be 
significantly increased in healing tissue [45].  It has also been shown that lumican is up-
regulated in some disease processes where there is a high cell turnover, such as in the 
growth and metastasis of some cancers [50, 459, 460].  
 
Like lumican, biglycan also tends to be up-regulated in healing tissue [45, 47] and both 
SLRPs are able to modulate cell growth, cell adhesion and migration following injury [38, 
461].  Plaas et al. (2000) showed that biglycan accumulated in rabbit MCL following 
injury and remained elevated in the repairing ligament for over two years [36].  Ordinarily 
decorin is more abundant in ligament, however during healing biglycan is expressed in 
higher concentrations [45, 47].  The fact that expression of these two proteoglycans was 
increased in O+M sheep combined with the increased collagen turnover and up-
regulation of MMP-I indicates that there is some disruption to the normal metabolism of 
the ligament and may lead to a disruption in the normal functional properties of the 
tissue.   
 
TEM analysis also revealed that O+M sheep displayed a very different fibril 
configuration than was seen in either the OVX or MENX groups.  Calculations revealed 
the O+M group had a significantly greater fibril density (as a % of total field) than the 
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NOC group, yet there was no significant difference between the O+M and the NOC 
groups for average fibril diameter.  This result does not reflect the abnormal bimodal 
fibril size distribution with unusually small and large fibrils, or the irregular fibril 
arrangement.  It is not clear precisely what causes this fibril pattern, but it may be the 
combined result of increased collagen metabolism and disruption to the finely 
coordinated process of fibrillogenesis.   
 
SEM examination of both the OVX and O+M groups showed the same striations that 
were prominent on the MENX samples but were not as obvious on the NOC samples.  
Again it is unclear what causes these striations but they may reflect a disruption to normal 
ligament structure.   
 
Results of the biochemical analysis showed there was a significant increase in the 
collagen content of O+M sheep compared to NOC.  This result is expected because 
although the large and small sized fibrils averaged to be the same size as the more 
consistent NOC fibrils, the O+M group had a greater fibril density than the NOC sheep.  
Results for S-GAG content however differed from expected in the O+M group.  While it 
was shown that mRNA expression of lumican and biglycan were increased in these sheep 
compared to controls, it was not reflected by an increase in S-GAG content at a 
biochemical level.  This may be due to a number of factors.  Firstly, the abnormally 
increased mRNA expression of these SLRPS may not translate to actual protein levels in 
this tissue, which would need to be confirmed via immunohistochemistry.  Secondly, the 
amount of S-GAG bound to the SLRPs may be reduced which could compromise their 
normal function and predispose them and their associated collagen fibrils to cleavage by 
degradative enzymes.  Thirdly, the increase in lumican and biglycan could be countered 
by a decrease in some other SLRP which was not revealed in this study.   
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In conclusion, the effects of OVX, MENX and combined O+M on ligament tissue are 
varied and complex.  The combination of ovariectomy and concurrent osteoarthritis 
(meniscectomy) showed a very different pattern of derangement to either treatment alone 
which may indicate a synergistic effect resulting in over-expression of certain genes with 
an equally disruptive effect on the normal structural arrangement of the ligament (as 
highlighted by the abnormal bimodal distribution of fibrils).  While these changes in gene 
expression and collagen structure have been observed, further biomechanical tests are 
required to elucidate what affect they have on the tensile strength of the tissue.  
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CHAPTER	5	
	
	
REVIEW	OF	HYPOTHESES	&	CONCLUSIONS	
 
 
 
Hypothesis 1: that osteoarthritis (meniscectomy) alters gene expression and collagen 
fibril structure and organisation in ACL.  
 
In order to prove this hypothesis, it must first be verified that meniscectomy did indeed 
induce osteoarthritis in the joints of the MENX sheep.  Gross morphology and 
histopathology results confirmed the presence of cartilage changes consistent with OA.  
In addition, subintimal fibrosis of the synovial tissue, a feature characteristic of chronic 
synovitis associated with OA [139, 245], was significantly greater in the MENX sheep 
compared to the non-operated controls.   These results demonstrate that osteoarthritis 
was present in the knees of the MENX sheep.   
 
 Having established the presence of OA, the hypothesis that osteoarthritis alters gene 
expression and collagen fibril structure and organisation in ACL can be addressed.  
Gene expression of decorin and elastin, two major structural components of ligament, 
were significantly reduced in the ACL of MENX sheep.   As these molecules are 
fundamental to the development of normal ligament structure and integrity, their 
deficiency leads to the formation of tissue that is structurally abnormal.   Furthermore, 
expression of the collagenase MMP-1 was increased, which is typical of OA, and is a 
clear indication that tissue remodelling was occurring in the ligament [462, 463].  
Biochemical analysis showed that the content of both collagen and S-GAG were 
significantly reduced in ACL in the presence of OA.  These changes in gene expression, 
and the reduction in the content of structural molecules in ACL correspond to changes 
in the structural appearance of the collagen fibrils.  TEM and SEM analysis, and 
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histological sections of ACL from MENX sheep displayed an abnormal fibril size 
profile and a pattern of arrangement that differed greatly from that seen in the ACLs of 
non-operated sheep.   Therefore, from this collective data, it can be concluded that the 
above hypothesis was proven to be correct.   
 
 
Hypothesis 2:  animals with worse osteoarthritic changes have more severe ligament 
derangement.   
    
From the results of the regression analysis comparing osteoarthritic changes (as 
determined by cartilage degradation score), and ligament derangement (indicated by 
decorin and elastin expression) within individuals, it was not possible to prove or 
disprove this hypothesis.  A major influencing factor is the reliability of the 
meniscectomy model, which generated a consistent grade of OA across the study group.   
This dependability of this model in generating OA is shown repeatedly in studies of 
knee pathology in mice and sheep [245, 247].   Due to this, there was inadequate variation in 
the degree of OA amongst individuals in the MENX group to relate to differences in the 
composition of the ligament.   Further information may be gained by examining the 
relationship between variables (ligament and cartilage changes) within individuals at 
different time-points.  It may be that variation between individuals in the progression of 
OA is more apparent in the earlier stages, but becomes less marked as the pathogenesis 
continues.    
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Hypothesis 3: that the decrease in ovarian hormone levels associated with menopause 
(ovariectomy) alters the normal composition and organisation of cruciate ligament 
tissue, in particular collagen fibril structure, which has the potential to influence the 
mechanical properties of the ligament, as observed in other connective tissue types 
post-menopause.     
 
The results of the ligament studies from OVX sheep presented in Chapter 4, support this 
hypothesis.    Molecular analysis revealed significant reductions in the expression of the 
main structural proteins of ligament, collagen types I & III, which constitute the majority 
of the tissue substance.  There were also significant reductions in the expression of 
multiple key SLRPs which are integral to normal collagen fibril formation and 
organisation of the collagen matrix, and elastin which provides ligament with the ability 
to undergo a degree of deformation without rupturing or tearing (elastic deformation) [464].    
These findings (except elastin which was only tested in the main study) were repeatable in 
two separate studies, and were present at both six and nine month time-points post 
ovariectomy.   Molecular results were corroborated by biochemical assays measuring the 
collagen and S-GAG (SLRP) content of the ACL from OVX sheep, which showed levels 
were significantly reduced compared to non-operated controls.   
 
TEM, SEM and histological examination provided confirmation that these molecular and 
biochemical results were associated with physical changes in ligament structure and 
organisation.  The collagen fibrils of ACL from OVX sheep were markedly narrower in 
diameter than non-operated controls, and much more haphazard in their arrangement.  
This was consistent with histological sections of the same ligament, which showed 
irregularly orientated fibre bundles, and a reduction in the density of elastin fibres.  
Furthermore, SEM examination revealed that OVX ligament fibre bundles had an unusual 
striated appearance and were much more loosely packed than those of non-operated 
controls.  Changes in the composition and organisation of ligament as a result of 
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ovariectomy would be expected to result in alteration of the normal mechanical properties 
of the tissue.   
 
In 2011 J. Gilmore, a member of our research group, conducted a study into the effects of 
ovariectomy on the biomechanical properties of the ovine stifle joint [465].  The results of 
this study provided some insight into what effect the ligament changes observed in the 
present study may have on the biomechanical function of the knee joint (see Appendix 5 
for results). The study utilised an Instron 5566 universal mechanical test frame to assess 
intact knee joints, and generate force displacement plots, from which posterior and 
anterior drawer were calculated, and ligament stiffness gradients determined. Results 
showed no difference between OVX and NOC knee joints for anterior drawer 
displacement, however posterior drawer displacement and total displacement were 
significantly reduced in OVX knee joints.  This corresponded to an increase in ligament 
stiffness during posterior drawer testing.   These findings do not fit with the theory that 
the structural changes observed in the present study could lead to increased ligament 
laxity, which would increase the risk of developing knee OA.  It is difficult to draw 
definitive conclusions about the effect of OVX on specific ligaments from this test as 
multiple other joint structures are involved, which may influence the results. However, an 
increase in ligament stiffness would have the potential to disrupt normal joint function.  
The present study showed that ovariectomy was associated with a decrease in elastin 
expression, which would reduce the ability of the ligament to deform under strain.  This 
could predispose the ligament to multiple micro-ruptures, which over time could lead to 
degeneration and biomechanical failure of the ligament.   This biomechanical study 
showed that OVX is associated with significant alteration in the biomechanical properties 
of the knee joint, however to further clarify the involvement of the cruciate ligaments in 
the mechanism of this alteration, additional studies should investigate these structures 
more specifically.   
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It is therefore concluded that the evidence presented here supports the hypothesis that 
ovariectomy alters the normal composition and organisation of cruciate ligament tissue, in 
particular collagen fibril structure, which has the potential to influence the mechanical 
properties of the ligament.  Further biomechanical studies would be required to define the 
exact nature of these changes.      
 
 
Hypothesis 4: that the combined effects of ovariectomy and meniscectomy have an even 
greater influence on ligament composition and structure than either meniscectomy or 
ovariectomy alone, and that these changes reflect those of postmenopausal women with 
concurrent osteoarthritis. 
 
The combination of ovariectomy and meniscectomy resulted in ACLs with a markedly 
disturbed gene expression profile compared to ligaments of non-operated controls, and 
that differed considerably from ACLs of either single treatment group (meniscectomy or 
ovariectomy alone).  When compared to those of NOC sheep, ACLs from the O+M 
group showed a general increase in the expression of major structural proteins (collagen 
types I and III) and up-regulation of MMP-1, indicating an increase in collagen turnover 
[47, 466, 467].  This result, combined with the increased expression of proteoglycans biglycan  
and lumican, is indicative of an attempted healing or remodelling response in ligament 
[36, 46].  In contrast, the MENX and OVX groups exhibited a general decrease in collagen 
and proteoglycan expression.   
 
In addition, microscopic analysis revealed a marked disturbance in normal collagen 
organisation. TEM examination of O+M ACL showed increased numbers of abnormally 
large and small collagen fibrils (bimodal size distribution), which were irregular in their 
arrangement. 
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While it is clear from these results that O+M ACL differs from that of non-operated 
controls in regard to composition and structure, it is difficult to determine whether the 
combination of ovariectomy and meniscectomy exerts a greater influence than either 
treatment alone.  Because the pattern of derangement resulting from the combined 
treatment is not simply a worsening of the effects of the single treatment groups, it is 
not clear whether the influence is lesser or greater, it is simply different.   To determine 
which treatment (OVX, MENX or O+M) has the greatest influence on ligament 
composition and structure, it would be valuable to compare ligament function between 
groups, utilising biomechanical studies and load to failure testing.    
 
Regarding whether or not these changes reflect those of postmenopausal women with 
concurrent osteoarthritis, it is reasonable to assume that they do.  The meniscectomy 
model successfully induces OA in sheep knee joints, as confirmed by the cartilage 
results, and the surgical removal of the ovaries induces a deficiency in ovarian hormone 
levels, that mimics the cessation of ovarian function at menopause.   To definitively 
affirm that the changes observed in sheep ligament accurately reflect those of 
postmenopausal women with OA, it would be necessary to conduct similar tests in 
human ACL samples.   Difficulty may arise however, in obtaining sufficient sample 
numbers and ensuring adequate control of variables within sample groups.  
 
 
REVIEW OF THE MAJOR FINDINGS AND STATISTICAL METHODOLOGY 
As stated in Chapter 2, the experimental design of the experiments in this study 
involved harvesting the ACL from both knee joints from each sheep and subjecting 
them to the same the same array of analyses.  This represents a potential weakness in 
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the power of the statistical analysis of the results.  Whilst it can be argued that the 
response of each knee joint to meniscectomy is an individual event, and unaffected by 
the surgical procedure on the contralateral limb, this argument cannot be made for the 
effect of ovariectomy.  The reasons behind this decision have been outlined in Chapter 2 
in the presentation of statistical methods, and related to economic factors as well as the 
need for large volumes of tissue to complete the multiple analyses planned on each 
ACL.  In retrospect, separating the analyses into two groups and allocating biochemistry 
and molecular studies to the left ACL and microscopy (TEM, SEM and histopathology) 
to the right ACL may have been preferable.   
 
While acknowledging this weakness in the statistical analysis, the consistency of the 
results across the various experimental methods used in this study provides strong 
support for the interpretation that the tissue of the ACL responds to both the presence of 
OA and the absence of ovarian hormones in a consistent manner in which collagen 
fibrillogenesis is disturbed resulting in structural change in the ligament.  This finding 
adds significantly to current knowledge of knee joint function in response to life-stage 
changes.  Repeating the experiments conducted in this study with a larger number of 
animals to increase the power of the statistical analysis was beyond the financial 
resources of this project.  Given the consistency of the results of these experiments, 
such a study would be unlikely to add substantially to the results of the current study or 
their interpretation. 
 
This prediction is supported by limited additional statistical analysis performed 
retrospectively.  A number of key results were re-analysed using the same statistical 
methods but pooling the results from the two limbs of individual sheep, thus halving the 
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number of samples in the analysis.  In all cases, the resultant p value was virtually 
identical to that in the original analysis. 
 
Another limitation of this study is that it utilises a single time point for analysis.  It 
would certainly strengthen the findings of the study if larger (n) numbers were used and 
if repeat test groups at a second time point were added, however the cost of surgery, 
housing the sheep and performing the analyses was excessive.   The time it would 
require to duplicate the entire study at a second time point was also prohibitive.  
 
CONCLUSIONS 
Results of this study suggest that the inflammatory milieu that exists within an 
osteoarthritic knee joint may have an effect on the expression of key structural genes 
and the organisation of the ACL microstructure.   The ACL itself did not show an 
increase in the expression of inflammatory mediators, however it would have been 
exposed to cytokines present within the joint capsule that originated from other soft 
tissues such cartilage and synovium.  Biomechanical changes in loading and joint 
stability would have provided further stimulus to the response seen in the ACL tissue.  
As a result of these factors, the organisation of ACL microstructure was diminished, and 
the expression of important ligament components was reduced.   
 
To further this research, it would be valuable to perform similar studies of joint 
structures located outside the joint capsule, such as the LCL or MCL.  These structures 
are separated from the internal inflammatory environment by the joint capsule, and 
therefore by comparing their results to those of the ACLs it could provide further 
information about the direct influence of cytokines.  Additional studies could also be 
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performed in wethers to determine if similar ligament changes occur with a decrease in 
male gonadal hormones.  
 
Of notable interest were the findings of ACL studies from ovariectomised sheep.   
These ligaments exhibited an even greater disruption to normal structural organisation 
and expression of major ligament components than those of the meniscectomised sheep. 
Currently there is a volume of research describing the effect of oestrogen deficiency on 
a number of connective tissues such as bone, skin, cartilage and blood vessels, but there 
is little information available about its effects on ligament, particularly in human 
subjects.  This study provides some insight, by demonstrating that a reduction in ovarian 
hormones has an influence on the organisation and composition of ligament.  This 
statement is supported by molecular, biochemical and microscopic analyses.  To 
confirm that gene expression relates to an actual reduction in protein production, it 
would be of value to perform immunohistochemistry studies on ACL samples from 
ovariectomised sheep.  
 
Contrary to expectations, the combination of ovariectomy and meniscectomy in sheep 
produced a pattern of collagen fibril derangement and a gene expression profile that was 
notably different from the single treatment groups.  It was anticipated that combining 
the treatments would exacerbate the effects of either single treatment, but this was not 
reflected in the results.   Normal structure and composition was indeed disrupted but it 
was due to an increase in expression of fundamental genes.  Furthermore, the 
appearance of the collagen fibrils was significantly different with an unusual bimodal 
size distribution.  This indicates that the modulation of normal fibril size was disrupted, 
with the multiple small fibrils suggestive of an increase in immature fibrils (due to more 
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rapid ligament turnover).   While these ligaments were not the same as those of the 
single treatment groups, they were clearly not representative of normal ACL.   The two 
treatments combined seem to have exerted a synergistic effect, producing results that 
were dissimilar to either treatment alone.  Previous studies into the combined effect of 
prior OVX and subsequent MENX in sheep showed a similar response in the knee joint, 
in which OVX resulted in thinning of the subchondral bone plate which was not 
exacerbated by subsequent MENX [468]. 
 
Finally, to complete the picture, it is important to confirm a link between the observed 
structural and compositional changes described in these studies, and the physical 
function of the ligaments. Further investigation should focus on examining the 
biomechanical performance and load to failure strength of ACL from similar 
experimental groups.  
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APPENDIX 1 ROTOR-GENE ANALYSIS REPORTS & PROFILE 
SETTINGS 
 
 
 
 
Quantitation Report 
Experiment Information 
Run Name fibromodulin (b) 2010-11-30 (1)
Run Start 11/30/2010 12:40:13 PM 
Run Finish 11/30/2010 2:21:10 PM 
Operator Alison D 
Notes fibromodulin (b) 
Run On Software Version Rotor-Gene 6.0.25 
Run Signature The Run Signature is valid. 
Gain FAM 8. 
Quantitation Information 
Threshold 0.0004 
Left Threshold 1.000 
Standard Curve Imported No 
Standard Curve (1) conc= 10^(-0.284*CT + 6.442) 
Standard Curve (2) CT = -3.517*log(conc) + 22.657
Reaction efficiency (*) 0.92446 (* = 10^(-1/m) - 1)  
M -3.51729 
B 22.65742 
R Value 0.9976 
R^2 Value 0.99521 
Start normalising from cycle 1 
Noise Slope Correction No 
No Template Control Threshold 0%  
Reaction Efficiency Threshold Disabled  
Normalisation Method Dynamic Tube Normalisation 
Digital Filter Light 
Sample Page Page 1 
Imported Analysis Settings   
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Profile 
Cycle Cycle Point 
Hold @ 95°c, 10 min 0 secs    
Cycling (45 repeats)  Step 1 @ 97°c, hold 10 secs 
  Step 2 @ 55°c, hold 15 secs 
  Step 3 @ 72°c, hold 20 secs, acquiring 
to Cycling A(FAM) 
Melt (72-95°c) , hold 45 secs on the 1st step, hold 5 
secs on next steps, Melt A(FAM) 
  
Raw Data For Cycling A.FAM 
 
 
Quantitation data for Cycling A.FAM 
 
 
 
233
Standard Curve 
 
 
 
No. Colour Name Type Ct Given Conc 
(Copies) 
Calc Conc 
(Copies) 
% Var 
A1 
 
OVX std - fibromodulin Standard 12.85 640 625 2.9% 
A2 
 
OVX std - fibromodulin Standard 12.86 640 621 2.5% 
A3 
 
OVX std - fibromodulin Standard 14.71 160 182 13.5% 
A4 
 
OVX std - fibromodulin Standard 14.69 160 184 14.8% 
A5 
 
OVX std - fibromodulin Standard 17.31 40 35 11.2% 
A6 
 
OVX std - fibromodulin Standard 17.15 40 37 7.9% 
A7 
 
OVX std - fibromodulin Standard 19.16 10 10 1.3% 
A8 
 
OVX std - fibromodulin Standard 18.98 10 11 11.1% 
B1 
 
OVX std - fibromodulin NTC     
B2 
 
OVX std - fibromodulin NTC     
B3 
 
ACL  - 05L Unknown 11.97  1,093  
B4 
 
ACL  - 05R Unknown 13.72  348  
B5 
 
ACL  - 09L Unknown 11.86  1,173  
B6 
 
ACL  - 09R Unknown 11.88  1,160  
B7 
 
ACL  - 12L Unknown 13.42  424  
B8 
 
ACL  - 12R Unknown 12.82  625  
C1 
 
ACL  - 15L Unknown 11.92  1,129  
C2 
 
ACL  - 15R Unknown 11.86  1,172  
C3 
 
ACL  - 48L Unknown 12.71  674  
C4 
 
ACL  - 48R Unknown 11.83  1,194  
C5 
 
ACL  - 97L Unknown 10.82  2,320  
C6 
 
ACL  - 97R Unknown 11.90  1,145  
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No. Colour Name Type Ct Given Conc 
(Copies) 
Calc Conc 
(Copies) 
% Var 
C7 
 
ACL  - 17L Unknown 12.84  619  
C8 
 
ACL  - 17R Unknown 12.66  698  
D1 
 
ACL  - 18L Unknown 12.84  617  
D2 
 
ACL  - 18R Unknown 12.03  1,051  
D3 
 
ACL  - 31L Unknown 12.90  595  
D4 
 
ACL  - 31R Unknown 12.92  587  
D5 
 
ACL  - 35L Unknown 11.62  1,371  
D6 
 
ACL  - 35R Unknown 13.87  314  
D7 
 
ACL  - 61L Unknown 13.79  332  
D8 
 
ACL  - 61R Unknown 12.82  627  
E1 
 
ACL  - 65L Unknown 12.75  655  
E2 
 
ACL - 65R Unknown 13.52  397  
 
 
This report generated by Rotor-Gene Real-Time Analysis Software 6.1 (Build 93) 
Corbett Research 2005  
All Rights Reserved  
ISO 9001:2000 (Reg. No. QEC21313)  
 
 
 
 
 
Melt Report 
Experiment Information 
Run Name  fibromodulin (b) 2010-11-30 (1)
Run Start 11/30/2010 12:40:13 PM 
Run Finish 11/30/2010 2:21:10 PM 
Operator Alison D 
Notes  fibromodulin (b) 
Run On Software Version Rotor-Gene 6.0.25 
Run Signature The Run Signature is valid. 
Gain FAM 8. 
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Melt Information 
Digital Filter Light 
Imported Analysis Settings   
Sample Page Page 1
Temp. Threshold 0°c 
Threshold 0. 
Melt data for Melt A.FAM 
 
 
 
 
 
 
 
Colour Name Genotype Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 
A1 
 
OVX std - fibromodulin  74 76 78 80 85.5 
A2 
 
OVX std - fibromodulin  74 76 78 80 85.5 
A3 
 
OVX std - fibromodulin  74 76 78 80 85.5 
A4 
 
OVX std - fibromodulin  74 76 78 80 85.5 
A5 
 
OVX std - fibromodulin  74 76 78 80 85.5 
A6 
 
OVX std - fibromodulin  74 76 78 80 85.5 
A7 
 
OVX std - fibromodulin  74 76 78 80 85.5 
A8 
 
OVX std - fibromodulin  74 76 78 80 85.5 
B1 
 
OVX std - fibromodulin  77 81.5 92   
B2 
 
OVX std - fibromodulin  76.3 78.2 83 87.5 92 
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Colour Name Genotype Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 
B3 
 
ACL  - 05L  74 76 78 80 85.3 
B4 
 
ACL  - 05R  74 76 78 80 85.5 
B5 
 
ACL  - 09L  74 76 78 80 85.5 
B6 
 
ACL  - 09R  74 76 78 80 85.3 
B7 
 
ACL  - 12L  74 76 78 80 85.3 
B8 
 
ACL  - 12R  74 76 78 80 85.5 
C1 
 
ACL  - 15L  74 76 78 80 85.5 
C2 
 
ACL  - 15R  74 76 78 80 85.5 
C3 
 
ACL  - 48L  74 76 78 80 85.3 
C4 
 
ACL  - 48R  74 76 78 80 85.5 
C5 
 
ACL  - 97L  74 76 78 80 85.3 
C6 
 
ACL  - 97R  74 76 78 80 85.2 
C7 
 
ACL  - 17L  74 76 78 80 85.3 
C8 
 
ACL  - 17R  74 76 78 80 85.2 
D1 
 
ACL  - 18L  74 76 78 80 85.5 
D2 
 
ACL  - 18R  74 76 78 80 85.3 
D3 
 
ACL  - 31L  74 76 78 80 85.3 
D4 
 
ACL  - 31R  74 76 78 80 85.5 
D5 
 
ACL  - 35L  74 76 78 80 85.5 
D6 
 
ACL  - 35R  74 76 78 80 85.5 
D7 
 
ACL  - 61L  74 76 78 80 85.3 
D8 
 
ACL  - 61R  74 76 78 80 85.5 
E1 
 
ACL  - 65L  74 76 78 80 85.3 
E2 
 
ACL - 65R  74 76 78 80 85.5 
Bin Name Temperature Sample No. Sample Name Peak
 
 
This report generated by Rotor-Gene Real-Time Analysis Software 6.1 (Build 93) 
Corbett Research 2005  
All Rights Reserved  
ISO 9001:2000 (Reg. No. QEC21313)  
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Table A2.1 List of Ovis aries & Bos taurus primer sequences utilised for RT-PCR analysis of ligament in this study.
Molecule Species 
Accession # 
Pos’n Oligo 
Bases 
Sequence 5’ to 3’ T °C Product 
(bp) 
Referenced 
Aggrecan (RT) Bos taurus 
U76615 
500F 
604R 
23 
20 
F – TCA CCA TCC CCT GCT ACT TCA TC 
R – TCT CCT TGG AAA TGC GGC TC 
58 105 MV, Smith et al., 2008 (A&R) 
Basic FGF (RT) Ovis aries 
L36136 
192F 
392R 
23 
24 
F – TCA AGC AGA AGA GAG AGG GGT TG 
R – CCA GTT CGT TTC AGT GCC ACA TAC 
54 201 MV, Smith et al., 2008 (A&R) 
β-actin (RT) Ovis aries 
N001009784 
711F 
976R 
22 
22 
F – GTC CGT GAC ATC AAG GAG AAG C 
R - GTG TTG GCG TAG AGG TCT TTG C 
59 266 MV, Smith et al., 2008 (A&R) 
 
Biglycan (RT) Ovis aries 
AF034842 
803F 
945R 
22 
22 
F – TGA TTG AGA ACG GGA GCC TGA G 
R – TTT GGT GAT GTT GTT GGT GTG C 
56 143 MV, Smith et al., 2008 (A&R) 
 
Collagen Type I (RT) Ovis aries 
AF129287 
379F 
485R 
22 
24 
F – ATC CCT GGA CAA CCT GGA CTT C 
R – TCA TCA TAG CCG TAA GAC AAC TGG 
57 107 MV, Smith et al., 2008 (A&R) (Gottingen) 
 
Collagen Type II (RT) Bos taurus 
X02420 
646F 
799R 
20 
22 
F – TGA CCT GAC GCC CAT TCA TC 
R – TTT CCT GTC TCT GCC TTG ACC C 
55 154 MV, Smith et al., 2008 (A&R) (unpublished) 
 
Collagen Type III (RT) Bos taurus 
L47641 
5F 
148R 
22 
22 
F – GCA GGG AAC AAC TTG ATG GTG C 
R – AAT AGT GGG ATG AAG CAG AGC G 
55 144 MV, Smith et al., 2008 (A&R) (Gottingen) 
 
CTGF (RT) Bos taurus 
BC113279 
548F 
860R 
22 
20 
F –  CGA GGA ATG GGT GTG TGA TGA G 
R – AGG CTT GGA GAT TTT GGG GG 
60 313 MV, Smith et al., 2008 (A&R) 
 
Decorin (RT) Ovis aries 
AF125041 
610F 
747R 
23 
22 
F – CCA AAG TGC GAA AGT CTG TGT TC 
R – CAG CAA TGC GGA TGT AGG AGA G 
54 138 MV, Smith et al., 2008 (A&R) 
 
Elastin (RT) Ovis aries 
M26189 
1098F 
1265R 
21 
24 
F – TGA AAC CCT CAC GCT GGA TTG 
R – AAG GAT GGA CGG ATG GAT GGA CAG 
57 168 MV, Smith et al., 2008 (A&R) 
 
Fibromodulin (RT) Bos taurus 
X16485 
598F 
720R 
22 
24 
F – GCT CCA TCT TGA CCA CAA CCA G 
R – CCT TTC ATA GAA CTG CCC ACT TCC 
55 123 MV, Smith et al., 2008 (A&R) 
 
GAPDH (RT) Ovis aries 
U94889 
292F 
430R 
23 
25 
F – CCT GGA GAA ACC TGC CAA GTA TG 
R – GGT AGA AGA GTG AGT GTC GCT GTT G 
58 139 MV, Smith et al., 2008 (A&R) 
 
iNOS (RT) Ovis aries 1444F 
1949R 
22 
21 
F	‐	CCC	TTC	CGC	AGT	TTC	TGG	CAG	C	
R	‐	CCT	CCA	CCT	GTT	CCT	CAT	TCA
60 91 Mershon et al., 2002 APS 
Lubricin (RT) Bos taurus 
AF056218 
1057F 
1223R 
21 
22 
F – CTG CCC AAC ATC AGA AAA CCC 
R – TTC CTT CGC CCA TCA GTC TAA G 
54 167 MV, Smith et al., 2008 (A&R) (unpublished) 
 
Lumican (RT) Bos taurus 
NM_173934 
827F 
931R 
22 
24 
F – TGG CTG ATA GTG GAG TTC CTG G 
R – GGT TTT CAT TGA CTG TCG GTA TGC 
50 105 MV, Smith et al., 2008 (A&R) (unpublished) 
 
MMP-1 (RT) Ovis aries 
AF267156 
124F 
245R 
24 
22 
F – CAT TCT ACT GAC ATT GGG GCT CTG 
R – TGA GTG GGA TTT TGG GAA GGT C 
55 122 MV, Smith et al., 2008 (A&R) (unpublished) 
 
PDGF (RT) Ovis aries 
NM001009471 
18F 
348R 
25 
21 
F – GCT CTT CCT GTC TCT CTG CTG CTA C 
R –AGC GTT GGT GCG GTC TAT GAG 
60 331 MV, Smith et al., 2008 (A&R) 
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APPENDIX 3  BIOCHEMICAL ASSAY REPORT 
 
 
 
 
 
Statistics DLL Version 4.24 
File Name gp  ACL collagen 1.40.TXT 
File Format Table 
File Time 26/01/2010 
4:54:47 
PM 
[Assay] C:\Program Files\Revelation Quicklink\Assays\COLLAGEN AD.asy 
Assay title COLLAGEN AD 
Read Time 26/01/2010 
4:54:22 
PM 
Operator AD 
Kit Lot Data 
Plate Lot Data 
Wells A1 - D9 
OD RESULTS 
Units OD 
CURVE FITTING 
equation 
Lin/Lin Linear regression with 
data extrapolation  Y = +0.0460  +0.5925 X  
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APPENDIX 4  COMBINED RESULTS FOR CHAPTERS 3 & 4 
 
 
 
A4.1 MOLECULAR BIOLOGY 
 
A4.1.1 Preliminary OVX Study: RT-PCR Results 
 
A4.1.1.1 ACL & PCL target gene expression for NOC1 and OVX1 groups 
 
 
RT-PCR TARGET GENE EXPRESSION - NORMALISED TO TOTAL RNA 
MEAN  (SE in brackets) 
 BIGLYCAN COLLAGEN TYPE I 
COLLAGEN 
TYPE II 
COLLAGEN 
TYPE III DECORIN FIBROMODULIN 
ACL ‐ NOC1  202.5 (23.3) 
245.0 
(55.9) 
263.5 
(55.5) 
524.7 
(47.3) 
582.3 
(30.3) 
570.7 
(26.9) 
ACL ‐ OVX1  231.2 (47.9) 
93.0 
(8.3) 
212.5 
(45.6) 
250.2 
(39.4) 
166.2 
(16.9) 
201.0 
(49.7) 
PCL ‐ NOC1  236.0 (38.7) 
345.8 
(52.2) 
188.7 
(91.4) 
508.5 
(70.6) 
549.2 
(49.3) 
556.3 
(55.2) 
PCL ‐ OVX1  258.7 
(30.2) 
112.2 
(11.9) 
270.5 
(59.6) 
222.3 
(29.3) 
278.3 
(41.1) 
312.0 
(53.1) 
Table A4.1: Results for the preliminary study OVX1 vs. NOC1 for ACL and PCL, showing mean RT-PCR 
expression and standard error (SE) for each target gene.  Results presented are from total RNA data.   
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Figure A4.1: Collagen type I total RNA expression for NOC1 vs. OXV1 groups, ACL & PCL. Figure A4.2: Collagen type II total RNA expression for NOC1 vs. OXV1 groups, ACL & PCL. 
Figure A4.3: Collagen type III total RNA expression for NOC1 vs. OXV1 groups, ACL & PCL. Figure A4.4: Decorin total RNA expression for NOC1 vs. OXV1 groups, ACL & PCL. 
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Figure A4.5: Fibromodulin total RNA expression for NOC1 vs. OXV1 groups, ACL & PCL. 
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Figure A4.6: Biglycan total RNA expression for NOC1 vs. OXV1 groups, ACL & PCL. 
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Figure A4.7: GAPDH total RNA expression for NOC1 vs. OXV1 groups, ACL & PCL.  
The expression of this gene was constant enough to serve as a housekeeping gene. 
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A4.1.1.2 Statistical analysis data for OVX1 vs. NOC, ACL & PCL   
TARGET	GENE	
NOC1	‐	ACL	
vs.	
OVX1	‐	ACL	
NOC1	‐	PCL	
vs.	
OVX1	‐	PCL	
NOC1	‐	ACL	
vs.	
NOC1	‐	PCL	
OVX1	‐	ACL	
vs.	
OVX1	‐	PCL	
P value (5% level of significance) 
COLLAGEN	TYPE	I	 0.023  0.001  0.220  0.081 
COLLAGEN	TYPE	II	 0.494  0.471  0.440  0.555 
COLLAGEN	TYPE	III	 0.001  0.004  0.700  0.605 
DECORIN	 <0.0001  0.002  0.520  0.027 
FIBROMODULIN	 0.0001  0.010  0.810  0.123 
BIGLYCAN	 0.602  0.654  0.590  0.639 
RT-PCR STATISTICAL DATA - PRELIMINARY OVX STUDY 
Table A4.2: RT-PCR statistical analysis (T-test) figures for NOC1 and OVX1 sheep ACL & PCL samples, calculated from total RNA results at a 
significance level of 5%.   
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A4.1.2 Main Study: RT-PCR Results  
 
A4.1.2.1 ACL target gene expression for all study groups  
 
 
 
 
 
RT-PCR TARGET GENE EXPRESSION - NORMALISED TO TOTAL RNA 
MEAN  (SE in brackets) 
 AGGRECAN BASIC FGF BIGLYCAN COLLAGEN TYPE I COLLAGEN TYPE II COLLAGEN TYPE III CTFG DECORIN ELASTIN FIBROMODULIN iNOS LUBRICIN LUMICAN MMP-1 PDGF 
NOC  279.3 (207.6) 
329.9 
(97.8) 
164.33 
(36.0) 
65.1 
(18.6) 
355.2 
(190.3) 
34.8 
(6.4) 
232.2 
(43.6) 
345.4 
(58.3) 
579.5 
(141.8) 
298.7 
(70.2) 
338.9 
(115.3) 
219.3 
(85.4) 
219.3 
(85.4) 
35.2 
(12.1) 
138.4 
(50.9) 
MENX  130.6 (44.1) 
164.7 
(21.9) 
165.3 
(33.0) 
48.4 
(5.8) 
252.0 
(85.6) 
36.0 
(5.7) 
131.5 
(30.5) 
150.1 
(20.9) 
234.5 
(33.7) 
209.4 
(30.4) 
266.9 
(90.0) 
100.2 
(15.5) 
100.2 
(15.5) 
123.1 
(28.7) 
95.5 
(15.8) 
OVX  66.2 (17.3) 
155.3 
(22.8) 
104.2 
(23.3) 
16.4 
(3.3) 
23.8 
(6.7) 
14.4 
(3.3) 
152.7 
(31.0) 
102.7 
(24.6) 
236.2 
(27.6) 
94.7 
(13.9) 
258.6 
(89.7) 
152.9 
(19.7) 
152.9 
(19.7) 
42.4 
(21.2) 
77.0 
(16.7) 
O+M  420.6 (122.2) 
523.3 
(76.9) 
749.6 
(168.3) 
477.0 
(131.0) 
1167.4 
(501.8) 
466.5 
(123.1) 
361.8 
(74.7) 
699.1 
(146.3) 
667.7 
(171.8) 
900.0 
(217.1) 
240.0 
(76.0) 
217.7 
(29.6) 
217.7 
(29.6) 
224.9 
(76.7) 
268.4 
(53.3) 
Table A4.3: Collective results for all groups, showing mean RT-PCR expression and standard error (SE) for each target gene.  Results presented are from total RNA data. Values 
represent an expression copy number.   
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RT-PCR TARGET GENE EXPRESSION - NORMALISED TO BETA ACTIN 
MEAN  (SE in brackets) 
 AGGRECAN BASIC FGF BIGLYCAN COLLAGEN TYPE I COLLAGEN TYPE II COLLAGEN TYPE III CTFG DECORIN ELASTIN FIBROMODULIN iNOS LUBRICIN LUMICAN MMP-1 PDGF 
NOC  2.50 (1.0) 
3.63 
(0.6) 
1.77 
(0.2) 
0.70 
(0.2) 
3.54 
(1.4) 
0.39 
(0.06) 
2.65 
(0.4) 
4.28 
(0.7) 
6.28 
(1.3) 
3.17 
(0.3) 
3.58 
(1.2) 
2.47 
(0.6) 
2.43 
(0.7) 
0.42 
(0.1) 
1.32 
(0.2) 
MENX  2.08 (0.8) 
2.39 
(0.3) 
1.31 
(0.3) 
0.68 
(0.1) 
4.09 
(1.6) 
0.48 
(0.05) 
1.73 
(0.3) 
2.13 
(0.3) 
3.22 
(0.3) 
3.12 
(0.7) 
3.74 
(1.3) 
1.41 
(0.2) 
2.18 
(0.5) 
1.59 
(0.3) 
1.32 
(0.2) 
OVX  1.77 (0.6) 
4.42 
(0.9) 
2.38 
(0.2) 
0.41 
(0.1) 
0.69 
(0.3) 
0.32 
(0.03) 
4.50 
(1.1) 
2.78 
(0.7) 
6.95 
(1.2) 
2.57 
(0.5) 
9.18 
(4.6) 
4.79 
(1.2) 
2.37 
(0.3) 
1.57 
(0.8) 
1.87 
(0.2) 
O+M  1.86 (0.7) 
2.25 
(0.4) 
2.46 
(0.2) 
1.55 
(0.4) 
2.71 
(0.8) 
0.36 
(0.19) 
1.33 
(0.2) 
2.29 
(0.2) 
2.19 
(0.4) 
2.70 
(0.2) 
3.88 
(2.4) 
0.65 
(0.2) 
1.70 
(0.2) 
0.77 
(0.3) 
0.90 
(0.1) 
Table A4.4: Collective results for all groups, showing mean RT-PCR expression and standard error (SE) for each target gene listed.  Results are shown normalised to β-actin.  Values 
represent an expression copy number.   
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Figure A4.8: Aggrecan total RNA expression for all study groups. 
(NOC = non-operated control; O/M = ovariectomy + meniscectomy; M 
= meniscectomy; O = ovariectomy). 
                     Figure A4.10: Basic FGF total RNA expression for all study groups. 
Figure A4.9: Aggrecan expression normalised to β-actin for all study 
groups.  NOC = non-operated control; O/M = ovariectomy + 
meniscectomy; M = meniscectomy; O = ovariectomy). 
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               Figure A4.11: Basic FGF expression normalised to β-actin for all study groups. 
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Figure A4.12: Biglycan total RNA expression for all study groups. Figure A4.13: Biglycan expression normalised to β-actin for all study groups. 
Figure A4.14: Type I collagen total RNA expression for all study groups.     Figure A4.15: Type I collagen expression normalised to β-actin for all study groups. 
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Figure A4.16: Type II collagen total RNA expression for all study groups. Figure A4.17: Type II collagen expression normalised to β-actin for all study groups. 
Figure A4.18: Type III collagen total RNA expression for all study groups.             Figure A4.19: Type III collagen expression normalised to β-actin for all study groups. 
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Figure A4.20: CTGF total RNA expression for all study groups. Figure A4.21: CTGF expression normalised to β-actin for all study groups. 
Figure A4.22: Decorin RNA expression for all study groups.       Figure A4.23: Decorin expression normalised to β-actin for all study groups. 
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Figure A4.24: Elastin RNA expression for all study groups.    Figure A4.25: Elastin expression normalised to β-actin for all study groups. 
Figure A4.26: Fibromodulin RNA expression for all study groups.      Figure A4.27: Fibromodulin expression normalised to β-actin for all study groups. 
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Figure A4.28: iNOS RNA expression for all study groups. Figure A4.29: iNOS expression normalised to β-actin for all study groups. 
Figure A4.30: Lubricin RNA expression for all study groups. Figure A4.31: Lubricin expression normalised to β-actin for all study groups. 
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Figure A4.32: Lumican RNA expression for all study groups.            Figure A4.33: Lumican expression normalised to β-actin for all study groups. 
  Figure A4.34: MMP-1 RNA expression for all study groups.            Figure A4.35: MMP-1 expression normalised to β-actin for all study groups. 
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Figure A4.36: PDGF RNA expression for all study groups.         Figure A4.37: PDGF expression normalised to β-actin for all study groups. 
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A4.1.2.2 Statistical analysis data for all study groups 
 
  
RT-PCR STATISTICAL DATA - NORMALISED TO TOTAL RNA 
P value (5% level of significance) 
STUDY 
GROUPS 
(x vs. y) 
AGGRECAN BASIC FGF BIGLYCAN COLLAGEN TYPE I 
COLLAGEN 
TYPE II 
COLLAGEN 
TYPE III CTFG DECORIN ELASTIN FIBROMODULIN iNOS LUBRICIN LUMICAN MMP-1 PDGF 
NOC vs. MENX 0.436 0.147 0.985 0.439 0.649 0.888 0.084 0.008 0.042 0.289 0.638 0.224 0.700 0.006 0.466 
NOC vs. OVX 0.159 0.096 0.175 0.017 0.096 0.010 0.152 0.001 0.027 0.009 0.588 0.457 0.186 0.765 0.264 
NOC vs. O+M 0.539 0.134 0.003 0.005 0.144 0.002 0.148 0.035 0.696 0.015 0.481 0.985 0.041 0.029 0.092 
MENX vs. OVX 0.137 0.773 0.137 0.0001 0.008 0.003 0.636 0.167 0.970 0.002 0.949 0.055 0.199 0.034 0.436 
O+M vs. OVX 0.007 0.0001 0.001 0.002 0.033 0.001 0.017 0.001 0.021 0.001 0.876 0.082 0.005 0.048 0.002 
O+M vs. MENX 0.069 0.001 0.005 0.008 0.116 0.005 0.015 0.003 0.035 0.009 0.820 0.003 0.029 0.310 0.010 
Table A4.5: Statistical analysis (T-test) results for total RNA expression of the listed target genes.  Significance was calculated at a level of 5%.  All significant values are 
highlighted in yellow. 
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RT-PCR STATISTICAL DATA - NORMALISED TO  β-ACTIN 
P value (5% level of significance) 
STUDY 
GROUPS 
(x vs. y) 
AGGRECAN BASIC FGF BIGLYCAN COLLAGEN TYPE I 
COLLAGEN 
TYPE II 
COLLAGEN 
TYPE III CTFG DECORIN ELASTIN FIBROMODULIN iNOS LUBRICIN LUMICAN MMP-1 PDGF 
NOC vs. MENX 0.750 0.114 0.234 0.927 0.793 0.288 0.078 0.020 0.042 0.947 0.927 0.162 0.776 0.001 0.997 
NOC vs. OVX 0.513 0.499 0.054 0.203 0.052 0.293 0.112 0.160 0.703 0.312 0.250 0.094 0.944 0.170 0.091 
NOC vs. O+M 0.607 0.073 0.036 0.064 0.607 <0.0001 0.007 0.017 0.005 0.235 0.063 0.028 0.311 0.298 0.105 
MENX vs. OVX 0.754 0.076 0.921 0.013 0.030 0.013 0.031 0.442 0.011 0.498 0.306 0.018 0.729 0.986 0.076 
O+M vs. OVX 0.925 0.045 0.817 0.008 0.028 <0.0001 0.008 0.520 0.001 0.796 0.090 0.004 0.083 0.343 0.0002 
O+M vs. MENX 0.839 0.781 0.798 0.054 0.424 0.0006 0.310 0.672 0.068 0.517 0.045 0.119 0.362 0.077 0.063 
Table A4.6: Statistical analysis (T-test) results for RNA expression normalised to B-actin.  Significance was calculated at a level of 5%.  All significant values are highlighted 
in yellow. 
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A4.2 BIOCHEMICAL ANALYSIS 
A4.2.1 ACL Collagen Content  
 
A4.2.1.1 Results for all study groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A4.2.1.2 Statistical significance for all study groups 
 
ACL COLLAGEN CONTENT: ALL GROUPS 
GROUP X vs. Y P value (*5% sig.) 
(X) (Y) 
NOC 	 MENX 0.070 * 
NOC 	 OVX 0.039 * 
NOC 	 O+M 0.001 * 
O+M 	 MENX 0.039 * 
O+M 	 OVX 0.0001 * 
MENX 	 OVX 	 0.002 * 
GROUP NOC MENX OVX O+M 
MEAN 57.16 60.58 53.56 67.3 
SE 1.07 1.39 1.33 2.51 
Table A4.7: ACL collagen content - results for all study groups, mean and 
SE. (Value shown as % of dry weight).   
Figure A4.38: ACL collagen content - charted results for all study groups. 
Table A4.8: Listing of statistical differences between all study groups, calculated using a 
T-test analysis at a significance level of 5%.  * denotes significant values.   
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A4.2.2 ACL S-GAG Content 
 
A4.2.2.1 Results for all study groups 
 
 
 
 
 
 
 
A4.2.2.2 Statistical significance for all study groups 
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GROUP NOC MENX OVX O+M 
MEAN 11.78 9.35 9.43 10.11 
SE 0.7 0.59 0.4 0.32 
ACL S-GAG CONTENT: ALL GROUPS 
GROUP X vs. Y P value (*5% sig.) 
(X) (Y) 
NOC 	 MENX 0.012 * 
NOC 	 OVX 0.005 * 
NOC 	 O+M 0.027 * 
O+M 	 MENX 0.249  
O+M 	 OVX 0.196  
MENX 	 OVX 	 0.907  
Table A4.9: ACL S-GAG content - results for all study groups, mean and 
SE.  (Value shown as % of dry weight).   
Figure A4.39: ACL S-GAG – charted results for all study groups. 
Table A4.10: Listing of statistical differences between all study groups for S-GAG 
content, calculated using a T-test analysis  at a significance level of 5%.  * denotes 
significant values.   
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Table A4.12: TEM results for ACL, average fibril diameter (in nanometers), for all study 
groups, mean and SE.  
A4.3 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
 
A4.3.1 Average Number of Fibrils          A4.3.2       Average Fibril Diameter   
Table A4.11: TEM Results for ACL, average number of fibrils, for all study groups, mean and SE.  
Figure A4.41: TEM ACL average fibril diameter (nm) - charted results for all study groups. Figure A4.40: TEM ACL average number of fibrils - charted results for all study groups. 
AVERAGE FIBRIL DIAMETER 
GROUP NOC MENX OVX O+M 
MEAN 151.05 128.64 96.87 148.14 
SE 2.28 5.15 1.79 5.97 
AVERAGE NUMBER OF FIBRILS 
GROUP NOC MENX OVX O+M 
MEAN 77.88 101.75 98.58 94.79 
SE 2.77 7.32 4.94 6.65 
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Table A4.14: TEM results for ACL, total fibril area (μm2) - charted results for all study 
groups, mean and SE. 
 
 
A4.3.3 Average Fibril Area           A4.3.4 Total Fibril Area 
 
 
  Table A4.13: TEM results for ACL, average fibril area (μm2) - charted results for all study 
groups, mean and SE. 
                    Figure A4.43: TEM ACL total fibril area (μm2) - charted results for all study groups. Figure A4.42: TEM ACL average fibril area (μm2) - charted results for all study groups. 
TOTAL FIBRIL AREA  (micrometers2) 
GROUP NOC MENX OVX O+M 
MEAN 2607.94 2517.26 1451.98 3188.68 
SE 37.90 77.12 50.36 96.97 
AVERAGE FIBRIL AREA  (micrometers2) 
GROUP NOC MENX OVX O+M 
MEAN 16.92 13.00 7.46 17.80 
SE 0.49 1.05 0.28 1.39 
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 A4.3.5 Fibril Density 
            
 
 
 
 
STATISTICAL DATA FOR TEM FIBRIL ANALYSIS  
STUDY GROUPS 
(x vs. y) 
AVERAGE 
NUMBER OF 
FIBRILS 
AVERAGE 
FIBRIL 
DIAMETER 
AVERAGE 
FIBRIL 
AREA 
TOTAL 
FIBRIL 
AREA 
FIBRIL 
DENSITY 
 
P value (5% level of significance) 
 
NOC vs. MENX  0.0084 0.0013 0.0072 0.4315 0.6772 
NOC vs. OVX  0.0158 <0.0001 <0.0001 <0.0001 <0.0001 
NOC vs. O+M  0.0466 0.6438 0.5155 <0.0001 <0.0001 
MENX vs. OVX  0.7172 <0.0001 0.0002 <0.0001 <0.0001 
O+M vs. MENX  0.4273 0.0045 0.0012 <0.0001 <0.0001 
O+M vs. OVX  0.6494 <0.0001 <0.0001 <0.0001 <0.0001 
Table A4.16: Anova statistical analysis data for TEM fibril results, average number of fibrils, average fibril diameter, 
average fibril area, total fibril area and fibril density.  Analysis was performed at a 5% level of significance.  
 
Table A4.15: TEM results for ACL fibril density (% of total field) - charted results for all 
study groups, mean and SE. 
Figure A4.44: TEM ACL fibril density (% of total field) - charted results for all study groups. 
 
FIBRIL DENSITY (% of total field) 
GROUP NOC MENX OVX O+M 
MEAN 48.1 47.3 27.3 59.9 
SE 1.3 1.4 0.9 1.8 
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A4.3.6 Fibril Diameter Distribution 
 
 
 
 
 
 
	
GROUP 
(x) 
	
n= 
 
FIBRILS  
<100 
(nm) 
 
 
P  
(x vs. NOC) 
 
FIBRILS 
100-200 
(nm) 
P  
(x vs. NOC) 
FIBRILS  
>200 
(nm) 
P  
(x vs. NOC) 
Mean number of fibrils per two TEM fields, approx. 5µm2 (% of total in brackets) 
 
NOC 12 1.2    (1)  154.4    (99) -        0.2    (<1) - 
MENX 10 63.5    (31) <0.0001 133.2    (65) <0.0001        6.8    (3) 0.9981 
OVX 12 94.8    (48) <0.0001 102.2    (52) <0.0001        0.3    (0) 0.2551 
O+M 12 54.6    (29) -      98.6    (53) <0.0001      33.4    (18) <0.0001 
Table A4.17: TEM results for ACL fibril diameter distribution for all study groups.  Fibril counts 
for each size range (nm) were compared to NOC for each experimental group.   
Figure A4.45: Chart showing ACL fibril diameter (size) distribution for all test 
groups compared to the NOC group, as determined using TEM analysis.   
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
0‐20
20‐40
40‐60
60‐80
80‐100
100‐120
120‐140
140‐160
160‐180
180‐200
200‐220
220+
%
 of
 To
ta
l Fi
br
ils
Fibril Size (nm) 
ALL GROUPS ‐ FIBRIL DIAMETER DISTRIBUTION
O+M
NOC
OVX
MENX
 
 
 
 
263
A4.3.7 Fibril Arrangement  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All TEM images used in this study are presented on pages 264-286; NOC figures A4.47-58, MENX 
figures A4.59-68, OVX figures A4.69-80, O+M figures A4.81-92.  
Figure A4.46: TEM 37000x images of ACL tissue from NOC (8666), MENX (8607), 
OVX (8700) and O+M (8584) sheep, demonstrating obvious differences in fibril size 
and arrangement between groups.     
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Figure A4.47:  TEM 37000x image of NOC ACL, sheep # 69L; image A-8736, B-8737. 
Figure A4.48:  TEM 37000x image of NOC ACL, sheep # 69R; image A-8641, B-8732. 
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Figure A4.49:  TEM 37000x image of NOC ACL, sheep # 70L; image A-8696, B-8712. 
Figure A4.50:  TEM 37000x image of NOC ACL, sheep # 70R; image A-8649, B-8650. 
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Figure A4.51:  TEM 37000x image of NOC ACL, sheep # 71L; image A-8717, B-8718. 
Figure A4.52:  TEM 37000x image of NOC ACL, sheep # 71R; image A-8593, B-8664. 
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 Figure A4.54: TEM 37000x image of NOC ACL, sheep # 72R; image A-8693, B-8694. 
Figure A4.53:  TEM 37000x image of NOC ACL, sheep # 72L; image A-8611, B-8612. 
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Figure A4.--:  TEM 37000x image of OVX ACL, sheep # 77L; image A-8723, B-8724. 55:  TEM 37000x image of NOC ACL, sheep # 77L; image A-8723, B-8724. 
Figure A4.56:  TEM 37000x image of NOC ACL, sheep # 77R; image A-8678, B-8679. 
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Figure A4.57:  TEM 37000x image of NOC ACL, sheep # 94L; image A-8685, B-8686. 
Figure A4.58:  TEM 37000x image of NOC ACL, sheep # 94R; image A-8666, B-8667. 
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Figure A4.59:  TEM 37000x image of MENX ACL, sheep # 68L; image A-8637, B-8638. 
Figure A4.60:  TEM 37000x image of MENX ACL, sheep # 68R; image A-8710, B-8711. 
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Figure A4.61:  TEM 37000x image of MENX ACL, sheep # 76L; image A-8734, B-8735. 
Figure A4.62:  TEM 37000x image of MENX ACL, sheep # 76R; image A-8598, B-8599. 
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Figure A4.63:  TEM 37000x image of MENX ACL, sheep # 78L; image A-8672, B-8673. 
Figure A4.64:  TEM 37000x image of MENX ACL, sheep # 78R; image A-8590, B-8591. 
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Figure A4.65:  TEM 37000x image of MENX ACL, sheep # 79L; image A-8596, B-8597. 
Figure A4.66:  TEM 37000x image of MENX ACL, sheep # 79R; image A-8606, B-8607. 
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Figure A4.67:  TEM 37000x image of MENX ACL, sheep # 95L; image A-8681, B-8705. 
Figure A4.68:  TEM 37000x image of MENX ACL, sheep # 95R; image A-8635, B-8636. 
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Figure A4.69:  TEM 37000x image of OVX ACL, sheep # 45L; image A-8699, B-8700. 
Figure A4.70:  TEM 37000x image of OVX ACL, sheep # 45R; image A-8703, B-8704. 
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Figure A4.71:  TEM 37000x image of OVX ACL, sheep # 52L; image A-8727, B-8728. 
Figure A4.72:  TEM 37000x image of OVX ACL, sheep # 52R; image A-8674, B-8675. 
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Figure A4.73:  TEM 37000x image of OVX ACL, sheep # 60L; image A-8585, B-8586. 
Figure A4.74:  TEM 37000x image of OVX ACL, sheep # 60R; image A-8668, B-8669. 
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Figure A4.75:  TEM 37000x image of OVX ACL, sheep # 63L; image A-8640, B-8722. 
Figure A4.76:  TEM 37000x image of OVX ACL, sheep # 63R; image A-8671, B-8701. 
 
 
 
 
279
 
Figure A4.77:  TEM 37000x image of OVX ACL, sheep # 91L; image A-8663, B-8714. 
Figure A4.78:  TEM 37000x image of OVX ACL, sheep # 91R; image A-8680, B-8706. 
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Figure A4.79:  TEM 37000x image of OVX ACL, sheep # 92L; image A-8613, B-8615. 
Figure A4.80:  TEM 37000x image of OVX ACL, sheep # 92R; image A-8731, B-8733. 
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Figure A4.81:  TEM 37000x image of O+M ACL, sheep # 03L; image A-8604, B-8605. 
Figure A4.82:  TEM 37000x image of O+M ACL, sheep # 03R; image A-8583, B-8584. 
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Figure A4.83:  TEM 37000x image of O+M ACL, sheep # 08L; image A-8738, B-8739. 
Figure A4.84:  TEM 37000x image of O+M ACL, sheep # 08R; image A-8725, B-8726. 
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Figure A4.85:  TEM 37000x image of O+M ACL, sheep # 10L; image A-8691, B-8692. 
Figure A4.86:  TEM 37000x image of O+M ACL, sheep # 10R; image A-8683, B-8684. 
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Figure A4.87:  TEM 37000x image of O+M ACL, sheep # 21L; image A-8658, B-8659. 
Figure A4.88:  TEM 37000x image of O+M ACL, sheep # 21R; image A-8647, B-8648. 
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Figure A4.89:  TEM 37000x image of O+M ACL, sheep # 27L; image A-8587, B-8588. 
Figure A4.90:  TEM 37000x image of O+M ACL, sheep # 27R; image A-8656, B-8657. 
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Figure A4.91:  TEM 37000x image of O+M ACL, sheep # 58L; image A-8682, B-8715. 
Figure A4.92:  TEM 37000x image of O+M ACL, sheep # 58R; image A-8676, B-8677. 
 
 
 
 
287
A4.4 SCANNING ELECTRON MICROSCOPY (SEM) 
  
Figure A4.93:  SEM 2000x images of ACL tissue samples.  A = NOC; B = MENX; C = OVX; D = O+M.  
Note the unusual light and dark striations in the SEM cross-sections, which were conspicuous on the OVX, 
MENX and O+M samples but were not as obvious on the NOC sample.   
A. B. 
 
 C. 
 
   D. 
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 A.  B. 
 C.   D. 
Figure A4.94:  SEM 170x images of ACL tissue samples.  A = NOC; B = MENX; C = OVX; D = O+M.  
Note the differences in the arrangement of the fibre bundles between groups.     
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A4.5 HISTOLOGY 
Figure A4.95: H&E 200x longitudinal sections of ACL tissue from NOC sheep. 
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Figure A4.96: Tol Blue 200x longitudinal sections of ACL tissue from NOC sheep. 
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 Figure A4.97: H&E 200x longitudinal sections of ACL tissue from MENX sheep. 
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Figure A4.98: Tol Blue 200x longitudinal sections of ACL tissue from MENX sheep. 
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 Figure A4.99: H&E 200x longitudinal sections of ACL tissue from OVX sheep. 
 
 45L   45R   52L 
  52R   60L   60R 
  63L   63R   91L 
  91R    92L    92R 
 
 
 
 
294
 
 
  
 
Figure A4.100: Tol Blue 200x longitudinal sections of ACL tissue from OVX sheep. 
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Figure A4.101: H&E 200x longitudinal sections of ACL tissue from O+M sheep. 
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Figure A4.102: Tol Blue 200x longitudinal sections of ACL tissue from O+M sheep. 
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APPENDIX 5  BIOMECHANICAL STUDY RESULTS 
 
Presented below are a brief description of the methods and results of J. Gilmore’s 
(2011) study, which examined the effect of ovariectomy on the biomechanical 
properties of the ovine knee joint.  Results are reproduced with the author’s permission. 
 
METHODS 
Whole ovine knee joints from OVX (n=6) and NOC (n=6) sheep were dissected free of 
surrounding soft tissues, leaving the collateral ligaments and joint capsule intact.  The 
tibia was secured to the upper plate of an Instron 5566 universal mechanical test frame, 
with the femur mounted in a vice secured to the base of the frame.  Posterior and 
anterior drawer tests were performed at 250N for 10 cycles, 1 cycle per second, and the 
data collected for analysis.  An example of a force displacement plot produced by the 
Instron 5566 is show below in Figure A5.1.  From the acquired data, anterior & 
posterior drawer, and total deformation were calculated. Stiffness gradients (σ) were 
generated from each drawer test to determine changes in ligament stiffness.   
 
 
 
 
 
 
 
 
 
 
 
Figure A5.1: Force displacement curves of anterior drawer (AD) and posterior drawer (PD) 
tests in OVX 263.      AD σ=277N/mm; AD displacement = 1.371 mm;   PD σ=252 N/mm; 
PD displacement = 1.753 mm; combined displacement = 3.124 mm (J. Gilmore, 2011). 
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RESULTS 
 
 
 NOC   n=6  
Mean (mm)  ± [SE]  
OVX   n=6 
 
Mean (mm)  ± [SE] 
P= 
ANTERIOR DRAWER    1.61     [0.038]    1.60     [0.122] 0.928 
POSTERIOR DRAWER    1.87     [0.053]    1.51     [0.091] 0.006 
TOTAL DISPLACEMENT    3.38     [0.067]    3.00     [0.143] 0.011 
 
   Table A5.1: Summary of biomechanical testing - joint displacement 
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Figure A5.2: results of biomechanical testing showing effect of ovariectomy on joint displacement 
in anterior and posterior drawer tests.  Data represent total displacement (mm) +/- se.  * p=0.006;  
** p=0.011 
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 NOC   n=6  
Mean (N/mm)  ± [SE]  
OVX   n=6 
 
Mean (N/mm)  ± [SE] 
P= 
ANTERIOR DRAWER    220.46     [8.014]    242.85     [12.429] 0.161 
POSTERIOR DRAWER    202.16     [15.346]    259.12     [7.449] 0.007 
 
Table A5.2: Summary of biomechanical testing - ligament stiffness 
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Figure A5.3: results of biomechanical testing showing the effect of ovariectomy on ligament
stiffness (N/mm) +/- se.  * p =0.007. 
